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Abstract 
 
To overcome the societal and financial burden of cardiovascular disease, a thorough understanding 
of the molecular and cellular programmes governing cardiac and coronary vascular development is 
vital. Cre-mediated genetic tracing in various models has provided valuable insight into cell-lineage 
contribution and inductive cues required for cardiac morphogenesis. Using mouse models, we have 
identified the transmembrane protein Cysteine-Rich Transmembrane BMP Regulator-1 (Crim1) as 
an essential protein for numerous aspects of heart development. The presence of six Cysteine-Rich 
Repeats (CRRs) in Crim1 render it to be a versatile molecule – these have been shown to bind a 
wide range of growth factors when Crim1 is co-expressed in the same cell as the growth factor 
(Wilkinson et al., 2003, Wilkinson et al., 2007). The main objective of this thesis is to examine the 
role that Crim1 plays both temporally and spatially during heart development, and how it functions 
in tandem with other factors to ensure the progression of this critical process. 
 
Crim1 is strongly expressed in the proepicardium (PE), epicardium, coronary vascular smooth 
muscle cells and, to a weaker extent, in coronary endothelial cells (Pennisi et al., 2007). 
Interestingly, Crim1 mutant homozygotes die perinatally on a C57BL6 background (Chiu et al., 
2012). Loss of Crim1 function leads to a reduced ventricular size and hypoplastic ventricular 
compact myocardium, and abnormal epicardial morphology including blebbing and a loss of the 
regular, cobblestone appearance of the epicardium. Furthermore, epicardium-restricted deletion of 
Crim1 resulted in increased epicardial epithelial-to-mesenchymal transition (EMT) and invasion of 
the myocardium, while primary epicardial cells lacking Crim1 displayed an increased migration.  
 
Growth factors like TGFs are known to promote epicardial EMT; however, we observed a 
paradoxical reduction in epicardial TGF signalling in Crim1 mutant embryos. Interestingly, there 
appeared to be an accumulation of -catenin, a cell-adhesion molecule present at cadherin-
dependent junctional complexes in epithelial cells, at epicardial cell-cell junctions, suggesting an 
interaction with Crim1 to promote stabilization of these junctions. There was also an increase in the 
level of phospho-ERK1/2 in the ventricular compact myocardium of mutants, though phospho-AKT 
levels remained unchanged. This indicates a cell-autonomous role for Crim1 in controlling 
epicardial migration, EMT and invasion, and a potential paracrine role in regulating myocardial 
development, likely through regulation of epicardium derived factors. 
 
Another notable defect observed in the absence of Crim1 is that the coronary vasculature also 
appears to be malformed. We found a reduction in coronary vascular endothelial cell endowment in 
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both ventricles, in Crim1Δflox/Δflox homozygotes and in endothelium-restricted mutants, identifying 
a cell-autonomous role for Crim1. To further study Crim1 function in vitro, lentiviral small hairpin 
ribonucleic acid (shRNA) targeting the CRIM1 gene was transduced into Human Cardiac 
Microvascular Endothelial Cells (HCMVECs), with a knockdown of more than 70% achieved at the 
transcript level. Trypan Blue viability assays in both HCMVECs and Human Umbilical Vein 
Endothelial Cells (HUVECs) indicate reduced viability in the absence of CRIM1.  Protein lysates 
obtained from both Crim1-knockdown HCMVECs and HUVECs indicate a reduction in phospho-
SMAD1/5 levels, but no change in phospho-ERK1/2 and phospho-AKT levels. 
 
We also sought to understand the role of Crim1 in growth factor modulation in endothelial cells in 
vivo. There was a decrease in phospho-SMAD1/5 activity in endothelial cells from ventricles of 
Crim1Δflox/Δflox homozygotes, suggesting a dysregulation of TGFβ/BMP signalling in these cells, 
confirming our in vitro data. However, there was an increase in endothelial phospho-SMAD1/5 
levels in ventricles of Crim1Flox/Flox; Tie2-Cre hearts, indicating a possible paracrine role for the 
other resident cells of the ventricular myocardium that retain Crim1 function.  
 
cDNA synthesised from HCMVECs that had lost Crim1 was then used in a human endothelial cell 
biology array. This revealed an upregulation of genes involved in increased inflammatory response 
and cell death, and, an increased probability of disease states including vascular lesions, infarction 
and heart failure, upon Ingenuity Pathway Analysis. Collectively, we illustrate a cell-autonomous 
role for Crim1 in the development of coronary vascular endothelial cells, in vivo and in vitro. 
 
We further report for the first time, that CRIM1 is able to bind Insulin-like Growth Factors (IGFs). 
This was shown by means of co-immunoprecipitation experiments, and reveals that the IGFBP 
domain of CRIM1, and CRRs 3-6 are responsible for this binding. Moreover, in HCMVECs lacking 
CRIM1, phosphorylation of the IGF-1 receptor was decreased, indicating the ability of CRIM1 to 
regulate IGF signalling.  
 
Our findings thus provide a platform for understanding how Crim1 functions in both the early and 
late stages of embryonic heart development in vivo. Many of these findings are mimicked in vitro, 
most significantly in the context of growth factor modulation in human cardiac microvascular 
endothelial cells, and aids in understanding the pathogenesis of disease states. This indicates 
translational relevance to humans, making the study of CRIM1 an exciting new avenue for future 
research in the field of cardiac development. 
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INTRODUCTION 
 
The heart is the first organ to form and function in the vertebrate embryo (Yutzey and Kirby 2002), 
and provides oxygen and nutrients to the body while also removing wastes. The process of 
cardiogenesis involves the tightly regulated, synergistic interaction and integration of various cell 
types and signalling molecules (Miquerol and Kelly 2013, Kelly, Buckingham et al. 2014) at 
varying stages. Congenital heart malformations are a major cause of foetal mortality and reflect the 
need for understanding the complexities of heart development. Furthermore, resolving damage to 
heart tissue due to disease and injury is also a burgeoning societal burden that requires urgent 
investigation. The limited regenerative potential of the heart has made it essential to uncover 
mechanisms to repair tissue following myocardial ischemia. Unsurprisingly, there is immense 
research in the context of heart regeneration, including therapies involving stem cells, genetic 
reprogramming of the epicardium and cells such as fibroblasts to cardiomyocytes, and tissue 
engineering, as strategies to restore myocardial function (Laflamme and Murry 2011).  
 
  In the following sections, we discuss the development of the heart, the interplay of growth factors 
involved in cardiogenesis, and introduce Crim1, a protein with the potential to regulate various 
aspects of developmental processes, including matters of the heart. 
 
Heart development – an overview. 
Heart development begins with cardiac progenitor cells traversing the primitive streak during 
gastrulation (Garcia-Martinez and Schoenwolf 1993, Schoenwolf and Garcia-Martinez 1995). 
Angioblastic cords form in the cardiogenic region upon the aggregation of the principal cardiac 
precursors, splanchnic mesenchymal cells, which arise in the lateral plate mesoderm from primary 
heart fields (Waldo, Kumiski et al. 2001). Two thin-walled endocardial heart tubes form when the 
cords canalize, and subsequently fuse to form a single two-layered heart tube (Manasek 1969). This 
comprises the outer myocardium and the inner endothelial tube - the endocardium - separated by 
cardiac jelly (Waldo, Kumiski et al. 2001). The heart tube undergoes rightward looping and 
increases in length; cardiac progenitor cells that contribute the heart tube are mainly 
responsible for its elongation(Miquerol and Kelly 2013).  Further investigations of cardiac lineage 
contributions have revealed the existence of two distinct lineages; a first lineage that gives rise to 
the left ventricle and atria, and a second lineage that contributes to the OFT myocardium, right 
ventricle and atria (Meilhac, Esner et al. 2004) The heart begins to grow due to cellular 
proliferation, and following cardiac chamber and cushion morphogenesis, cardiac septation and 
valve development ensue (Miquerol and Kelly 2013). The epicardium of the heart, which has 
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formed by the migration of propepicardial cells as a single sheet over the surface of the heart, via 
epithelial to mesenchymal transition (EMT) contributes various cell types to the myocardium, 
including coronary vascular smooth muscle cells, cardiac fibroblasts and a proportion of coronary 
vascular endothelial cells (Virágh and Challice 1981, Männer 1993, Virágh, Gittenberger-de Groot 
et al. 1993, Mikawa and Gourdie 1996, Gittenberger-de Groot, Vrancken Peeters et al. 1998). The 
myocardium is divided into two distinct components – the outer compact myocardium and the inner 
trabeculated myocardium. This is followed by development of the coronary vasculature, which 
supports the growing ventricular wall by providing blood supply (Miquerol and Kelly 2013) (Figure 
1.1). 
 
 
Figure 1.1: Origin and lineage relationship of cardiac cell types.  
A, Contribution of the three populations of embryonic heart progenitors, cardiogenic mesoderm (red), cardiac neural 
crest (purple) and proepicardial organ (yellow) to different heart compartments during cardiac morphogenesis in the 
mouse. Progenitors of the cardiogenic mesoderm are first recognizable under the head folds (HFs) of the embryo at 
E7.5, then move ventrally to the midline (ML) and form initially the linear heart tube and ultimately the four chambers 
of the heart. After the looping of the heart tube (E8.5), cardiac neural crest progenitors migrate from the dorsal neural 
tube to engulf the aortic arch arteries and contribute to vascular smooth muscle cells of the outflow tract (OFT) around 
E10.5. At the same time in mouse development, the proepicardial organ precursors contact the surface of the developing 
heart, give rise to the epicardial mantle (yellow) and contribute later to the coronary vasculature. In the fetal heart 
(∼E14), the chambers separate due to septation and are connected to the pulmonary trunk (PT) and aorta (Ao). Cranial 
(Cr)-caudal (Ca), right (R)-left (L), and dorsal (D)-ventral (V) axes are indicated. AA, aortic arch; IVS, interventricular 
septum; LA, left atrium; LV, left ventricle; PhA, pharyngeal arches; PLA, primitive left atrium; PRA, primitive right 
atrium; RA, right atrium; RV, right ventricle. Image adapted from (Laugwitz et al., 2008). 
 
Cellular contributions to heart structure 
Cells that arise from the different heart fields as well as those from the cardic neural crest and 
proepicardium, all contribute to the vertebrate heart development (Torrent-Guasp, Kocica et al. 
2005). Primary or first heart field (FHF) progenitors give rise to the nascent heart tube and form the 
left ventricle and atria (Stennard and Harvey 2005). The second heart field comprises progenitor 
cells of the arterial and venous poles of the heart tube (Dyer and Kirby 2009). The pharyngeal 
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mesoderm gives rise to part of the myocardium that forms the cardiac outflow tract (OFT) 
(Mjaatvedt, Nakaoka et al. 2001, Waldo, Kumiski et al. 2001), and part of the right ventricle (Zhou, 
Cashman et al. 2011), after the primary heart tube forms (de la Cruz, Sanchez Gomez et al. 1977) 
and as it elongates (Zaffran, Kelly et al. 2004). This is called the anterior heart field (AHF) region 
(Kelly, Brown et al. 2001, Mjaatvedt, Nakaoka et al. 2001). It is distinct from the secondary heart 
field (SHF) (Dyer and Kirby 2009) which generates the distal outflow tract myocardium and 
proximal aortic and pulmonary trunk smooth muscle (Waldo, Kumiski et al. 2001, Waldo, Hutson 
et al. 2005, Ward, Stadt et al. 2005, Sun, Liang et al. 2007).  
 
Endocardial endothelial cells undergo Endothelial-to-Mesenchymal Transformation (EndoMT) and 
invade the cardiac jelly to form the atrioventricular (AV) canal endocardial cushions (Akiyama, 
Chaboissier et al. 2004). Cardiac neural crest cells (CNCCs) supply vascular smooth muscle cells in 
addition to the SHF–derived smooth muscle progenitors and play a role in cardiovascular patterning 
(Kirby and Waldo 1995, Waldo, Hutson et al. 2005). CNCCs are involved in OFT endocardial 
cushion formation (Akiyama Haruhiko et al, 2004). These later contribute to the formation of the 
valves and septa of the four-chambered heart (Markwald, Runyan et al. 1984, Akiyama, Chaboissier 
et al. 2004).  Ecto-mesenchymal cardiac neural crest cells are involved in pharangeal arch 
patterning and form tissues that partition the vessels of the heart (Kirby and Waldo 1995). They are 
responsible for aorticopulmonary septation and division of the truncus arteriosus and bulbus cordis 
along with outflow tract endocardial cushion formation, aortic arch remodelling as well as 
contribution of smooth muscle to the arch arteries, aorta and pulmonary trunk as they mature (Kirby 
and Waldo 1990, Waldo, Miyagawa-Tomita et al. 1998, Li, Liu et al. 1999, Maschhoff and Baldwin 
2000, Stoller and Epstein 2005, Brown and Baldwin 2006). 
 
The PE is a transient structure located between the sinus horns and liver primordium (Virágh, 
Gittenberger-de Groot et al. 1993), and also derived from the lateral plate mesoderm (Serluca 
2008). By attaching to the inner groove of the AV junction of the rudimentary heart (Männer , Ishii, 
Garriock et al. 2010), proepicardial cells form its outer layer, the epicardium (Virágh and Challice 
1981, Männer 1993, Virágh, Gittenberger-de Groot et al. 1993, Mikawa and Gourdie 1996, 
Gittenberger-de Groot, Vrancken Peeters et al. 1998). The migration of these cells to the 
myocardium depends on the species, and occurs either by proepicardial vesicle budding or via the 
formation of an extracellular matrix bridge that possibly guides the cells to their destination 
(Nahirney, Mikawa et al. 2003) (Figure 1.2). Following the attachment, a population of epicardial 
cells undergo EMT and form subepicardial cells, whereas another subset of these cells migrate 
through the subepicardial space and into the myocardium (Virágh and Challice 1981).  
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Figure 1.2: Formation of the epicardium from the proepicardium. 
A, B, Species-specific migration of proepicardial cells over the myocardium, by vesicles budding off (mouse model, A) 
or via the formation of an extracellular matrix bridge guiding the proepicardial cells to the myocardium (avian model, 
B).C-E, Scanning electron micrographs showing the formation of the normal PE-derived tissue bridge to the heart in 
three-day old chick embryos (Hamburger and Hamilton (HH)- stages 16-18).Brown coloration marks the PE and PE-
Derived primitive epicardium. C, at HH-stage 16, the PE appears as a cauliflower-shaped accumulation of mesothelial 
villous protrusions (*) covering the surface of the right horn of the sinus venosus. D, At HH-stage 17, the tips of some 
PE villi (*) adhere to the dorsal surface of the developing ventricles (Ven). E, At HH-stage 18, a secondary PE-derived 
tissue bridge (*) is formed, which bridges the free pericardial cavity between the ventral wall of the sinus venosus and 
the dorsal wall of the developing ventricles (sinu-ventricular ligament). From the point of its attachment to the heart, the 
primitive PE-derived epicardium spreads over the naked myocardial surface of the heart. AV, atrioventricular canal; 
LA, future left atrial appendage; Li, liver; RA, future right atrial appendage. C-E adapted from (Männer, 2013). 
 
These epicardium-derived cells (EPDCs) are destined to form various cell types, including coronary 
vascular smooth muscle cells, cardiac fibroblasts and a proportion of coronary vascular endothelial 
cells (Virágh and Challice 1981, Männer 1993, Virágh, Gittenberger-de Groot et al. 1993, Mikawa 
and Gourdie 1996, Gittenberger-de Groot, Vrancken Peeters et al. 1998) (Figure 1.3). The 
contribution of the PE to the cardiomyocyte lineage is controversial. Van Wijk and colleagues have 
suggested that different growth factor cues can modulate the differentiation of proepicardial cells 
into cardiomyocytes (Kruithof, van Wijk et al. 2006, Schlueter, Männer et al. 2006, van Wijk, van 
den Berg et al. 2009). Some studies based on lineage tracing suggest that a small number of 
proepicardial cells are fated to become cardiomyocytes based on the expression of markers such as 
Tbx18 (Cai, Martin et al. 2008, Zhou, Ma et al. 2008). However, this interpretation has been refuted 
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based on the inherent expression of these markers during development, which skew lineage-tracing 
analyses (Christoffels, Grieskamp et al. 2009). Similarly, there has also been much speculation 
about the origins of coronary endothelial cells. It is a matter of contention whether the PE is the 
only contributor of endothelial cells to the coronary vasculature, as the liver bud and sinus venosus 
have also been demonstrated to supply these cells (Poelmann, Gittenberger-de Groot et al. 1993, 
Red-Horse, Ueno et al. 2010, Cossette 2011). Some studies indicate that endothelial cells originate 
in the PE and others suggest that the PE is used as a channel for endothelial cell migration from the 
adjacent liver bud and sinus venosus (Cossette and Misra 2011, Pennisi 2016). 
 
 
Figure 1.3: Epicardial EMT and invasion of the myocardium by EPDCs 
A subset of epicardial cells undergo EMT and populate the subepicardial space. Another set of cells invades the 
myocardium; these EPDCs are precursors to cardiac fibroblasts, coronary smooth muscle cells and a small proportion of 
coronary endothelial cells. 
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The endothelial cells, by vasculogenesis, assemble de novo to form a primary vascular plexus 
(Wada, Willet et al. 2003). These structures undergo angiogenesis to form arteries, veins and 
capillaries (Bernanke and Velkey 2002, Ratajska, Ciszek et al. 2003, Wada, Willet et al. 2003). A 
venous connection arises between the vascular plexus and coronary sinus, and an arterial 
connection arises with aortic sinus developing coronary ostia which give rise to the right and left 
coronary arteries (Hutchins, Kessler-Hanna et al. 1988). A study by Tomanek et al provides 
evidence that a population of hemangioblast precursors that differentiate into erythrocytes are 
derived from the proepicardium (Tomanek, Ishii et al. 2006). These hemangioblasts form blood 
islands in the epicardium, which later penetrate the myocardium and coalesce into a primary 
capillary plexus (Risau 1991). From these pre-existing channels arise new vessels, by angiogenesis. 
The sinus venosus has also been studied in detail for its contribution to intramyocardial cardiac 
endothelial cells. Zhang and colleagues have confirmed, by employing the use of multiple 
transgenic mouse lines, that the sinus venosus is indeed a major contributor to myocardial 
endothelial cells (Zhang, Pu et al. 2016).  Tian and colleagues have suggested that subepicardial 
cells that originate from the sinus venosus give rise to both arterial and venous endothelial cells 
(Tian, Hu et al. 2013). Red-Horse and colleagues have demonstrated that blood vessels sprout from 
the sinus venosus and to a lesser extent, the endocardium. Venous endothelial cells of the sinus 
venosus dedifferentiate into a coronary plexus and invade the myocardium, and consequently 
redifferentiate into arteries and capillaries. This implies that some venous cells are reprogrammed 
into becoming arterial cells while the other, mostly superficial ones, retain venous plasticity (Red-
Horse, Ueno et al. 2010). Extensive remodelling of coronary vessels occurs during development, 
and the regulated mechanisms leading to the integration of the coronary vasculature to the systemic 
circulation are still incompletely understood (Reese, Mikawa et al. 2002). 
 
Growth factors involved in heart development. 
The molecular and cellular events that orchestrate cardiac development are relatively well-studied, 
but not fully understood. This is partly due to multiple cellular populations from different origins, 
which respond to numerous growth factors at varying times. This, combined with the crosstalk 
between different signalling pathways that regulate cardiac differentiation and morphogenesis, and 
the pace at which cardiogenesis occurs, makes the heart a challenging organ to study.  
 
The growth factors that direct cardiac organogenesis, and are intimately involved with heart 
development, include, but are not restricted to, TGFβ, BMPs, Fibroblast Growth Factors (FGFs), 
VEGFs, PDGFs, IGFs and members of the Wnt family. These are expressed in various stages of 
heart development and in different locations. Interaction between these ligands and their receptors 
 8 
is vital for cardiogenesis to occur appropriately; the successful development of conditional 
knockout models has allowed for the roles of these molecules in target cells to be determined.  
Here, we summarize our current understanding of how these factors affect different aspects of 
cardiogenesis (Figure 1.4). 
 
 
Figure 1.4: Epicardial-myocardial signalling pathways in coronary vascular development.  
Shown is a schematic of the crosstalk between the epicardium (blue) and myocardium (red) during the early stages of 
coronary development. An FGF-Shh-VEGF/Ang2-dependent pathway is important for the generation of coronary 
endothelial progenitors (right), whereas catenin, PDGF, TGFare important for the development of the coronary 
vascular smooth muscle (left). Image modified from Olivey and Svensson (2010). 
 
Development and homeostasis are both regulated by the evolutionarily conserved TGFβ 
superfamily of growth factors (Wu and Hill, 2009). Members of this family include TGFβs, BMPs, 
growth and differentiation factors (GDFs) and Nodal, among others. TGFβ signalling can occur via 
two primary pathways, the SMAD-dependent or canonical pathway, and the SMAD-independent or 
non-canonical pathway. In the former, TGFβs signal via type I and II serine/threonine kinase 
receptors.Binding of the ligand to the type II receptors results in the formation of a heterotetrameric 
complex which then activates the type I receptors. The activated type I receptor phosphorylates the 
SMAD proteins which translocate into the nucleus,where they interact with transcription factors to 
modulate the transcription of target TGF-β-responsive genes (Wu and Hill, 2009). The non-
canonical pathway entails activation of mitogen-activated protein kinases (MAPKs), AKT, among 
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others (Wang et al., 2014). Since TGFβs stimulate EMT, resulting in a loss of epithelial cell 
characteristics and induction of a mesenchymal phenotype, it follows that many of these genes 
should, in principle, include those involved in regulating cell adhesion, increased motility and 
expression of mesenchymal markers. Indeed, this has been demonstrated by way of microarray 
analysis of the genes upregulated and downregulated by TGFβs (Xie et al., 2004).  
 
Some ligand-receptor interactions require TGFβ co-receptors such as the membrane-bound 
proteoglycan betaglycan, which is also referred to as TGFβ receptor type III, and endoglin. While 
betaglycan binds TGFβs 1, 2 and 3 with high affinity, endoglin recognizes only TGFβs 1 and 3. 
Endoglin is predominantly expressed on endothelial cells (Cheifetz et al., 1992). TGFβ-1 and BMP-
9 mediated phosphorylation of SMADs 1, 5 and 8 and consequent inhibition of endothelial cell 
migration is dependent on the phosphorylation of endoglin by the type 1 TGFβ receptors ALK-5 
and ALK-1, as well as TβRII (Ray et al., 2010). 
 
TGFβs 1, 2 and 3 are expressed in various stages of heart development and in different locations 
including endocardial-endothelial cells, the epicardium, the AV canal myocardium and the OFT 
(Arthur and Bamforth, 2011). The TGFβ receptors and co-receptors are expressed in overlapping 
sites, and the interaction between ligand and receptors is vital for different aspects of cardiogenesis; 
EMT, as previously mentioned, as well as coronary vessel and cushion development (Arthur and 
Bamforth, 2011). Formation of the cardiac cushions requires endothelial to mesenchymal 
stimulation in the endocardium, which follows the activation of the TGFβ signalling pathway by 
different TGFβ isoforms (Boyer et al., 1999). TGFβ-2 has been shown to stimulate the expression 
of Slug, a protein characterized by the zinc finger motif, which has been implicated in neural crest 
cell migration and transformation (Nieto et al., 1994) as well as the initial steps of EMT in the AV 
canal that lead to cushion formation (Romano and Runyan, 1999, Romano and Runyan, 2000). 
TGFβ-2 is also thought to increase the migration of endocardial cells that are undergoing EMT, 
through the cardiac jelly, to form cushion mesenchyme cells (Azhar et al., 2003). TGFβ signal 
transduction is also involved in the differentiation of vascular smooth muscle cells, generated upon 
the formation of EPDCs after epicardial EMT (Sridurongrit et al., 2008). PDGFR-β is one of the 
genes upregulated by TGFβ (Xie et al., 2004), and both are involved in EMT and vascular smooth 
muscle cell development in the heart (Arthur and Bamforth, 2011, Sridurongrit et al., 2008, Lu et 
al., 2001). Further studies will be required to correlate the time of expression of both factors as well 
as whether they work in synergy to mediate the aforementioned roles. 
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BMPs, a sub family of the TGFβ family (Ashe, 2005), are activated by the cleavage of inactive pre-
protein into homo or heterodimers, in their secreted form (van Wijk et al., 2007). As in the case of 
TGFβs, downstream signalling occurs via both canonical and non-canonical pathways. In the case 
of canonical signalling, they bind to Type 1 and Type 2 BMP Receptors (BMPRs), showing greater 
affinity for the former. Formation of the ligand-receptor complex leads to the phosphorylation of 
Type 1 BMPRs, by Type 2 BMPRs, which in turn phosphorylate and activate their downstream 
mediators, the SMAD proteins. These positively and negatively regulate the transcription of target 
genes (Wang et al., 2014). 
 
The BMPs largely involved in cardiac development are BMP-2, BMP-4, BMP-5, BMP-6, BMP-7 
and BMP-10. BMP-2 signaling plays a role in proepicardial cell migration towards the AV junction, 
with the ligand being present in the AV myocardium and the receptor being present in the 
proepicardium (Ishii et al., 2010). BMP-2 also functions in the development of the endocardial 
cushions (heart valve precursors), atria and ventricles, as well as mesenchyme formation in the AV 
cushions and efficient EMT (Ma et al., 2005, Rivera-Feliciano and Tabin, 2006). BMP-4 is 
expressed in the lateral plate mesoderm (Fujiwara et al., 2002), sinus venosus, myocardial outflow 
tract (Yuasa and Fukuda, 2009) and in the PE proper (Kruithof et al., 2006). Its absence causes 
defective myocardial OFT septation, impaired formation of coronary vessels (Liu et al., 2004a) and 
other cardiac anomalies (Jiao et al., 2003). The absence of either BMP-5, -6 or -7 does not cause 
impaired development of the heart, but knocking down both BMP-6 and BMP-7, or BMP-5 and 
BMP-7, results in cardiac defects (van Wijk et al., 2007, Yuasa and Fukuda, 2009). The absence of 
BMP-10 leads to impaired ventricular trabeculation and formation of thin ventricular walls 
(Neuhaus et al., 1999). BMPs have also been shown to be involved in increasing the expression of 
IGF-1 but inhibiting that of IGFBPs in osteoblasts, indicating the possibility of a similar mechanism 
in the context of heart development(Canalis and Gabbitas, 1994, Gabbitas and Canalis, 1995).  
 
BMP signal transduction is regulated by various proteins which exert a pro- or anti-BMP effect by 
sequestering BMPs and inhibiting BMP-receptor interactions, hindering BMP transport across cells 
and thus disturbing the BMP gradient required for downstream signaling and maintaining some 
BMPs in inactive form by preventing the cleavage of pre-BMPs (Umulis et al., 2009b). These 
include the intracellular SMAD6 (Galvin et al., 2000) and MAPKKK TAK1 (Monzen et al., 1999), 
membrane-bound co-receptors such as BAMBI (BMP and Activin membranebound inhibitor) 
(Balemans and Van Hul, 2002) and DRAGON (Samad et al., 2005), or extracellular secreted 
proteins such chordin (Piccolo et al., 1996), crossveinless-2 (CV2), twisted gastrulation (Tsg) 
(Zakin et al., 2008, Umulis et al., 2009b), noggin (Smith and Harland, 1992) and the DAN family of 
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BMP antagonists comprising members including Dan itself, cerebrus, gremlin and protein related to 
dan and cerberus (PRDC) among others (Rider, 2010, Pearce et al., 1999, Topol et al., 1997, Hsu et 
al., 1998, Minabe-Saegusa et al., 1998). 
 
The pseudoreceptor BAMBI(BMP and activin membrane-bound inhibitor) is related to TGF-β 
family type I receptors but without the intracellular serine/threonine (ser/thr) phosphotransferase 
domain (Onichtchouk et al., 1999). It serves to inhibit BMPs by interacting with BMPRs via its 
intracellular domain to hinder receptor-complex formation (Onichtchouk et al., 1999). On the other 
hand, Lin et al have described that in Wnt Signalling, while BAMBI can interact with the Wnt 
receptor Frizzled 5 via both intracellular and extracellular domains, LRP6 and Dishevelled 
interaction requires the intracellular domain. Subsequent signalling leads to an increase in 
intracellular β-Catenin and expression of genes involved in stimulating cell proliferation (Lin et al., 
2008). It has also been found that hBAMBI can act in synergy with Smad6 and Smad7 to negatively 
regulate BMP signal transduction (Yan et al., 2009).  
 
Chordin, a BMP inhibitor, possesses four VWFC domains, of which VWFC1 and VWFC3 are 
implicated in BMP-2 binding and VWFC1 and VWFC4 are implicated in BMP-7 binding (Zhang et 
al., 2007). This is an example of reversible inhibition due to the chordin-cleaving ability of tolloid 
metalloproteinases (Zakin and De Robertis, 2010). Ont1, a member of the olfactomedin family 
assists in the breakdown of chordin and enhances the action of the tolloid proteinases (Inomata et 
al., 2008). Twisted gastrulation binds to both chordin and BMP to act as a negative regulator of 
BMP activity (De Robertis, 2009).  
 
CV2, another VWFC-containing BMP-modulating protein, binds to and inhibits BMPs via VWC1 
(Zhang et al., 2010, Zhang et al., 2008). On the other hand, to exert its pro-BMP effect, it is 
suggested that CV2 forms a ternary complex with both chordin and BMP, and reduces the affinity 
of chordin for BMP, thus allowing BMPs to activate their downstream effectors via the BMPRs 
(Zhang et al., 2010). 
 
Noggin is related to the cystine-knot growth factors and specifically inhibits BMP-2, BMP-4 and, to 
a lesser extent, BMP-7 (Groppe et al., 2002, Monzen et al., 1999). It binds to its target and masks 
receptor binding sites present on BMPs, thereby preventing them from binding to type I and type II 
cell surface BMPRs (Groppe et al., 2002, Zimmerman et al., 1996). However, it has been suggested 
that the antagonistic effect of Noggin in blocking the BMP signal transduction pathway transiently 
during early cardiogenesis may be crucial for cardiomyocyte differentiation (Yuasa et al., 2005). As 
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previously mentioned, BMP signaling modulates EMT and endocardial cushion formation. The 
absence of Noggin increases BMP signal transduction, subsequently leading to an increase in 
myocardial cell proliferation and ultimately a thicker myocardium, and larger endocardial cushions 
(Choi et al., 2007). 
 
Thereare 22 FGFs that bind to and activate FGF Receptors (FGFRs) or receptor tyrosine kinases 
(Vega-Hernandez et al., 2011). The presence of FGFs and FGFRs in cardiac and vascular 
mesoderm indicates they are involved in cardiac development and the coronary vasculogenesis 
(Vega-Hernandez et al., 2011). When an FGF binds to the extracellular domain of the FGFR, the 
receptor dimerizes. Dimerization leads to a rapid activation of the protein’s cytoplasmic kinase 
domains, the first substrate of which is the receptor itself. The activated receptor becomes 
autophosphorylated at intracellular tyrosine residues (McKeehan et al., 1998), which in turn are 
docking sites for Phosphotyrosine Binding Proteins or Src homology 2 proteins (Forman-Kay and 
Pawson, 1999, Pawson et al., 1993). The RAS-RAF-MAPK and phospholipase C-γ signaling 
pathways are activated(Szebenyi and Fallon, 1999), leading to the regulation of cellular processes 
such as cell proliferation, migration and differentiation (Lavine and Ornitz, 2008).  
 
 FGF-2 has been shown to influence proepicardial cell and hemangioblast proliferation as well as 
the formation of cardiomyocytes from cardiac precursors (Rosenblatt-Velin et al., 2005, Kruithof et 
al., 2006, Burger et al., 2002, Faloon et al., 2000). FGF-9 and FGF-16 expressed in the epicardium 
are involved in the regulation of myocardial proliferation along with other factors (Vega-Hernandez 
et al., 2011, Li et al., 2011). Myocardial FGF-10 signaling to its receptors in the epicardium appears 
to propel EPDCs to the fibroblast lineage (Vega-Hernandez et al., 2011). An FGF gradient across 
the myocardium has been shown to be essential in nascent blood vessel patterning (Pennisi and 
Mikawa, 2005). FGF signaling is implicated in EMT (Mikawa and Gourdie, 1996), activation of 
EPDC movement into the myocardium and its subsequent invasion, following which coronary 
vessel formation takes place (Pennisi and Mikawa, 2009). It is also involved in regulation of 
myocardial growth and differentiation (Lavine and Ornitz, 2008). Myocardial FGF signaling and 
Hedgehog (HH) activation are required for the formation of the coronary vascular plexus (Mikawa 
and Gourdie, 1996). BMP-2 and FGF-2 signaling are implicated in the separation of myocardial 
progenitors and proepicardial progenitors, with BMP-driven determination of myocardial cell fate 
and FGF-driven determination of proepicardial cell fate (van Wijk et al., 2009). 
VEGFs are a family of cystine-knot-containing (Wiesmann et al., 1997) growth factors which are 
critical regulators of angiogenesis and vasculogenesis. They comprise the isotypes VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor PIGF (Holmes et al., 2007). 
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These are secreted in their homodimeric form and linked by intra and inter-chain DS bonds (Muller 
et al., 1997). Of the 6 isoforms of VEGF-A isoforms, some are secreted and freely diffusible, 
whereas some remain sequestered to the extracellular matrix or are membrane-bound (Robinson 
and Stringer 2001). VEGFs bind to VEGF receptor (VEGFR) tyrosine kinases VEGFR-1, VEGFR-
2 and VEGFR-3. VEGFR-1 binds to VEGF-A, VEGFB, PIGF, VEGFR-2 binds VEGF-A, VEGF-
C, VEGFD, VEGF-E and VEGFR-3 binds VEGF-C and VEGF-D (Robinson and Stringer, 2001). 
VEGF receptor signaling is similar to FGF receptor signaling. Binding of VEGF to VEGFR leads to 
dimerization of the receptor and transphosphorylation (between the dimerized receptor molecules) 
at tyrosine residues in the VEGFR domains, activating Src homology proteins and the PLC-γ, Akt 
and Ras-Raf signaling pathways (Fuh et al., 1998, Semela and Dufour, 2004b, Semela and Dufour, 
2004a). 
 
VEGF-A plays an important role in endothelial cell proliferation, migration, vascular permeability 
and VEGF-B, which is primarily expressed in the heart, is implicated in myocardial blood vessel 
development (Claesson-Welsh, 2008, Li et al., 2008, Olofsson et al., 1996). VEGF expression in the 
myocardium is dependent on Hedgehog activation, which in turn depends on myocardial FGF 
signalling (Lavine et al., 2006); this may play a role in inducing epicardial EMT (Tomanek et al., 
2001). In mice lacking VEGF-A in the ventricular myocardium, myocardial wall thickness was 
reduced (Giordano et al., 2001). Cardiac function was also not preserved, likely due to a decrease in 
microvessel recruitment in the absence of myocardial VEGF (Giordano et al., 2001). Embryonic 
lethality was observed in mouse embryos in which the VEGF allele was ablated, due to defective 
angiogenesis and vessel formation (Ferrara et al., 1996).  
 
VEGF signal transduction can be regulated by the co-receptors heparin sulphate proteoglycan 
(HSPG) and Neuropilin (Olsson et al., 2006). VEGFs display varying affinities for Heparin and 
HSPGs and their activity can be modulated by exposure to both these molecules at different 
concentrations. The mechanism of regulation varies, from presenting the ligand to its receptor, 
stabilizing the ligand-receptor complex, preserving ligand integrity as well as sequestering VEGFs 
at the cell surface or within the matrix to render them unavailable for interaction with VEGFRs or 
their co-receptors (Robinson and Stringer, 2001). VEGFs also bind to Neuropilins 1 and 2, which 
are expressed on endothelial cells. Nrp-1 binds VEGF-A with high affinity (Parker et al., 2012) and 
potentiates its interaction with VEGFR-2, playing a role in VEGF-A-induced signaling. The VEGF-
A-Nrp-1 complex has also been shown to induce endothelial cell migration (Wang et al., 2003, 
Herzog et al., 2011). Neuropilin-2, which is co-expressed with VEGFR-3, may function as a co-
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receptor for VEGF-C (Karkkainen et al., 2001), enhance VEGF-C activity and also be essential for 
the formation of small lymphatic vessels and capillaries (Yuan et al., 2002). 
 
The PDGF family comprises PDGF-A, PGDF-B, PGDF-C and PGDF-D. These exist either as 
homodimers, or the heterodimer PGDF-AB. They bind to their PGDF tyrosine kinase receptors 
(PDGFR) PDGFR- αα, PDGFR-ββ and PDGFR-αβ (Kang et al., 2008). PDGFR- ββ binds PDGF-
BB and PDGF-AB, and PDGFR-αα binds all three PDGF isoforms. The interaction between 
PDGFR-αα and PDGF-AA is specifically via a PDGF-AA binding site located in the extracellular 
domain of its PDGF receptor (Heidaran et al., 1990). Thus, PDGF-BB can interact with both α and 
β receptors whereas PDGF-AA can interact with only PDGFR-αα (Heidaran et al., 1991). PDGF-
CC can bind PDGFR-αα and PDGFR- αβ (Cao et al., 2002). PDGFRs, like VEGFRs, dimerize 
upon binding of their PDGF ligands, leading to a cascade of events that ultimately result in the 
regulation of cell growth and migration.  
 
PDGFs have been shown to play a role in angiogenesis (Cao et al., 2002) but not specifically 
coronary angiogenesis. Epithelial and mesenchymal cells secrete PDGF-A, which may act as a 
mitogen that stimulates ventricular development and cardiomyocyte proliferation (Kang et al., 
2008). Both PDGF receptors are implicated in efficient EMT, upon which EPDCs give rise to 
fibroblasts and vascular smooth muscle cells (Mellgren et al., 2008, Smith et al., 2011).  PDFG-BB 
can stimulate proepicardial cells expressing smooth muscle markers to undergo EMT and 
subsequently commit to the coronary smooth muscle cell lineage. This differentiation is mediated 
through PDGFR-β (Lu et al., 2001). On the other hand, it has been shown that PDGFR-α plays an 
important role in the formation of cardiac fibroblasts (Smith et al., 2011). PDGFR-α signaling, and 
to a lesser extent PDGFR-β signaling, is involved in the migration and functioning of cardiac neural 
crest cells (Van den Akker et al., 2008). PDGFR-α has been shown to influence correct atrial and 
ventricular septation along with outflow tract formation (Van den Akker et al., 2008). 
 
The IGFs share molecular similarity with insulin. There exist 2 IGF ligands, IGF-1 and IGF-2, 
which bind to the IGF-1R and IGF-2R receptors. Due to their sequence homology with insulin, they 
also bind the insulin receptor. The IGF receptor is a heterotetramer, with the 2 extracellular α 
subunits participating in ligand binding and the 2 intracellular β subunits possessing tyrosine kinase 
activity (Laustsen et al., 2007). Binding of IGF to its receptor triggers a signalling cascade that 
ultimately regulates cell growth, proliferation and apoptosis.  
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IGFs have been implicated as epicardial mitogentic factors functioning in a paracrine manner; IGF-
2 has been shown to be secreted from the epicardium and exert a mitogenic effect on the formation 
of the compact myocardium (Li et al., 2011). It has been shown by Hertig and colleagues that IGF-1 
and neuregulin-1 act in synergy to stimulate the morphogenesis of cardiac chambers. This occurs 
via the phosphatidylinositol 3-kinase (PI 3-K) pathway; inhibiting PI 3-K by Wortmannin results in 
the suppression of IGF-1 and NRG-1-induced Deoxyribonucleic acid (DNA) synthesis during 
ventricular chamber and cushion development (Hertig et al., 1999).  
 
IGFBPs can be divided into 2 groups based on the level of affinity for IGF-1 and IGF-2. IGFBP-
related Proteins (IGFBP-rP) 1-10 bind to IGFs with low affinity and IGFBPs 1-6 bind to IGFs with 
high affinity (Sun et al., 2011).The action of IGFBPs can be local, where they exert paracrine and 
autocrine control over regulating IGF function and signal transduction, or systemic, where there 
exists an endocrine control over IGFs in circulation (Yamada and Lee, 2009). IGFBPs consist of N-
terminal and the C-terminal domains connected by a ‘hinge’ region in the middle. Both the N- and 
the C- terminals are essential for IGF binding. The limiting factor in the interaction between IGFs 
and IGFBPs seems to be the first 16 amino acids of the N-Terminal region of the IGFs (Bayne et 
al., 1988). IGFBPs regulate the availability of IGFs as well as reduce their activity by sequestering 
them so they cannot bind to and activate IGF receptors. They prolong the half-life of IGFs and are 
also vehicles for IGF trafficking.  
 
In the later stages of heart development, IGFBP-4 interacts with the G-protein-coupled-receptor 
Frizzled, and coreceptor low-density lipoprotein receptor-related protein 6 and prevents Wnt-
Receptor binding, thus promoting cardiogenesis by stimulating cardiomyocyte differentiation (Zhu 
et al., 2008). It has been demonstrated by Tamura et al that the expression and action of VEGFs in 
vascular endothelial cells is disturbed in the presence of IGFBP-rP1 (also called IGFBP-7 due to 
high sequence similarity to the IGFBPs) (Tamura et al., 2009). Contrastingly, IGFBP-3 has been 
shown to exert a pro-angiogenic effect on endothelial cells by upregulating VEGF (Granata R et al, 
2007). The C-terminal of IGFBPs 1 and 2 contains an RGD motif for integrin binding (Jones et al., 
1993). This may subsequently facilitate interactions with the extracellular matrix, via cell-surface 
integrins. Indeed, IGFBP-1 binds to the α5β1 integrin and stimulates cell migration in certain cells, 
thus exerting an IGF-independent effect (Jones et al., 1993, Gleeson et al., 2001). IGFBP-3 has also 
been shown to function in an IGF-independent manner by binding to the TGFβ type V receptor and 
inhibiting cellular growth (Leal et al., 1997). 
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Members of the Wnt family are glycoproteins involved in diverse cellular processes. There exist 
two categories of Wnt signalling based on the complex morphological changes mediated – the 
canonical pathway mediated by the Wnt1 group and the non-canonical pathway mediated by the 
Wnt5a group (Eisenberg and Eisenberg, 2006). An exquisite balance exists between activating and 
repressing canonical Wnt/β-Catenin and non-canonical Wnt signalling in the various stages of 
cardiogenesis. 
 
Wnt1/ Wnt3a bind to the 7-transmembrane-domain receptor Frizzled, and along with its co-
receptors result in the inhibition of GSK-3β kinase activity, a decrease in β-Catenin 
phosphorylation, and a concomitant increase in the amount of intracellular β-Catenin (the primary 
mediator of the canonical pathway). This in turn is required for the activation of T-cell 
Transcription Factor (TCF) and Lymphoid Enhancing Factor (LEF), which act upon target genes 
such as cyclinD1 to regulate cell cycle progression (Giles et al., 2003, Pal and Khanna, 2006). 
Canonical signalling promotes gastrulation and mesoderm formation before the cardiac fields form, 
as well as the expression of genes involved in early cardiac specification, but the inhibition of this 
signalling is required during the later stages of cardiogenesis (Zhu et al., 2008, Ueno et al., 2007). 
The canonical pathway also influences the correct migration of cardiac neural crest cells and their 
proliferation, the failure of which causes defects in outflow tract septation and endocardial cushion 
formation. In an elegant study, Zamora and colleagues have shown that β-Catenin is involved in 
formation of the subepicardial space, epicardium-derived cell invasion of the myocardium, as well 
as the differentiation of epicardial progenitors to form coronary smooth muscle cells (Zamora et al., 
2007). Correspondingly, the compact myocardium in these mice lacking β-Catenin is also thin, 
likely due to a reduction in proliferation of cardiomyocytes (Zamora et al., 2007). Isl-1 and FGF-10 
are expressed by progenitor cells of the anterior heart field (Cai et al., 2003, Cohen et al., 2007). Isl-
1 has been shown to be essential in the formation and development of the outflow tract, right 
ventricle and atria (Cai et al., 2003). In the absence of β-Catenin signalling, the expression of FGF-
10 is reduced, leading to a decrease in the expression of Isl-1 by AHF cells. This ultimately leads to 
impaired right heart morphogenesis (Cohen et al., 2007). Both Wnts and Wnt receptors are also 
expressed in abundance by endothelial cells, and Wnt signalling has been implicated in 
angiogenesis and vascular development (Cai et al., 2003).  
 
Crescent and Dickkopf proteins are inhibitors of Canonical Wnt signalling (Brott and Sokol, 2005, 
Schneider and Mercola, 2001). Secreted frizzled-related proteins (sFRPs) compete with Wnts to 
bind the frizzled receptor, in another mechanism of canonical Wnt/β-Catenin inhibition (Eisenberg 
and Eisenberg, 2006). In the planar cell polarity pathway (a part of non-canonical Wnt signalling), 
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Wnt5a/ Wnt11 bind the Frizzled receptor and via RhoA and Rac, effect cell growth, proliferation, 
migration and polarity. The Wnt5a group is implicated in exerting an inhibitory effect on the Wnt1 
group (Eisenberg and Eisenberg, 2006), in conjunction with the above mentioned repressors 
Crescent and Dickkopf, thus promoting cardiac development. Wnt11 and Wnt7a are differentially 
expressed in specific cardiac conduction tissues (Bond et al., 2003). Wnt11, in an autocrine or 
paracrine manner, may stimulate the recruitment of myocytes to differentiate into conduction cells.  
Wnt7 seems to be expressed at the same time as connexin40, a cardiac conduction marker 
expressed in the ventricular conduction system, and may serve to modulate its function (Bond et al., 
2003) A direct association is observed between GATA transcription factors and the expression of 
the Wnt11 gene; inhibiting the expression of both GATA4 and GATA6 resulted in a marked change 
(reduction) in the levels of Wnt11 expressed, thus confirming that Wnt11 functions downstream of 
GATA factors to effect cardiogenesis (Afouda et al., 2008). 
 
Cooperative interaction between growth factors directs development of the epicardium, 
myocardium, and coronary vasculature. 
During the early stages of heart development, there is significant crosstalk between the inner groove 
of the AV myocardium, that expresses BMPs, and proepicardial cells, which express BMPRs (Ishii 
et al., 2010). The extracellular matrix bridge contains matrix molecules like HSPGs and fibronectin 
(Nahirney et al., 2003); the former having the ability to interact with BMPs. Predictably, the 
experimental mis-expression of Noggin in the myocardium before proepicardial protrusion and 
migration impairs the attachment of proepicardial cells to the myocardium, possibly by interfering 
with proepicardial expression of signaling molecules (BMPs in particular) or adhesion factors (Ishii 
et al., 2010). The closeness of the liver bud to the proepicardial organ may provide an inductive cue 
for the expression of proepicardial marker genes such as Wt1, Capsulin and Tbx18 (Ishii et al., 
2007). In addition, the regulation of Tbx18 by BMP4, Dkk1 and Noggin, and that of Wt1 by 
Noggin and Wnt3a, along with the role played by BMPs and FGFs, reveals that other paracrine 
factors are also involved in proepicardial induction and differentiation (Ishii et al., 2007). Co-
operative interaction between FGFs and BMPs possibly mediates the differentiation of 
proepicardial cells into myocardial or epicardial lineages (Kruithof et al., 2006). 
 
The subepicardial space also contains EPDCs (Pérez-Pomares et al., 1997, Dettman et al., 1998, 
Gittenberger-de Groot et al., 1998) and ECM proteins secreted by both epicardium and myocardium 
(Bouchey et al., 1996). Furthermore, it includes FGFs and VEGFs (Tomanek and Zheng, 2002) and 
BMPs (Yamagishi et al., 1999). FGF signaling from the epicardium to the myocardium and back 
may play a role in inducing EMT and in myocardial proliferation; moreover, FGFR1 signalling has 
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been implicated in the invasion of the myocardium by EPDCs (Pennisi and Mikawa, 2009). Cross-
talk between the epicardium, subepicardium and myocardium is also essential in coronary and 
coronary vascular development (Kang and Sucov, 2005). Overexpression of FGFR1 in the 
proepicardium resulted in propelling EPDCs to the endothelial cell lineage (Pennisi and Mikawa, 
2009). Furthermore, FGF-2 and VEGF may function cooperatively in order to simulate coronary 
vasculogenesis. Taken together, it is evident that multiple factors acting in tandem contribute to 
cardiogenesis in the developing embryo.   
 
CRIM1 
One such unique factor that could be at the nexus of growth factor signalling within the heart is 
Crim1. Crim1 is a novel transmembrane protein coded for by the Crim1 gene (Kolle et al., 2000, 
Glienke et al., 2002). Genes encoding CRIM1are evolutionarily conserved in vertebrates – this 
includes both humans and rodents (Kolle et al., 2000), the chicken (Kolle et al., 2003), zebrafish 
(Kinna et al., 2006) and Xenopus laevis(Ponferrada et al., 2012). In the nematode Caenorhabditis 
elegans, a Crim1 homolog called crm-1 has been found, although studies on its function are limited 
(Fung et al., 2007). Northern blot analyses initially revealed strong CRIM1 expression in the 
placenta, kidney, heart and skeletal muscle (Glienke et al., 2002). Further investigations using 
different transgenic models have revealed that this expression is defined and tightly regulated in the 
limbs, kidney, brain, spinal cord, lens, and vasculature (Kolle et al., 2000, Lovicu et al., 2000, Kolle 
et al., 2003, Pennisi et al., 2007, Fan et al., 2014, Phua et al., 2012, Glienke et al., 2002).  
 
 
Figure 1.5: Schematic representation of the domain structure of CRIM1. 
CRIM1 possesses different domains such as 6 CRRs, an IGFBP-like domain, an RGD motif, an antistasin domain in the 
extracellular region. Adapted from original created by Dr. David Pennisi. 
 
Structurally, the presence of six CRR motifs, an IGF Binding Protein like domain and an RGD 
motif (Kolle et al., 2000)(Figure 1.5) suggest Crim1 to be a versatile molecule, and while the CRRs 
have been shown to mediate the binding of Crim1 to TGFβ, BMP, VEGF and PDGF when Crim1 is 
co-expressed in the same cell as the growth factor (Wilkinson et al., 2003, Wilkinson et al., 2007), 
the functional significance of the IGFBP domain and the RGD motif remain unknown. The 
localization of Crim1 is also exciting – it has been found in the golgi and endoplasmic reticulum, 
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where proteins are modified post-translationally, and on the cell surface, where ligand-receptor 
interactions take place (Glienke et al., 2002, Wilkinson et al., 2003). 
 
During development, the regulation of growth factor signalling is crucial, and proteins that can 
modulate the effect of growth factor activity have received much attention. This can occur by 
sequestering the growth factors and increasing their half-life, or tethering them so that they cannot 
bind their receptors. Conversely, they can also present growth factors to their receptors and increase 
downstream signalling, or, compete with receptors and hinder growth factor-receptor interactions, 
thereby decreasing downstream signalling. Diffusible growth factor-binding proteins can 
additionally act as facilitators of growth factor transport across cells through the extracellular space, 
which can cause changes in growth factor gradients resulting in either their positive or negative 
regulation (Umulis et al., 2009a). For example, proteins containing multiple cysteine-rich repeats 
such as chordin and noggin, are known to have antagonistic effects on BMP signal transduction. In 
case of the former, it binds BMPs directly (Larraín et al., 2000), and the latter, by masking binding 
sites on the receptor, prevents BMP binding to type I and type II cell surface BMPRs (Zimmerman 
et al., 1996, Groppe et al., 2002). Crossveinless-2, however, enhances BMP signaling by reducing 
the affinity of chordin for BMP and thus allowing downstream signal transduction to take place 
(Zhang et al., 2010). It is important to note, though, that whether these regulatory molecules are 
agnostic or otherwise, depends on their developmental context. This is exemplified in studies 
performed on mice lacking Crim1, which indicate that this protein can act as both an agonist and an 
antagonist during organogenesis.  
 
To further explore its specific role in development, Crim1
FLOX
, a conditional loss-of-function allele 
was generated, by flanking exons 3 and 4 of Crim1 with LoxP sites (Chiu et al., 2012). The 
Crim1
FLOX
 line, when crossed with the CMV-Cre deletor line, generated Crim1
Δflox
 mice, 
intercrosses from which produced Crim1
Δflox/Δflox
mutants (Chiu et al., 2012). Similarly, a genetrap 
line was also created by inserting a β-geo cassette into intron 1 of Crim1, creating a non-functional 
hypomorph (Pennisi et al., 2007). We have described perinatal lethality in mice homozygous for the 
Crim1
KST264
genetrap and embryonic lethality in Crim1
∆flox
 null alleles (Pennisi et al., 2007, Chiu et 
al., 2012). These mice display defects in several organ systems (Glienke et al., 2002, Pennisi et al., 
2007, Lovicu et al., 2000, Phua et al., 2012, Fan et al., 2014), which further substantiates the 
significance of Crim1 during development.  
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The role of Crim1 in organogenesis. 
Numerous studies in the past decade have taken us closer to understanding the role of Crim1 in 
organogenesis, by first mapping its expression patterns, and then analysing its roles in different 
organ systems. A summary of these findings is outlined below. 
 
Kidney. 
The role of Crim1 in the kidney has been studied extensively. In the mouse kidney, during 
development, Crim1 expression is observed in smooth muscle cells lining the endothelium, within 
parietal epithelial cells, mesangial cells and glomerular podocytes from 15 days post coitum 
(dpc)(Pennisi et al., 2007, Georgas et al., 2000, Wilkinson et al., 2007). At the same age, analysis of 
kidneys from Crim1
KST264/KST264 
mice revealed smaller kidneys compared to their wild type 
littermates, suggesting that Crim1 plays a role in nephrogenesis (Pennisi et al., 2007). Glomerular 
lesions and capillary defects, along with podocyte effacement, were also observed in 
Crim1
KST264/KST264 
mice (Wilkinson et al., 2007). Crim1 is also expressed alongside VEGF-A in 
renal glomerular podocytes. When Crim1 was ablated, VEGF-A diffusion away from the podocytes 
leading to a disruption in the VEGF-A gradient was demonstrated, with a corresponding activation 
of the VEGF-A receptor Flk1 in adjacent vascular endothelial cells (Wilkinson et al., 2007).  This 
indicates that Crim1 can modulate VEGF-A signalling by regulating the delivery of VEGF-A to 
endothelial cells within the glomerulus (Wilkinson et al., 2007).  
 
Renal abnormalities have also been observed in the adult kidney. By using Crim1
KST264/KST264
 
outbred mice, which show survival of a small number of homozygous mutants, renal defects such as 
multiple glomerular cysts, interstitial fibrosis and endothelial cell thickening were revealed 
(Wilkinson et al., 2007). Another study showed that endothelial anomalies, including a 
discontinuous endothelium with aberrant deposition of collagen, and an increase in vascular 
permeability, exist in Crim1
KST264/KST264
 adult mice, along with renal fibrosis (Phua et al., 2012). 
This is posited to be due to an association of Crim1 and TGFβ-1, which enhances EndoMT (Kim et 
al., 2001, Varga and Wrana, 2005, Phua et al., 2012). CRIM1 expression has also been 
demonstrated in the glomerular podocytes of the adult human kidney, as seen in vivo by performing 
immunohistochemical experiments on renal tissue (Nyström et al., 2009). BMPs and VEGFs are 
also expressed in this location (Godin et al., 1999, Simon et al., 1995), suggesting that CRIM1 
could regulate the activity of these growth factors by sequestering them and controlling their release 
into the local environment (Nyström et al., 2009). 
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Placenta. 
An organ that is crucial during embryogenesis is the placenta. Placental development ensues after 
implantation, and consists of syncytiotrophoblast cells from the labyrinthine zone and 
spongiotrophoblast cells and glycogen trophoblast cells from the junctional zone. In murine models, 
Crim1 expression is observed in multiple placental cell types at different stages – at 9.5 dpc in 
chorionic trophoblasts, at 13.5 dpc and 15.5 dpc in syncytiotrophoblasts, and at 13.5 dpc in 
spongiotrophoblasts (Pennisi et al., 2012). In mice lacking Crim1, placental development is 
hindered; the size of the placenta is reduced from 13.5 dpc until 17.5 dpc, along with a decrease in 
the size of Crim1
KST264/KST264
 homozygous embryos themselves (Pennisi et al., 2012). Sinusoidal 
trophoblast cell endowment in reduced, and the number of glycogen cells is increased, in 
Crim1KST264/KST264 placentae at 15.5 dpc, possibly due to aberrations in growth factor signalling 
(Pennisi et al., 2012), including pathways such as such as the IGF and VEGF pathways (Randhawa 
and Cohen, 2005, Charnock-Jones et al., 1994). 
 
Lens and retinal vasculature. 
Crim1 expression in the developing eye is observed from 9.5 dpc until at least day 21 postnatally 
(P) 21 (Lovicu et al., 2000). It starts in the lens placode, the precursor to the lens, and proceeds, by 
11.5 dpc, to all lens cells. . Crim1 transcripts have also been observed in the corneal epithelium and 
endothelium by 15.5 dpc, and even later at 18.5 dpc in the retinal epithelium and retinal ganglion 
cells, until P21, when Crim1 is expressed only in the lens (Lovicu et al., 2000). In 
Crim1
glcr11
(glaucoma relevant 11) mutants, aptly named to describe their glaucoma and cataract 
phenotype, lens defects are observed from 16.5 dpc. These include junctional aberrations due to cell 
adhesion defects, abnormalities in polarity and a decrease in the number of lens epithelial cells that 
can proliferate, which ultimately results in a smaller, irregular lens (Zhang et al., 2016). True to 
their name, lens cataracts and atypical cell proliferation within the retina are also displayed by 
Crim1
glcr11
 mutant mice by P60. Defects in cell adhesion in these mutants is likely due to an 
interaction between Crim1 and β1 integrin, both of which are expressed in lens epithelial cells and 
lens fiber cells (Zhang et al., 2016). Further analysis revealed that Crim1 can indeed affect the 
phosphorylation of focal adhesion kinase (FAK) and ERK, downstream effectors of the β1 integrin 
signalling pathway, and ultimately results in membrane-bound Crim1 regulating lens 
morphogenesis (Zhang et al., 2016). 
 
In vascular endothelial cells, Crim1 expression is observed, both in vivo and in vitro (Glienke et al., 
2002). Its role in vascular development has been analysed in postnatal mouse retinas (Fan et al., 
2014). This has been made possible by employing Pdgfrb-iCreER mice and crossing them with the 
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Crim1
Flox
 allele, so as to enable inducible deletion of Crim1 specifically from endothelial cells of 
the vasculature (Fan et al., 2014). This resulted in defective retinal vascular development, and 
includes aberrations such as reduced vessel density and branching, as well as vessel regression 
visible in the first week of postnatal development (Fan et al., 2014). As previously mentioned, 
VEGF-A plays an important role in endothelial cell development, and indeed, analysis of VEGF-A 
and Crim1 mutants revealed angiogenesis defects and reduced expansion of the vasculature that was 
more severe in double mutants compared to individual knockouts, indicating that Crim1 and VEGF 
function along similar pathways during the development of the retinal vasculature (Fan et al., 2014). 
Furthermore, loss of Crim1 also resulted in abnormal VE-cadherin distribution at junctions of cells 
at the angiogenic front (Fan et al., 2014). This is congruent with endothelial tube formation defects 
observed in CRIM1-deficient HUVECs (Glienke et al., 2002), and indicates a cell adhesion 
anomaly in the absence of CRIM1. Interestingly, the cytoplasmic domain of CRIM1 has been 
shown to interact indirectly with β-catenin and N-cadherin in Xenopus(Ponferrada et al., 2012), and 
the RGD domain has been implicated in integrin signalling in the murine lens (Zhang et al., 2016). 
 
Nervous system. 
During the development of the murine spinal cord, Crim1 expression is observed in the floor plate 
from 9.5 dpc, and in motor neurons at later stages (Kolle et al., 2000). Crim1 is also expressed in 
the forebrain and hindbrain from 11.5dpc, and in the midbrain at 13.5 dpc (Kolle et al., 2000). 
However, how Crim1 affects the formation and development of the nervous system is still 
unknown. Insights from Crim1 function in cell adhesion and polarity, arising from cooperative 
interaction between Crim1 and β1 integrins at the leading edges of lens epithelial cell projections 
could assist in our understanding neural development, as both cell adhesion and polarity are crucial 
in neural stem cell differentiation within the embryonic brain. 
 
Crim1 in heart development? 
The heart expresses high levels of Crim1, but its role in cardiac development has not yet been 
examined in detail. There is evidence of Crim1 expression, owing to studies using the Crim1
KST264
 
genetrap line, in the mouse proepicardium at 9.5 dpc, and the epicardium at all stages of 
development. In the later stages, strong Crim1 expression is also observed in coronary vascular 
smooth muscle cells, and also in coronary vascular endothelial cells, albeit at lower levels (Pennisi 
et al., 2007). Many epicardium-derived growth factors are also required for the development of the 
myocardium, along with other aspects of heart development. Much like its role in nervous system 
development, little is known about the signals that Crim1 could modulate during cardiac 
development. With its dynamic expression in different organs, Crim1 appears to be central in 
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governing key developmental processes, in a cell-autonomous manner as well as through regulation 
of paracrine factors and controlling the availability of growth factors to adjacent tissues. 
Identification of such signalling pathways will provide much insight into the complex role of Crim1 
during heart development. The presence of six cysteine-rich repeats, the IGFBP-like domain and the 
RGD motif, alongside an intracellular domain whose biological significance has not been fully 
explored, renders Crim1 to be a multifaceted protein with the potential to modulate the activity of 
several growth factors, thus laying the foundation of my project. 
 
 
 
Figure 1.6: Schematic representation of the established and potential roles of Crim1. 
Some potential functions of Crim1 in the context of development include tethering growth factors to the cell surface, 
presenting them to their receptors, affecting the production of growth factors and their delivery to the cell surface for 
signalling or secretion. 
 
 
As such, we hypothesize that Crim1 plays both cell-autonomous and paracrine roles in epicardial 
and compact myocardial development within the nascent embryo via possible mechanisms as 
indicated in Figure 1.6. Furthermore, we postulate that coronary vasculature development and 
homeostasis is dependent on Crim1 function. We also hypothesize that a number of the functions 
mediated by Crim1 are dependent on its ability to bind growth factors and modulate their signalling. 
Finally, we posit that Crim1 can bind IGFs, likely via its IGFBP domain, and regulate downstream 
signalling. 
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Overall aim: To investigate the role of Crim1 in cardiac development 
 
Aim 1: Examining the cell-autonomous and paracrine roles of Crim1 in the 
epicardium and compact myocardium. 
 
Aim 2: Examining the cell-autonomous role of Crim1 in the coronary 
vasculature, specifically in endothelial cells, and growth factor signalling 
perturbed upon loss of Crim1 function. 
 
Aim 3: Investigating whether the IGFBP domain of Crim1 can serve to bind 
IGFs and modulate downstream signalling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
Materials and general methods  
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Ethics Statement. 
This study conformed to The University of Queensland’s Animal Welfare Unit guidelines for 
animal use in research (AEC approval numbers: AIBN/274/08/NHMRC, SMBS/420/11/NHMRC), 
and followed the National Institutes of Health Guide for the Care and Use of Animals and the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. All 
experimental protocols were approved by The University of Queensland’s Animal Ethics Unit. 
 
Mouse Lines. 
The mouse lines used in this study were the Crim1
FLOX
 conditional mutant (Chiu et al., 2012), 
Crim1
∆flox
 conditional null (Chiu et al., 2012), and Crim1
KST264
genetrap line (Pennisi et al., 2007), 
ROSA26 Cre-reporter line (R26R) (Soriano, 1999), WT1-Cre line (Wilm et al., 2005), WT1-
CreERT2 line (Zhou and Pu, 2012), Mlc2v-Cre line (Chen et al., 1998) and Tie2-Cre line(Koni et 
al., 2001, Kisanuki et al., 2001). The Crim1
KST264
 mouse line was created as part of a genetrap 
screen (Leighton et al., 2001), resulting from insertion of a β-Geo cassette into intron 1 of Crim1, 
thereby resulting in the fusion of exon 1 and the β-Geo cassette within the Crim1 transcript, but 
creating a hypomorph with the expression of a minor, alternately spliced isoform of Crim1, instead 
of a complete null (Pennisi et al., 2007). The Crim1 conditional knockout mouse line, Crim1
FLOX
 
was generatedby flanking exons 3 and 4 with unidirectional LoxP sites (Chiu et al., 2012). These 
Crim1
FLOX
 mice were crossed with a deletor line containing the ubiquitously expressed CMV-Cre to 
create the Crim1
Δflox 
line (Chiu et al. 2012). All lines were maintained on a C57Bl6 genetic 
background. 
 
Animal Breeding. 
Embryos were obtained from timed matings between Crim1
+/Δflox
intercrosses, 
Crim1
+/KST264
 intercrosses, or Crim1
FLOX/FLOX
;R26R females mated with Crim1
+/FLOX
; WT1-
Cre, Crim1
+/FLOX
; +/WT1-CreERT2 or Crim1
+/FLOX
; Mlc2v-Cre males. 
 
Sample collection. 
Pregnant mice were sacrificed by cervical dislocation and dissected in order to obtain embryo and 
heart samples at appropriate embryonic (E) stages. Embryos were also staged according to 
published compendia (Theiler, 1989) by assessing morphological landmarks visible under the 
dissecting microscope. For all embryos, a small tail-tip sample was collected for genotyping. 
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Genotyping. 
Genotyping was performed according to published methods (Chiu et al., 2012). Tail-tip samples 
were immersed in 50 μL of DNA QuickExtract (Epicentre, EPQE09050), given a strong vortex and 
a brief centrifugation. Samples were placed in a heating block at 65°C for 20 minutes, after which 
they were vortexed again and centrifuged. The samples were then placed in a heating block at 98°C 
for 10 minutes and subsequently diluted with 150μL ultrapure water. Polymerase Chain Reactions 
(PCR) comprised 0.4mM primers, 2μLgDNA, and 0.15μLTaq-polymerase (BioLine) made up to 
25μL with PCR myTaq red buffer (BioLine) and ultrapure water. PCR amplicons were detected 
using standard gel electrophoresis, with 1.5% agarose gels.  
 
Primer pairs for genotyping 5’ – 3’ sequence Amplicon (size) 
F2 (forward) + B3 (reverse) F2: 
TTCTTGGGTTCACAGTTAGTCC 
B3: AATGGAATCTTCAGGGCAAC 
389bp (wild-type allele)  
471bp 
(Crim1
FLOX
allele) 
F2 (forward) + CKO (reverse) F2: 
TTCTTGGGTTCACAGTTAGTCC 
CKO: 
CTCTGAAGGTCATCAACAGC 
~600 bp 
Cre (forward + reverse) Cre-For: 
CCTGGAAAATGCTTCTGTCCG 
Cre-Rev: 
CAGGGTGTTATAAGCAATCCC 
~400bp 
LacZ (forward + reverse) LacZ-For: 
CAGCACATCCCCCTTTCGCC 
LacZ-Rev: 
CCAACGCAGCACCATCACCG 
~500bp 
Wt1-CreERT2 - Common, 
WT1-CreERT2 - Reverse 
Wt1-CreERT2 Common: 
ATCGCAGGAGCGGAGAAC  
Wt1-CreERT2 WT- Reverse: 
GAAGGGTCCGTAGCGACA  
Wt1-CreERT2 Cre: 
GCAAACGGACAGAAGCATTT 
192 bp and 400 bp 
Heterozygote 
(+/Wt1CreERT2) 
 
 
 
Polymerase Chain Reaction (PCR) cycling conditions: 
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The PCR cycle conditions used for F2/B3 and Cre genotyping were:  
Initial denaturation: 95°C for 5 minutes 
37 cycles of:  
Denaturation: 95°C for 30 seconds 
Annealing: 54°C for 30 seconds 
Extension: 72°C for 45 seconds 
Final extension: 72°C for 4 minutes 
Cooling: 4°C 
 
The PCR cycle conditions used for F2/CKOR genotyping were:  
Initial denaturation: 95°C for 5 minutes 
37 cycles of:  
Denaturation: 95°C for 30 seconds 
Annealing: 54°C for 30 seconds 
Extension: 72°C for 1 minute 
Final extension: 72°C for 4 minutes 
Cooling: 4°C 
 
The PCR cycle conditions used for LacZ genotyping were:  
Initial denaturation: 95°C for 5 minutes 
35 cycles of:  
Denaturation: 95°C for 30 seconds 
Annealing: 66°C for 30 seconds 
Extension: 72°C for 45 seconds 
Final extension: 72°C for 4 minutes 
Cooling: 4°C 
 
The PCR cycle conditions used for WT1-CreERT2 genotyping were:  
Initial denaturation: 95°C for 3 minutes 
36 cycles of:  
Denaturation: 94°C for 30 seconds 
Annealing: 51°C for 30 seconds 
Extension: 72°C for 45 seconds 
Final extension: 72°C for 4 minutes 
Cooling: 4°C 
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Figure 2.1: Schematic representation of the Crim1 alleles detected by genotyping. 
Black rectangles represent the coding regions of 17 exons that make up the fully functional wild-type Crim1 allele, and 
white rectangles represent the 5’ and 3’ untranslated regions (UTR). Arrows represent the location where the forward 
(F2) and reverse (B3, PGK, CKO) primers will amplify. The F2/B3 primer pair will detect and amplify the Crim1 WT 
and FLOX sequences. The Crim1
FLOX
 allele has the addition of LoxP sites (red triangles). These are the recognition 
sites for Crerecombinase. Note the removal of exons 3 and 4 in the subsequent Crim1
∆flox
. However the Crim1 
neomycin resistance cassette (blue rectangle) that was used as a selective marker during the initial generation of these 
mice, is retained in Crim1
∆flox 
alleles. The removal of the neomycin cassette via FLPe recombination at the FRT sites 
(green ovals) has allowed for the generation of the Crim1
∆flox∆frt
 allele. The process of eliminating the neomycin cassette 
occurred during the progress of this project. Hence, data in this thesis has utilised both mouse strains. Schematic not 
drawn to scale. Image created by Renee Chand. 
 
Sample preparation. 
Embryonic hearts were dissected in Phosphate Buffered Saline (PBS) and fixed for 1-2 hours in 4% 
paraformaldehyde (PFA)/PBS at 4°C, washed in PBS, and photographed in whole-mount as 
required. Embryonic samples from the WT1-Cre, WT1-CreERT2 and Mlc2v-Cre (β-galactosidase 
activity being a readout of Cre activity based on the R26R reporter) and Crim1
+/KST264
 intercrosses 
(β-galactosidase activity being under the control of the endogenous Crim1 promoter) were X-Gal-
stained in whole-mount as previously described (Pennisi et al., 2007). The hearts were processed for 
paraffin or cryosectioning. For paraffin processing, hearts were dehydrated through a series of 
graded ethanol baths (70%, 80%, 90%, 95% 100% Ethanol), and then infiltrated with wax. They 
were subsequently embedded in wax blocks and 7 µm sections cut on a microtome. For obtaining 
cryosections, samples were washed in PBS, cryoprotected in 30% sucrose/PBS at 4 °C for 4-6hours, 
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embedded in Tissue-Tek
®O.C.T™ compound (Sakura Fine technical, Tokyo, Japan) and 10μm 
sections were cut on a cryostat and air-dried. Some X-Gal-stained sections were counterstained with 
nuclear fast red (NFR; Vector Laboratories), while others were subjected to immunohistochemical 
analyses as specified. 
 
Immunohistochemistry. 
For paraffin-embedded sections, samples were de-waxed by submerging in xylene baths twice for 5 
minutes, a series of graded ethanol (100%, 90%, 80%. 70%) once for 5 minutes each, and finally 
water for 5 minutes. They were then put through two PBS washes for 3 minutes each, one wash 
with PBS-TritonX 0.15% to permeabilize the sample for 3 minutes and three PBS washes for 5 
minutes. The slides were then outlined with a PAP pen, and treated with 0.3% hydrogen peroxide 
solution for 20 minutes to quench endogenous peroxidase activity. They were then washed in PBS 
three times for 5 minutes each, blocked with 5% Bovine Serum Albumin (BSA) for 1 hour at room 
temperature, and incubated in primary antibody (Ab) overnight at 4°C. The samples were washed 
again with PBS three times for 5 minutes each, incubated in secondary antibody for 1 hour at room 
temperature, and after three more PBS washes, subjected to 1% 3,3′-Diaminobenzidine (DAB) 
staining. Finally, the slides were subjected to ethanol washes (70%, 80%, 90%, 100%) for 3 
minutes, 2 washes in xylene for 5 minutes, and mounted with coverslips and DPX. For all 
immunohistochemical procedures, no-Ab and no-primary Ab controls were always included.  
 
Immunofluorescence. 
Cryosectioned samples were allowed to equilibrate to room temperature by air-drying, and put 
through two PBS washes for 3 minutes, one wash with 0.15% TritonX-PBS (PBS-Tx) for 3 
minutes, and two washes with PBS for 3 minutes, following which they were blocked in 5% BSA 
for 1 hour. They were then incubated with primary antibodies overnight at 4°C. They were then 
washed three times with PBS for 5 minutes, and incubated in secondary antibodies for 1 hour at 
room temperature. They were also incubated with 4',6-diamidino-2-phenylindole (DAPI) for 10 
minutes at room temperature, after which they were washed with PBS three times for 5 minutes, 
mounted in PBS-glycerol 50% and coverslips sealed with nail polish. For immunofluorescence 
procedures, no-Ab and no-1°Ab controls were always included.  
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Antibodies. 
PRIMARY ANTIBODY SPECIES SPECIFICITY DILUTION CATALOG # 
Phosphohistone H3 Rabbit Polyclonal 1:300 Millipore #06-570 
Cleaved Caspase 3 Rabbit Monoclonal 1:200 Cell Signalling 
#9664 
Phospho-AKT Rabbit Monoclonal 1:1000 Cell Signalling 
#4060 
Phospho-ERK1/2 Rabbit Monoclonal 1:200 (IF) 
1:2000 (WB) 
Cell Signalling 
#4370 
Phospho-SMAD1/5 Rabbit Monoclonal 1:100 Cell Signalling 
#9516 
Phospho-SMAD1/5 Rabbit Monoclonal 1:150 Thermo Fisher 
Scientific#700047 
Phospho-SMAD2 Rabbit  Polyclonal 1:300 Millipore AB3849 
Phospho-IGF-1R Rabbit Monoclonal 1:1000 Cell Signalling 
#3024S 
Total AKT Rabbit Polyclonal 1:1000 Cell Signalling 
#9272 
Total ERK 1/2 Rabbit Polyclonal 1:1000 Santa Cruz sc-93 
Total SMAD1/5/8/9 Rabbit  Polyclonal 1:1000 Novus 
BiologicalsNB100-
56656 
 
Total IGF-1R Rabbit  Polyclonal 1:1000 Santa Cruz, sc-712 
Smooth muscle α-actin Mouse Monoclonal 1:200 Santa Cruz, sc-3225 
β-catenin, whole antiserum Rabbit Wh. antiserum 1:300 Sigma Aldrich 
#C2206 
β-catenin (active) Mouse Monoclonal 1:100 Millipore #05-665 
SM22 alpha Rabbit Polyclonal 1:300 Abcam Ab14106 
Periostin Rabbit Polyclonal 1:200 Abcam Ab92460 
Wilms’ Tumor 1 Mouse Monoclonal  Dako #M3561 
CD31 (PECAM-1) Rat Monoclonal 1:300 BD Pharmingen 
#550274 
HA Tag Rabbit Monoclonal 1:1000 Cell Signalling 
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#3724 
Myc Tag Mouse Monoclonal 1:1000 (WB) 
1:1000 (IP) 
Cell Signalling 
#2276 
Angiogenesis Sampler Kit: 
Phospho-Akt (Ser473) 
Phospho-p44/42 MAPK 
(ERK1/2 Thr202/Tyr 204) 
Rabbit Multiple multiple Cell Signalling 
#8696 
Normal IgG Mouse  1:1000 Thermo Fisher 
Scientific 
#02-6200 
GAPDH Rabbit Monoclonal 1:10000 Cell Signalling 
#2118 
-tubulin Rabbit Polyclonal 1:10000 Cell Signalling 
#2146 
Crim1 Mouse Monoclonal 1:200 R&D Systems 
#253511 
Isolectin B4   1:100 Thermo Fisher 
Scientific 
#MP21410 
MF20 (supernatant) Mouse Monoclonal  Developmental 
Studies Hybridoma 
Bank 
 
 
SECONDARY ANTIBODY SPECIES DILUTION CATALOG # 
AlexaFluor 594 Rat 1:500 Thermo Fisher 
Scientific 
#A-21209 
 Mouse 1:500 Thermo Fisher 
Scientific#R3712
1 
 Rabbit 1:500 Thermo Fisher 
Scientific#R3711
7 
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AlexaFluor 488 Rat 1:500 Thermo Fisher 
Scientific#A-
21208 
 Mouse 1:500 Thermo Fisher 
Scientific#R3712
0 
 Rabbit 1:500 Thermo Fisher 
Scientific#R3711
6 
HRP conjugate Rabbit 1:500 (IHC) 
1:10000 (WB) 
Promega; 
#W4011 
 Mouse 1:500 (IHC) 
1:10000 (WB) 
Promega; 
#W4021 
Anti-rabbit Biotin Rabbit 1:500 Sigma; # B7389 
IgG mouse IRDYE Mouse 1:10000 Licor #926-32212 
IgG rabbit IRDYE Rabbit 1:10000 Licor #926-68073 
 
TSA plus Cyanine 3 system was used for signal amplification in the case of pERK1/2 and pAKT 
(PerkinElmer #NEL744001KT). The Vectastain Elite ABC kit (Standard) was also used (Vector 
Laboratories; #PK6100). 
 
Bacterial transformation. 
Stellar competent cells (PT 5505-2) were used for bacterial transformation. Briefly, cells were 
thawed on ice, and 5-15 ng DNA was added to 20 L competent cells in eppendorf tubes. The tubes 
were placed on ice for 30 minutes, following which the cells were heat-shocked at 42°C for 1 
minute. They were placed on ice for 2 minutes, after which 250 L SOC medium prewarmed to 
37°C was added to each tube. The cells were then incubated on a shaker for 30 minutes at 37°C, 
after which appropriate amounts of culture were plated on Luria agar plates (10 g Tryptone, 5 g 
Yeast extract, 10 g Sodium Chloride, 15 g Agar dissolved in 1 L dH20) containing Ampicillin, and 
incubated overnight at 37°C. 
 
Mini and Midi preps for plasmid DNA purification. 
LB broth (10 g Tryptone, 5 g Yeast extract, 10 g Sodium Chloride dissolved in 1 L dH20) was 
inoculated with bacteria containing plasmid of interest, and DNA purification was carried out 
according to manufacturers’ protocols (QiagenMiniprep, Machary Nagel Midiprep). 
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DNA Sequencing. 
The DNA to be sequenced (800-1000 ng) and each primer (0.64 µM) in a total volume of 12 µL 
were sent to Australian Genome Research Facility (AGRF, University of Queensland, QLD, 
Australia) for the ‘purified DNA’ sequencing service. 
 
Cell lines. 
H-CMVECs and pooled HUVECs (Lonza, CC-7030 and CC-2519) were cultured in EGM-2MV 
and EGM-2 BulletKit media respectively (Lonza, CC-3202 and CC-3162). HEK293 cells and 
Lenti-X cells (Kind gift from Dr. Aaron Smith) were cultured in Dulbecco's Modified Eagle 
Medium  (DMEM) media supplemented with Pen/Strep antibiotic and 10% FBS. All cell lines were 
maintained at 37°C in a humidified incubator containing 5% Carbon Dioxide (CO2). 
 
Immunoblotting. 
Protein Extraction  
Cells were scraped in radioimmunoprecipitation (RIPA) buffer (150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, 20 mMTris (pH8.0), 1 mM Na3VO4, 10mM Na4P2O7, 2 
mMEthylenediaminetetraacetic acid (EDTA) plus Complete EDTA-free protease inhibitor cocktail 
(Roche, Mannhein, Germany). Extracts were cleared by centrifugation at full speed for 10minutes 
at 4°C. Protein concentration was determined by bicinchoninic acid assay (BCA) (Pierce, IL, USA). 
 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS‐PAGE)  
Equal amounts of protein were incubated at 100°C for 5 minutes in sample buffer (2X - 0.125M 
Tris-hydrochloric acid HCl, pH 6.8, 4% SDS, 10% β-mercaptoethanol, 40% glycerol, 0.05% 
bromphenol blue), loaded into appropriate SDS-PAGE gels and separated by electrophoresis. 
Appropriate amounts of 40% acrylamide (BioRad, CA, USA), 1.5 M TrisHCl pH 8.0, 10% 
ammonium persulphate (APS), 10% SDS, N,N,N’-tetra-methylethylenediamine (TEMED (Roche)) 
and dH2O were used to prepare resolving gel mixes, which were then set in a Mini-PROTEAN® 
casting apparatus (BioRad). Isopropanol was overlaid onto the gel to ensure a straight interface. 
After polymerisation, the isopropanol was removed and stacking gel mix (40% Acrylamide, 05 M 
TrisHCl pH 6.8, 10% TEMED, 10% APS, dH20) was poured on top of the resolving gel, with a 
spacer comb inserted. Electrophoresis was performed in Mini-PROTEAN
®
 Tetra cell tanks 
(BioRad), in running buffer (TrisHCl, Glycine, 10% SDS, dH20) at 180 V for 1 hour. Precision 
Plus Protein™ Dual Color Standards (BioRad, CA, USA) was used as a size reference. 
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Electroblotting and Probing of Membranes  
After electrophoresis, gels were transferred onto PVDF membranes (Immobilon-Fl, Merck 
Millipore), set up in transfer tanks (BioRad, CA, USA) and run in transfer buffer (TrisHCl, Glycine, 
Methanol, dH20) at 90 V for 1.5 hours. Membranes were blocked with 5% BSA or 5% skim milk in 
Tris Buffered Saline (TBS) containing 0.1% Tween (TBS-T) for 2 hours at room temperature. Blots 
were probed by incubating with specific primary antibody diluted in blocking buffer overnight at 
4°C. Membranes were then washed with TBS-T thrice for 10 minutes, thrice. Blots were incubated 
with secondary antibody diluted in blocking buffer for 1-2 hours at room temperature. They were 
washed again and visualised either with a chemi-luminescent reagent (Merck Millipore) via 
exposure to X-ray film, or by using the Licor scanner. All densitometry quantitation was performed 
on immunoblots using ImageJ
®
 software. All test values were normalised to respective loading 
control and represented relative to experimental control and graphed with Prism 6. 
 
Stripping ofPolyvinylidene fluoride (PVDF) Membranes  
PVDF blots were stripped when required using Re-Blot Plus Mild Stripping Solution (Millipore, 
CA, USA) according to the manufacturer’s instructions and re-probed for other proteins of interest, 
or loading controls. Before re-blocking and re-probing, blots were washed with TBS-Tx for 10 
minutes. 
 
Data documentation and quantification. 
Bright-field images of tissue sections were captured using an Olympus BX-51 BF/DF slide 
microscope with Canon digital cameras with DP Controller software (Olympus). Whole-mount 
images were captured using either an Olympus SZX-12 stereo-microscope with DP Controller 
software, or a Zeiss Stemi 2000 stereo-microscope with an AxioCam digital camera with 
AxioVision software (Zeiss). Fluorescent images of tissue sections were captured on an Olympus 
IX-81 laser scanning confocal microscope and an Olympus FV1000 upright laser scanning confocal 
microscope with Olympus Fluoview software (Ver3.1a). Images were adjusted for colour levels, 
brightness and contrast, and figures compiled, using Adobe Photoshop software. The number of 
samples included in data averages is indicated in the figure legends where applicable, and 
quantification procedures are outlined in detail in individual chapters. 
 
Statistical analyses. 
Statistical significance between pooled data from mutant and control groups was determined using a 
two-tailed, unpaired Student’s t-test with or without Welch’s correction, a one-way ANOVA with 
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Dunnett’s post-test, a two-way ANOVA with Bonferroni’s post-test, or a Z test as specified in the 
figure legends. Quantified data shown are mean ± standard deviation. GraphPad Prism v6.0 was 
used to conduct all analyses and generate graphs. 
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Chapter 3 
 
 
Examining the cell-autonomous and paracrine roles of 
Crim1 in the epicardium and compact myocardium. 
 
 
 
 
 
 
 
 
 
The data contained in this chapter was published in the journal Scientific 
Reports in January 2016. 
 
 
Crim1 has cell-autonomous and paracrine roles during embryonic heart 
development. 
Iyer S, Chou FY, Wang R, Chiu HS, Raju VK, Little MH, Thomas WG, Piper 
M, Pennisi DJ. 
Sci Rep. 2016 Jan 29;6:19832. doi: 10.1038/srep19832. 
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Author Contributions: 
Figures 3.2, 3.4, 3.5H, 3.7, 3.10, 3.19C: complete experiments were performed by Dr. David 
Pennisi 
Figures 3.5A-G, 3.6:complete experiments were performed by Han Chiu and Dr David Pennisi 
Figures 3.8, 3.9, 3.25, 3.27, and handling of WTI1-CreERT2 mice, sectioning and staining in figure 
3.13: complete experiments were performed by Grace Chou (Honours student under supervision of 
Dr. David Pennisi) 
Figures 3.21, 3.22: complete experiments were performed by Richard Wang (Honours student 
under supervision of Dr. David Pennisi) 
 
These experiments were included in the thesis to allow a comprehensive story on the role of Crim1 
in embryonic heart development. 
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Introduction. 
The proepicardium supplies cells that migrate to and encompass the myocardium of the rudimentary 
heart as a single sheet known as the epicardium.  Epicardial cells, via a process called Epithelial to 
Mesenchymal Transition (EMT), give rise to cells of the coronary vasculature, cardiac fibroblasts 
and valve cells upon invading the myocardium, or reside in the subepicardium as subepicardial 
cells. This process requires the interplay of various factors that both promote and restrain epicardial 
EMT and invasion, including TGFs, BMPs, PDGFs, FGFs, Neurofibromin 1 (NF1) and Wilms 
Tumour 1 (WT1) (Morabito et al., 2001, Pennisi and Mikawa, 2009, Martínez-Estrada et al., 2010, 
Smith et al., 2011, Baek and Tallquist, 2012, Sánchez and Barnett, 2012). The myocardium is 
divided into two distinct components – the outer compact myocardium and the inner trabeculated 
myocardium, and complex morphogenetic patterning events both establish and regulate this 
process. Both the epicardium and the myocardium provide secreted factors that are essential not 
only to initiate an epicardial EMT and enable the process to reach completion, but also for 
myocardial growth, development and differentiation of epicardial lineages and the coronary 
vasculature. 
 
This dual role of the epicardium – to contribute epicardium-derived lineages as well as to provide 
regulatory signals required for the development of the myocardium, and the molecular factors that 
govern cardiogenesis, are not completely understood. There are a number of animal models that 
have been studied that either have an incompletely formed epicardium or lack the epicardium 
entirely, and all these animals display defects in myocardial development (Gittenberger-de Groot et 
al., 2000, Pennisi et al., 2003, Yang et al., 1995, Moore et al., 1999). For example, in avian 
embryos, when epicardium outgrowth was inhibited, it resulted in the formation of thin compact 
myocardium containing disorganized cardiomyocyte arrangement(Gittenberger-de Groot et al., 
2000). The compact myocardium developed normally in epicardium-rescue hearts (Gittenberger-de 
Groot et al., 2000), further corroborating a role for the epicardium in the formation of the 
myocardium. When epicardium formation was inhibited microsurgically by Pennisi and colleagues, 
again, the thickness of the compact myocardial zone was reduced, accompanied by a decrease in 
proliferation of cardiomyocytes (Pennisi et al., 2003). 
 
In another study using WT1 null mice, where the epicardium either did not form, or was present 
only partially, the ventricular myocardial wall was thin, and the number of EPDCs was greatly 
reduced, or completely absent (Moore et al., 1999). This corresponds to a failure of the correct 
development of the myocardium, as these EPDCs give rise to resident vascular smooth muscle cells 
of the ventricle (Moore et al., 1999), among other cell types. In embryos deficient in integrin 4, an 
 40 
epicardial cover overlying the myocardium was missing, and this was posited to lead to cardiac 
haemorrhage (Yang et al., 1995). Similarly, in the embryos of mice lacking Vascular Cell Adhesion 
Molecule-1 (VCAM-1), an epicardial sheath surrounding the myocardium was absent. Moreover, 
the myocardium itself showed aberrations such as reduced thickness and organization, when 
compared to control hearts (Kwee et al., 1995). Myocardial defects in observed in VCAM-1-
deficient embryos and blood leakage from the heart in integrin 4-deficient embryos could be a 
secondary pathology, directly related to abnormal epicardium formation. 
 
CRIM1 is important for the development of multiple organ systems including the kidney, eye and 
placenta. Interestingly, a study by Pennisi and colleagues in 2007 revealed that Crim1 is 
additionally expressed in the proepicardium as well as in the heart; in the epicardium, smooth 
muscle cells, the endothelium of coronary arteries and endocardial endothelial cells (Pennisi et al., 
2007). While this implies a role for Crim1 in cardiac development, its precise role is unknown and 
will be evaluated in this chapter. This chapter will focus on the epicardium, and subsequent 
myocardial development, as well as the cell-autonomous and paracrine roles Crim1 may play in 
regulating the development of the myocardium. 
 
Materials and Methods. 
Ethics Statement. 
Please refer to the Materials and General Methods chapter for the detailed ethics statement. 
 
Animal Breeding. 
The mouse lines used in this study were the Crim1
KST264
 line (Pennisi et al., 2007), 
Crim1
FLOX
conditional knock-out (Chiu et al., 2012), the Crim1
Δflox
line (Chiu et al., 2012), the 
ROSA26 Cre reporter line (R26R) (Soriano, 1999), the Mlc2v-Cre line (Chen et al., 1998)and the 
WT1-Cre and WT1-CreERT2 lines (Wilm et al., 2005, Zhou and Pu, 2012). 
Embryos were obtained from timed matings between Crim1
+/Δflox
intercrosses, 
Crim1
+/KST264
 intercrosses, or Crim1
FLOX/FLOX
; R26R females mated with Crim1
+/FLOX
; WT1-
Cre, Crim1
+/FLOX
; +/WT1-CreERT2 or Crim1
+/FLOX
; Mlc2v-Cre males. Timed matings were set up 
between Crim1
+/flox
; WT1-Cre males and Crim1
FLOX/FLOX
; R26R females to produce Crim1
+/FLOX
; 
WT1-Cre; R26R and Crim1
FLOX/FLOX
; WT1-Cre; R26R embryos collected at 15.5dpc (at this stage, 
the myocardium has expanded and cells derived from the epicardium have begun to differentiate 
into various lineages), Crim1
+/FLOX
; +/WT1-CreERT2 males and Crim1
FLOX/FLOX
; R26R females, for 
the production of Crim1
+/FLOX
; +/WT1-CreERT2; R26R and Crim1
FLOX/FLOX
; +/WT1-CreERT2;R26R 
embryos collected at 15.5dpc and 17.5dpc (at 17.5dpc, cells derived from the epicardium have 
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differentiated into cardiac fibroblasts, coronary vascular smooth muscle cells, and a small 
percentage of coronary vascular endothelial cells), and between Crim1
+/FLOX
; Mlc2v-Cre males and 
Crim1
FLOX/FLOX
; R26R females to produce Crim1
+/FLOX
; Mlc2v-Cre; R26R and Crim1
FLOX/FLOX
; 
Mlc2v-Cre; R26R embryos collected at 13.5dpc (at this stage, the myocardium has started to expand 
through proliferation of cardiomyocytes). The presence of a vaginal plug regarded as 0.5 dpc. 
 
Tamoxifen Administration. 
Tamoxifen (MP Biomedicals, 02156738) was dissolved in corn oil and 100% ethanol at a 
concentration of 20mg/ml in a 65ºC incubator for 1 hour. The suspension was vortexed thoroughly. 
Tamoxifen was stored at -30°C until use. At 9.5dpc and 10.5dpc, prior to embryo harvestation, 2mg 
tamoxifen per dose (Chong et al., 2011) was injected intraperitoneally to pregnant dams. 
 
Sample preparation. 
Embryonic hearts were dissected, photographed in whole-mount as required, and prepared by 
paraffin or cryoembedding and sectioning, for immunohistochemical analyses as detailed in the 
Materials and General Methods chapter. 
 
Scanning Electron Microscopy. 
13.5dpc embryos were collected from intercrosses of Crim1
+/∆flox
 mice, and the hearts were 
dissected and fixed in 2.5% glutaraldehyde in PBS for 1 hour at room temperature. Samples were 
washed three times with PBS and stored at 4°C until processing for scanning electron microscopy 
as described (Ashe et al., 2012), using a CM-500 Benchtop Scanning Electron Neoscope. 
 
Antibodies and Lectin. 
Primary antibodies/lectin used in the study were: rabbit polyclonal anti-phospho-Histone H3 
(PHH3) (pSer10; Millipore #06-570); rabbit monoclonal anti-cleaved caspase 3 (CC3) (activated 
caspase 3; Cell Signalling Technology #9664); rabbit monoclonal anti-phospho-AKT (pSer473; 
D9E; Cell Signalling Technology #4060); rabbit monoclonal anti-phospho-ERK1/2 
(pThr202/pTyr204; D13.14.4E; Cell Signalling Technology #4370); rabbit monoclonal anti-
phospho-SMAD1/5 (pSer463/pSer465; Thermo Fisher Scientific #700047); rabbit polyclonal anti-
phospho-SMAD2 (pSer465/pSer467; Millipore AB3849); mouse monoclonal anti-smooth muscle 
α-actin (clone 1A4, Santa Cruz Biotechnology, sc-3225); rabbit anti-β-catenin (whole antiserum; 
Sigma Aldrich #C2206); rabbit polyclonal SM22 alpha (Abcam Ab14106); rabbit polyclonal anti-
periostin (Abcam Ab92460); mouse monoclonal anti-Wilms‟ Tumor 1 (WT1; Dako #M3561); 
MF20 (supernatant, Developmental Studies Hybridoma Bank) and Isolectin B4 (Thermo Fisher 
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Scientific). Secondary antibodies for immunofluorescence experiments were Alexa Fluor-488, −594 
or −633-conjugated secondary antibodies (Thermo Fisher Scientific). TSA plus Cyanine 3 system 
was used for signal amplification in the case of pERK1/2 and pAKT (PerkinElmer 
#NEL744001KT) Secondary antibodies for immunohistochemistry experiments were anti-rabbit 
HRP (Promega; #W4011), anti-mouse HRP (Promega; #W4021), anti-rabbit biotin (Sigma; # 
B7389). The Vectastain Elite ABC kit (Standard) was also used (Vector Laboratories; #PK6100). 
 
Immunohistochemistry. 
Immunohistochemical analyses were performed as outlined in the Materials and General Methods 
section. For experiments that required the use of mouse antibodies, the mouse-on-mouse kit (Vector 
MOM kit; BMK 2202) was utilised. Sections were blocked with blocking reagent for 1 hour, after 
which they were primed with MOM diluent for 5 minutes. Primary and secondary antibodies were 
diluted in MOM diluent. Immunohistochemistry using PHH3 was performed and sections 
counterstained with 1% DAB followed by NFR staining. Immunohistochemistry to detect periostin 
used anti-rabbit biotin and Vectastain ABC as secondary and tertiary antibodies, respectively. 
Vectastain ABC reagents were prepared as per manufacturer‟s protocols. It was added for 30 
minutes at room temperature after incubation with anti-rabbit biotin, followed by hematoxylin 
staining. 
 
Immunofluorescence. 
Heat-induced antigen retrieval with 10 mM citrate buffer (pH 6.0) was used on paraffin sections for 
detection of cleaved caspase 3 and phospho-histone H3. Tyramide amplification was used for signal 
amplification of phospho-ERK1/2 and phospho-AKT and performed according to manufacturer‟s 
protocol. 
 
Primary Epicardial Explant Cultures and Migration Assays. 
11.5 dpc embryos were collected from intercrosses between Crim1
+/KST264
 mice. The ventricles were 
dissected from the rest of the heart in sterile PBS and cultured in DMEM supplemented with 10% 
FCS and penicillin/streptomycin in four-well tissue culture plates. The ventricular mass was 
removed upon epicardial outgrowth from the primary culture. The epicardial cells were then grown 
to confluence and were passaged once and plated at a high confluence. The primary epicardial cells 
were used in a modified Boyden chamber assay after further culturing for two days. Epicardial 
cultures were collected after trypsin treatment to completely dissociate cells, washed and 
resuspended in DMEM (with 10% FCS). 1,000 cells in identical volumes were placed in the upper 
chamber of 6.5 mm transwell culture inserts (polycarbonate filter, 5.0 µm pore size, Corning). After 
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16 hours of culture, the cells in the upper part of the transwell inserts were removed using a cotton 
swab. The cells that had migrated through the polycarbonate filter were quantified after fixation in 
4% PFA in PBS and staining with DAPI. Epicardial identity was confirmed after enrichment by 
immunofluorescence for the transcription factor WT-1 (Zhou and Pu, 2012, Rudat and Kispert, 
2012), using standard techniques as described (Pennisi and Mikawa, 2009). 
 
Cell culture and transfection. 
HEK293 cells were cultured in DMEM with 10% FBS and 0.1% Pen-Strep. Transfection was 
performed using Lipofectamine 2000 (Thermo Fisher Scientific) according to manufacturer‟s 
protocol.  
 
Protein Fragment Complementation Assay. 
This assay consists of a „bait‟ protein, „prey‟ protein and, incomplete fragments of a third protein 
which acts as the reporter. On their own, reporter fragments are incomplete. Interaction between 
„bait‟ and „prey‟ proteins bring the reporter fragments in close proximity, which allows for the 
formation of a functional reporter protein whose activity can be measured (Remy and Michnick, 
2003). When the Venus fluorescent protein is split into N-terminal (V1; amino acid residues 1-158) 
and C-terminal (V2; amino acid residues 159-239) amino acid fragments, neither displays 
fluorescence. However, when V1 and V2 are linked to 2 proteins that interact, it allows reformation 
of the Venus fragments and thus, fluorescence is generated (Porrello et al., 2011). Moreover, 
transient protein interactions can be identified, as once V1 and V2 recombine, they form a stable 
structure, thus capturing brief protein interactions.  
 
Figure 3.1: Representation of Protein Fragment Complementation Assay (PCA) 
Schematic representation of the PCA which consists of a „bait‟ protein, „prey‟ protein and, incomplete fragments of a 
third reporter protein. Reporter fragments are incomplete on their own; interaction between „bait‟ and „prey‟ proteins 
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bring the reporter fragments in close proximity, allowing for the formation of a functional reporter protein whose 
activity can be measured (Remy and Michnick, 2003). 
 
Leucine zipper transcription factors are well known to dimerize (Vinson et al., 2006). Zipper-V1 
and Zipper-V2 constructs, were used to optimize the Protein Fragment Complementation Assay. 
These, and a full-length CRIM1 plasmid, were used to generate CRIM1-V1 and CRIM1-V2 
constructs.  
 
To generate CRIM1 containing NOT1 and CLA1 sites, primers were designed as follows: 
NOT1-CRIM1 FOR- 5‟-AGCGGCCGCACCATGTACTTGGT-3 
CLA1-CRIM1 REV- 5‟-TTATCGATCACTGTTTGGTAGAAATTGTC-3‟ 
 
Phusion PCR was performed according to manufacturer‟s protocol, using full-length CRIM1 as a 
template. Cycling conditions were as follows: 
Initial denaturation: 98°C for 30 seconds 
30 cycles of:  
Denaturation: 98°C for 10 seconds 
Annealing: 69°C for 25 seconds 
Extension: 72°C for 1 minute 
Final extension: 72°C for 7 minutes 
Cooling: 4°C 
 
Zipper-V1 and Zipper-V2 were digested using Not1 and Cla1 restriction enzymes to release Zipper. 
All products were run on a gel to verify size, and then gel purified. A ligation using T4 DNA Ligase 
with the purified V1 (vector), V2 (vector), and CRIM1 containing Not1 and Cla1 sites, while 
maintaining a 3:1 insert:vector ratio, was performed at 4°C overnight. The ligation products were 
used to transform competent cells, with appropriate negative controls. Colonies were observed as 
expected, and 10 colonies from each plate were picked. A colony PCR was performed to confirm 
CRIM1-V1 and CRIM1-V2, using appropriate positive and negative controls. CRIM1-V1 and 
CRIM1-V2 were used to transfect HEK293 cells as described above. 
 
Reverse Transcription, Quantitative Real-time PCR and Analysis. 
Ventricular samples from Crim1
+/+
 and Crim1
Δflox/Δflox
hearts were miscrodissected, homogenized 
and frozen in RLT. Total ribonucleic acid (RNA) was extracted using an RNeasy Mini Kit (Qiagen, 
#74104). Reverse transcription was performed using SuperscriptIII (Thermo Fisher Scientific). 
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Briefly, 500ng total RNA was reverse-transcribed with random primers and deoxynucleotide 
triphosphates (dNTPs). cDNA was diluted 1/5 with RNase/DNase free water. qPCRs were carried 
out in a QuantStudio6 (Applied Biosystems) using SYBR green (Takara) and standard qPCR 
conditions. The QuantStudio6 software was used for analysis, with TFIID used as a relative 
standard. All samples were tested in triplicate. Relative transcript levels were assessed using the 
ΔCt method. Statistical analyses were performed using a two-tailed unpaired t-test.  
 
The primer sequences used in this study were purchased from Sigma-Aldrich, Australia, and are 
detailed below: 
 
Periostin:Forward  5‟-AAGCTGCGGCAAGACAAG-3‟ 
Periostin: Reverse 5‟-TCAAATCTGCAGCTTCAAGG-3‟ 
Collagen1a: Forward 5‟-AGACATGTTCAGCTTTGTGGAC-3‟ 
Collagen1a: Reverse 5‟-GCAGCTGACTTCAGGGATG-3‟ 
Collagen3a: Forward 5‟-ACGTAGATGAATTGGGATGCAG-3‟ 
Collagen3a: Reverse 5‟-GGGTTGGGGCAGTCTAGTG-3‟ 
Collagen5a: Forward 5‟-CTACATCCGTGCCCTGGT-3‟ 
Collagen5a: Reverse 5‟-CCAGCACCGTCTTCTGGTAG-3‟ 
Transgelin: Forward 5‟-CCTTCCAGTCCACAAACGAC-3‟ 
Transgelin: Reverse 5‟-CTAGGATGGACCCTTGTTGG-3‟ 
Alpha smooth muscle actin: Forward 5‟-ACTCTCTTCCAGCCATCTTTCA-3‟ 
Alpha smooth muscle actin: Reverse 5‟-ATAGGTGGTTTCGTGGATGC-3‟ 
Myosin heavy chain 11: Forward 5‟-ACGCCCTCAAGAGCAAACT-3‟ 
Myosin heavy chain 11: Reverse 5‟-CCCTTCTGGAAGGAACAATG-3‟ 
Calponin1: Forward 5‟-GAAGGTCAATGAGTCAACTCAGAA-3‟ 
Calponin1: Reverse 5‟-CCATACTTGGTAATGGCTTTGA-3‟ 
Myosin heavy chain 7: Forward 5‟-TGCTGAGGCCCAGAAACAAGTG-3‟ 
Myosin heavy chain 7: Reverse 5‟-CTGGATTTGAGTGTCCTTCAGCAG-3‟ 
Nkx2-5: Forward 5‟-ATTGACGTAGCCTGGTGTCTCG-3‟ 
Nkx2-5: Reverse 5‟-AGTGTGGAATCCGTCGAAAGTGC-3‟ 
Tie2: Forward 5‟-AGAGGCCGAACATTCCAAGTAGC-3‟ 
Tie2: Reverse 5‟-GGCCAAACAAACTGGCTTCTGC-3‟ 
Pdgfrα: Forward 5‟-TTGCACAGCCTCTGTTTGTTGC-3‟ 
Pdgfrα: Reverse 5‟-ATGGTGTCATGCAAGGCCCAAAG-3‟ 
Pdgfrβ: Forward 5‟-CAGTCCCGGCTACCCTATCT-3‟ 
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Pdgfrβ: Reverse 5‟-GACCCAGAGTTTTCTCGGCA-3‟ 
Tcf21: Forward 5‟-CATTCACCCAGTCAACCTGA-3‟ 
Tcf21: Reverse 5‟-CCACTTCCTTCAGGTCATTCTC-3‟ 
TFIID: Forward 5‟-ACGGACAACTGCGTTGATTTT-3‟ 
TFIID: Reverse 5‟-ACTTAGCTGGGAAGCCCAAC-3‟ 
 
Data documentation and quantification. 
Bright-field and fluorescent images were captured as outlined in the Materials and General Methods 
chapter, and images were adjusted using Adobe Photoshop software.  
 
For the analysis of 13.0 dpc compact myocardium thickness and cell density, sections were labelled 
with actin and Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), and nuclei counter-
stained with DAPI. Three-five non-consecutive sections for each sample were imaged at 40X field 
of view, on a laser scanning confocal microscope. The actin-positive area of the ventricle was 
considered as the compact myocardium. Olympus Fluoview or ImageJ software were used to 
determine the area from confocal images, and the number of DAPI-stained nuclei were quantified 
using ImageJ software to calculate cell density. 
 
For the quantification of the pHH3+ and CC3+-cells at 13.0dpc, five-seven non-consecutive 
sections for each sample were imaged at 40X field of view, on a laser scanning confocal 
microscope. Cells were scored as epicardial or sub-epicardial if they were on the periphery of the 
section and were actin-negative.  
 
For the analysis of epicardium-derived cells using the WT1-Cre line, 16 non-consecutive, coronal 
sections from each sample (X-Gal+; WT1-Cre) were quantified and the total number X-Gal+ cells 
in the ventricles was counted. For analysis using the WT1-CreERT2 line, two-four non-consecutive, 
coronal sections from each sample (X-Gal+; WT1-CreERT2) were quantified and the average of X-
Gal+ cells in the mid-ventricular region per sample was measured.  Cells were scored as epicardial, 
sub-epicardial if they were on the periphery of the section, or intramyocardial. 
 
For quantification of intensity of phospho-SMAD levels, at least five sections for each sample were 
imaged using a laser scanning confocal microscope. For quantification of phospho-ERK1/2 and 
phospho-AKT levels, at least two sections for each sample were imaged. Signal intensity was 
determined using the Integration function of the Olympus Fluoview Software and the number of 
DAPI-positive nuclei in the demarcated area was quantified using ImageJ software. 
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For quantification of β-catenin, sections were co-immunolabelled for MF20, which recognizes the 
heavy chain of myosin II in cardiomyocytes, and 40x images were acquired using a laser scanning 
confocal microscope from at least two sections for each sample.  Cells were considered to be 
epicardial or sub-epicardial if they were on the periphery of the section and were MF20-negative. 
 
Statistical Analyses. 
To determine the statistical significance of the prevalence of phenotypes among mutant and control 
groups, a Z test was used. For the analysis of the location of epicardium-derived cells (X-Gal+, 
WT1-Cre; epicardial, sub-epicardial, or intramyocardial), a two-way ANOVA with Bonferroni‟s 
post-test was used. For all other analyses, statistical significance between pooled data from mutant 
and control groups was determined using a two-tailed, unpaired Student‟s t-test. Quantified data 
shown are mean ± standard deviation. 
 
Results. 
Crim1 expression during heart development. 
A genetrap line for Crim1, called Crim1
KST264
(Pennisi et al., 2007),was used to assess Crim1 
expression in the developing heart. The presence of a LacZ reporter working under the control of 
the Crim1 locus allowed us to observe Crim1-promoter driven reporter geneexpression at 9.5 dpc in 
the proepicardium and in the epicardium at all stages examined (12.5 dpc, 13.5 dpc, 15.5 dpc, 17.5 
dpc and 18.5 dpc) (Figure 3.2A-J). As previously reported by Pennisi and colleagues, Crim1 
expression was also seen in coronary vascular smooth muscle cells and coronary vascular 
endothelial cells (Pennisi et al., 2007)(Figure 3.2E-G, J). Smooth muscle cell expression was 
confirmed using immunohistochemical analyses against transgelin (Figure 3.3F). The expression of 
Crim1 in the outflow tract mesenchyme, endocardium and valve leaflets was confirmed using 
periostin double labelling (Figure 3.3A-E). This distinctive expression pattern indicates that Crim1 
is likely involved in heart development. 
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Figure 3.2: Crim1 expression as monitored by the Crim1
KST264 
genetrap reporter reveals a 
dynamic pattern during heart development. 
A, micrograph of a histological section of a 9.5 dpc Crim1
+/KST264
 embryo that has been X-Gal-stained, paraffin-
embedded, and counter-stained with nuclear fast red. B, higher magnification view of the boxed area in A. The 
proepicardial cells are X-Gal-positive (arrow, B). C–G, Whole-mount views of Crim1+/KST264 hearts after X-Gal staining 
(blue) at 12.5 dpc (C), 15.5 dpc (D), 17.5 dpc (E), and 18.5 dpc (F) Note Crim1 expression in the OFT mesenchyme 
(double arrows, C) and smooth muscle of the great vessels (arrows, D-F). G, Magnified left lateral view of the ventricle 
of the heart shown in F. Note the Crim1-LacZ expression in the developing coronary vasculature (arrows) and in the 
epicardium (double open arrowheads). H-J, histological sections Crim1-LacZ expression in the epicardium (arrows) and 
M, in the coronary vasculature (open arrowhead). my, myocardium; pe, proepicardium. Scale bars, A, 100 µm; B, 20 
µm; C, 200 µm; D–F, 500 µm; G, 200 µm; H-J, 20 µm. 
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Figure 3.3: Crim1 is expressed in the outflow tract, mitral valve leaflets and coronary 
vascular smooth muscle cells. 
A, Periostin immunohistochemistry on an X-Gal stained Crim1
+/KST264
 transverse section at 12.5 dpc. B, higher 
magnification view of the boxed area in A, showing periostin- and X-Galpositive outflow tract mesenchymal cells 
(arrows). C, Periostin immunohistochemistry on an X-Gal stained Crim1
+/KST264
 coronal section at 13.5 dpc. D, higher 
magnification view of boxed area in C, showing periostin- and X-Gal-positive mesenchymal cells (arrows). E, 3 
Periostin immunohistochemistry on an X-Gal stained Crim1
+/KST264
 coronal section at 18.5 dpc, showing periostin- and 
X-Gal-positive mitral valve leaflet cells (arrows). F, Transgelin immunohistochemistry on an X-Gal stained 
Crim1
+/KST264
 coronal section at 18.5 dpc, showing transgelin- and X-Gal-positive coronary vascular smooth muscle 
cells (arrows). Scale bars, A, C, 100 µm; B, D, E, 40 µm; F, 10 µm. 
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Defective heart development in embryos lacking Crim1. 
Crim1
∆flox/∆flox
displayed a reduced ventricular size at 14.5 dpc (Figure 3.4A, B, D, E), and also at 
17.0 dpc accompanied by distended atria (Figure 3.4C, F).  Analysis of the epicardium of 
Crim1
∆flox/∆flox 
hearts at 13.5 dpc revealed abnormal epicardial morphology compared to wildtype 
controls (Figure 3.5A-H). This included epicardial blistering as visualised with histological analyses 
(Figure 3.5A-C), and irregular appearance along with loss of squamous morphology as observed 
performing electron scanning microscopy on Crim1
∆flox/∆flox 
hearts (Figure 3.5 D-G). 
 
 
Figure 3.4: Heart defects in Crim1
Δflox/Δflox
embryos.  
A–B, D-E Representative whole-mount views of 14.5 dpc embryonic hearts (A, B, Crim1+/+; D, E, Crim1Δflox/Δflox). B, E, 
Magnified, left lateral views of A and D, respectively. C,F, Representative whole-mount views of 17 dpc embryonic 
hearts (C, Crim1
+/+
; F, Crim1
Δflox/Δflox
). Note the reduced size of the ventricles in the Crim1
Δflox/Δflox
heart (D, E, F). Scale 
bars, A–F, 500 µm. 
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Figure 3.5: Epicardial defects in hearts of Crim1
Δflox/Δflox
embryos.  
A-C, Hematoxylin and eosin-stained sections of the ventricular region of 13.5 dpc Crim1
+/+
 (A) and two different 
Crim1
Δflox/Δflox
(B, C) hearts. Note the irregular appearance of the epicardium in Crim1
Δflox/Δflox
embryos, with one example 
showing blebbing (B). D-G, Scanning electron micrographs of the ventricular surface of 13.5 dpc Crim1
+/+
 (D, F) and 
Crim1
Δflox/Δflox
(E, G) hearts. E, Note the loss of the even spacing of cells of the mesothelial epicardium, and G, diffusely 
arranged microvilli. H, Quantification of penetrance of epicardial defects between Crim1
+/+
 and Crim1
Δflox/Δflox
hearts at 
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13.5 dpc. Z-score -3.8801. *, P<0.0001. cm, compact myocardium; ep, epicardium. Scale bars, A-C, 50 µm; D, E, 20 
µm; F, G, 2 µm. 
 
Crim1 is dispensable for PE formation. 
To address whether these anomalies were due to changes in formation of the PE, we used in situ 
hybridisation for PE markers Gata4 and Tbx18 on hearts of Crim1
∆flox/∆flox 
embryos. There were no 
gross changes in marker gene expression between mutant and wildtype control embryos (Figure 
3.6A-F), suggesting that while not required for early PE specification, Crim1 may regulate 
epicardial migration or adhesion at a later time point during development. 
 
 
Figure 3.6: Crim1 is dispensible for specification or early development of the proepicardium. 
A-F, Micrographs of 9.5 dpc embryos from Crim1
+/+
(A, C, E) and Crim1
Δflox/Δflox
(B, D, F) embryos stained for Gata4 
mRNA expression (purple stain, A and B) and Tbx18 mRNA expression (purple stain, C and D). E, F, Micrographs of 
histological sections of wholemount in situ hybridization-stained embryos showing Tbx18 expression. The PE is 
indicated (arrows). Scale bars, A and E, 50 µm. 
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Crim1 regulates compact myocardial development. 
A decrease in the size of Crim1
∆flox/∆flox 
ventricles at 14.5 dpc prompted us to investigate changes in 
thickness of the compact myocardium. At 13.0 dpc, when myocardial development has started, we 
observed a reduction in compact myocardial thickness in Crim1
∆flox/∆flox 
hearts (Figure 3.7A, B, D). 
However, this reduction was not due to a decrease in cell density (Figure 3.7C). It is noteworthy 
that different mutants lacking either the epicardium itself, or epicardium-derived factors, share a 
similar phenotype (Yang et al., 1995, Moore et al., 1999, Kwee et al., 1995, Chen et al., 2002, 
Pennisi et al., 2003, Männer, 1993, Gittenberger-de Groot et al., 2000). We went on to analyse 
whether there were any changes in proliferation or apoptosis of epicardial and myocardial cells, 
using markers PHH3 and CC3 respectively (Figure 3.7E-L). While epicardial cell proliferation and 
apoptosis was unchanged between conditional nulls and controls, there was an almost two-fold 
increase in proliferation and a four-fold increase in apoptosis of compact myocardial cells at 13.0 
dpc (Figure 3.7E-L). This indicates that loss of Crim1 results in increased cell death in the compact 
myocardium, but it is not known whether this is due to compact myocardial Crim1 acting in an 
autocrine way or a paracrine effect of epicardial Crim1. 
 
 
Figure 3.7: Crim1 is necessary for normal compact myocardial development.  
A and B, Merged confocal images of left ventricular sections of 13.0 dpc hearts from Crim1
+/+
 (A) and Crim1
Δflox/Δflox
 
(B) hearts stained with DAPI (blue), PECAM-1 (red), and actin (green). C, Compact myocardium cell density was 
unchanged in Crim1
Δflox/Δflox
hearts. D, Reduced ventricular compact myocardial thickness in Crim1
Δflox/Δflox
hearts at 13.0 
dpc (n=6–8). E and F, Merged confocal images of ventricular sections of 13.0 dpc hearts stained with Phospho-Histone 
H3 (PHH3, white), DAPI (blue), and actin (green). An epicardial cell (arrowhead, E) and myocardial cell (arrowhead, 
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F) immuno-positive for PHH3 are shown. G, No difference in proliferation in the epicardium of Crim1
Δflox/Δflox
hearts.H, 
An almost two-fold increase in proliferation in the compact myocardium of Crim1
Δflox/Δflox
hearts.I and J, Examples of 
merged confocal images of ventricular sections of 13.0 dpc hearts stained with cleaved caspase 3 (CC3, white), DAPI 
(blue), and actin (green). An epicardial cell (arrowhead, I) and myocardial cell (arrowhead, J) immuno-positive for CC3 
are shown. K, No difference in apoptosis in the epicardium of Crim1
Δflox/Δflox
 hearts.H, A four-fold increase in apoptosis 
in the compact myocardium of Crim1
Δflox/Δflox
hearts.cm, compact myocardium; ep, epicardium; n.s., not significant. 
(n=4–5), *, P<0.05; **, P<0.01. Scale bars A, B, 50 μm; E, F, I, J, 20 μm.  
 
Effect of Crim1 deletion on cardiomyocytes within the myocardium. 
We first used the Mlc2v-Cre line for the cardiomyocyte-specific deletion of Crim1 from the 
compact myocardium, so as to assess the posited autocrine role of Crim1. This line has been 
previously used and has been shown to be both efficient and specific to cardiomyocytes of the 
ventricle (Chen et al., 1998, O'Brien et al., 1993, Minamisawa et al., 1999). We crossed 
Crim1
FLOX/FLOX
; R26R mice with the Crim1
+/FLOX
; Mlc2v-Cre line to generate Crim1
+/FLOX
; R26R; 
Mlc2v-Cre controls and Crim1
FLOX/FLOX
; R26R; Mlc2v-Cre mutant mice. Embryonic hearts were 
collected at 13.5dpc and stained for X-Gal. We assessed proliferation and apoptosis of 
cardiomyocytes at 13.5 dpc using PHH3 and CC3 but found no significant changes between 
conditional null and control hearts (Figure 3.8A-H). Additionally, there were no differences in the 
thickness of the compact myocardium in these hearts at this age (Figure 3.8I). It is important to note 
that the phenotype demonstrating a reduction in compact myocardium thickness is observed before 
epicardial EMT and invasion of the myocardium occurs, and thus, we can infer that while 
myocardial depletion of Crim1 may not be responsible for the observed defect, epicardial Crim1 
could regulate myocardial development in a paracrine manner.  
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Figure 3.8: Myocardial deletion of Crim1 does not affect cardiomyocyte proliferation and 
survival and thickness of compact myocardium. 
A, D representative whole mount images of X-Gal stained Crim1
+/FLOX
; Mlc2v- Cre; R26R and Crim1
FLOX/FLOX
; Mlc2v-
Cre; R26R hearts at 13.5 dpc. B, E merged confocal images of DAPI (blue) and pHH3 (red), with a pHH3-positive 
nucleus (arrow). C, F merged confocal images of DAPI (blue) and CC3 (red), with a CC3-positive nucleus (arrow). G, 
No significant difference in percentage of pHH3-positive cells in the compact myocardium of left and right ventricles in 
control and mutant hearts (n=4-6). H, No significant difference in percentage of CC3-positive cells in the compact 
myocardium of left and right ventricles in control and mutant hearts (n=4-5). I, No significant difference in thickness of 
compact myocardium in the left ventricle of control and mutant hearts (n=3).cm, compact myocardium; ep, epicardium; 
n.s, not significant. Scale bars, B, C, E, F 20 µm. 
 
Effect of epicardium-specific deletion of Crim1 on the compact myocardium. 
To further assess the role of epicardial Crim1 in the development of the myocardium, we used the 
Crim1
FLOX
 line and an inducible transgenic line for the epicardium-specific deletion of Crim1, the 
WT1-CreERT2 line,which has been shown to be restricted to the epicardium and epicardium-
derived lineages, (Zhou and Pu, 2012). We crossed Crim1
FLOX/FLOX
; R26R mice with the 
Crim1
+/FLOX
; WT1-CreERT2 line to generate Crim1
+/FLOX
; R26R; +/WT1-CreERT2 controls and 
Crim1
FLOX/FLOX
; R26R; +/WT1-CreERT2 mutant mice. Two doses of Tamoxifen were administered 
prior to embryo collection, at 9.5 dpc and 10.5 dpc, and the LacZ reporter was used to confirm that 
Cre activity in embryonic hearts from 12.5 dpc was restricted to the epicardium, upon X-Gal 
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staining (data not shown). Its specificity was confirmed using immunohistochemical analyses 
against the cardiomyocyte marker MF20, which showed limited overlap between X-Gal positive 
cells that had lost Crim1 function, and cardiomyocytes (Figure 3.9A, B). However, decreased 
thickness of the myocardial wall was not observed in Crim1
FLOX/FLOX
; R26R; +/WT1-
CreERT2hearts at 15.5 dpc (data not shown). We hypothesise that this is due to incomplete 
penetrance and variable expressivity of the WT1-CreERT2 line, as previously reported(Rudat and 
Kispert, 2012). This occurrence was confirmed upon quantifying the percentage of epicardial cells 
lacking Crim1 in the left and right ventricles (only 37.5% of cells had Crim1 ablated), indicating 
that the majority of epicardial cells stillexpressed Crim1 in this line (pooled genotypes, n=6). This 
could potentially compensate for any myocardial defects that could have been caused due to a 
complete loss of epicardial Crim1. 
 
 
Figure 3.9: Fidelity of the WT1-CreERT2 line.  
A,B MF20 immunohistochemistry performed on 13.5 dpc WT1-CreERT2 X-Gal stained sections showing MF20-
negative epicardium (arrows) and MF20-negative EPDCs (open arrowheads), A, WT1-CreERT2 13.5 dpc X-gal stained 
section showing that most epicardial cells are X-Gal-positive (arrow). B, WT1-CreERT2 17.5 dpc X-Gal stained section 
showing MF20-negative EPDCs (open arrowheads), confirming that the EPDCs are not cardiomyocytes. ep; 
epicardium. Scale bar, A, B, 50 µm. 
 
Cell-autonomous role of Crim1 in epicardial migration in vitro. 
The epicardial defects observed in the conditional null embryos, as well as the potential role of 
epicardial Crim1 in modulating myocardial development, prompted us to investigate the role of 
Crim1 in the development of the epicardium. First, we cultured primary embryonic epicardial cells 
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isolated from the Crim1
KST264 
line and used these in a transwell migration assay, a modified Boyden 
chamber assay. As mentioned previously, the Crim1
KST264 
allele allowed us to monitor Crim1 
expression using X-Gal staining in the representative samples of explant cultures, which revealed 
ubiquitous Crim1-LacZ expression in primary epicardial cells (data not shown). Furthermore, WT1 
labelling of the primary epicardial cultures from Crim1
KST264/KST264 
hearts confirmed epicardial 
identity after enrichment (Figure 3.10A-C).  These cells exhibited an increase in the rate of 
migration compared to heterozygote controls, indicating that the loss of Crim1 from the epicardium 
resulted in an increase in epicardial migration (Figure 3.10D-E). 
 
 
Figure 3.10: Crim1 plays a cell-autonomous role in epicardial migration, in vitro. 
D, Schematic of the transwell assay used for the in vitro migration assay. A, Representative micrograph of a primary 
11.5 dpc ventricular explant after attachment and migration of epicardial cells. The front of the epicardial monolayer is 
indicated (arrows). The primary explant is denoted by an asterisk. B, Primary epicardial cells after removal of the 
ventricular explant, passage and subsequent culture. Note maintenance of a “cobblestone” appearance of the cellular 
monolayer. C, Epicardial identity after enrichment was confirmed by immunostaining for WT1 (green nuclear signal). 
The no-primary antibody control showed no signal (inset). D, Schematic of the transwell assay used for the in vitro 
migration assay. E, Crim1
KST264/KST264
primary epicardial cells showed increased migration in vitro relative to controls 
(n=3–5 and representative of three independent experiments) *, P<0.05.Scale bar, A, 100 µm; B, C, 50 µm. 
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Cell-autonomous role of Crim1 in epicardial migration and myocardial invasion,in vivo. 
To confirm our observations in vivo, and also to assess whether Crim1 regulated epicardial 
migration, we used transgenic lines for the epicardium-specific deletion of Crim1, namely 
Crim1
FLOX
, WT1-Cre(Wilm et al., 2005) and WT1-CreERT2(Zhou and Pu, 2012). We first crossed 
Crim1
+/FLOX
; R26R mice with the Crim1
+/FLOX
; WT1-Cre line to generate Crim1
+/FLOX
; R26R; WT1-
Cre controls and Crim1
FLOX/FLOX
; R26R; WT1-Cre mutant mice with Crim1 deleted from epicardial 
cells and their derivatives. The fidelity of this line was also confirmed by MF20 
immunohistochemistry (Figure 3.11A-C).  
 
 
Figure 3.11: Fidelity of the WT1-Cre line.  
A-C MF20 immunohistochemistry performed on 15.5 dpc WT1-Cre X-Gal stained sections showing MF20-negative 
epicardium (arrows) and MF20-negative EPDCs (open arrowheads), ep; epicardium. Scale bar, A-C, 25 µm. 
 
Epicardium-restricted Cre activity was assessed by the R26R LacZ reporter. Embryonic hearts were 
collected at 15.5dpc and X-Gal stained. We assessed the location of X-Gal-positive cells at 15.5 dpc 
in Crim1
FLOX/FLOX
; R26R; WT1-Cre and littermate controls, determining whether tagged cells 
remained epicardial, or had undergone epicardial EMT and migrated to the sub-epicardium or to an 
intramural myocardial location. Section data showed a distinct staining of epicardial cells, and 
epicardium-derived cells in the subepicardium and myocardium. Quantification of X-Gal-positive 
cells in the right ventricle of Crim1
+/FLOX
; R26R; WT1-Cre hearts revealed a greater number of 
epicardial cells and a lower number of intramyocardial cells compared to their Crim1
FLOX/FLOX
; 
R26R; WT1-Cre littermates (Figure 3.12A-J). There was a significant decrease in the proportion of 
X-Gal-positive epicardial cells, and an associated increase in intramyocardial X-Gal-positive cells 
in the right ventricle of Crim1
FLOX/FLOX
; R26R; WT1-Cre hearts compared to controls. However, it is 
not known why this phenotype was observed only in one ventricle.Thus, this suggests that with a 
loss of Crim1 function, there is an increase in the number of epicardial cells that have undergone 
EMT and invaded the myocardium (Figure 3.12I, J).  
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Figure 3.12: Crim1 plays a cell-autonomous role in epicardial migration and invasion of the 
myocardium, in vivo, as observedby using the WT1-Cre line. 
A, E, Whole-mount dorsal views of 15.5dpc embryonic hearts after X-Gal-staining (blue) of Crim1
+/FLOX
; R26R; WT1-
Cre and Crim1
FLOX/FLOX
; R26R; WT1-Cre genotype, respectively. B, F, Higher magnification views of the boxed areas 
in F and K, respectively. C-H Histological sections of hearts from Crim1
+/FLOX
; R26R; WT1-Cre (C, D) and 
Crim1
FLOX/FLOX
; R26R; WT1-Cre (G, H) 15.5dpc embryos, showing X-Gal
+
 epicardial cells (arrows), subepicardial cells 
(double arrowheads), and intramyocardial cells (open arrowheads). I, J, The proportion of X-Gal
+
 cells that are 
epicardial, sub-epicardial, or intramyocardial in the left (I) and right (J) ventricles. Note the decrease in epicardial X-
Gal
+
 cells, and increase of intramyocardial X-Gal
+
 cells in the right ventricles of Crim1
FLOX/FLOX
; R26R; WT1-Cre 
hearts, indicating increased epicardial EMT and invasion of the myocardium by epicardial cells with loss of Crim1 
function (n=7–8; *, P<0.01). Ep, epicardial; S.E., subepicardial; My, intramyocardial; LV, left ventricle; RV, right 
ventricle. Scale bars, 20 µm.  
 
It is important to note, however, that the Cre was active only in a very small minority of epicardial 
cells and EPDCs. Although the WT1-Cre line allowed us to examine a cell-autonomous role for 
Crim1, a drawback of this line is that complete activation of Cre is not achieved in all epicardial 
cells (unpublished data, (Rudat and Kispert, 2012)), thus requiring an alternate Cre line that is 
specific to the epicardium and its derivatives, to examine the effect of a more global epicardial loss 
of Crim1 function. 
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Therefore, the WT1-CreERT2 line was used to circumvent this problem (Zhou and Pu, 2012). 
Again, we crossed Crim1
FLOX/FLOX
; R26R mice with the Crim1
+/FLOX
; WT1-CreERT2 line to 
generate Crim1
+/FLOX
; R26R; +/WT1-CreERT2 controls and Crim1
FLOX/FLOX
; R26R; +/WT1-
CreERT2 mutant mice. Upon X-Gal staining, we observed that like in the case of WT1-Cre mice, 
absence of Crim1 in the epicardium resulted in increased epicardial EMT and invasion of the 
myocardium of right ventricles compared to controls (Figure 3.13A-H). These in vivo data are 
consistent with primary epicardial culture migration studies conducted, and suggest that in the 
absence of Crim1, epicardial EMT and migration of EPDCs into the myocardium is increased. 
 
 
Figure 3.13: Crim1 plays a cell-autonomous role in epicardial migration and invasion of the 
myocardium, in vivo,as observedby using the WT1-CreERT2 line. 
A, B, Whole-mount dorsal views of 15.5 dpc embryonic hearts after X-Gal staining (blue) of Crim1
+/FLOX
; WT1-
CreERT2; R26R and Crim1
FLOX/FLOX
; WT1-CreERT2; R26R genotype, respectively. Two doses of Tamoxifen were 
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administered at 9.5 dpc and 10.5 dpc prior to harvesting the embryos. C-D, E-F, Histological sections of hearts from 
Crim1
+/FLOX
; WT1-CreERT2; R26R and Crim1
FLOX/FLOX
; WT1-CreERT2; R26R 15.5 dpc embryos, respectively, and D, 
F, magnified views of boxed regions showing X-Gal-positive epicardial, sub-epicardial and intramural cells. G, H, 
Quantification of X-Gal-positive cells showing increased myocardial EPDCs in the right ventricles of mutant hearts 
(n=4-6; *P<0.05). ep, epicardial; se, sub-epicardial; my, intramyocardial; LV, left ventricle; RV, right ventricle. Scale 
bars, C, E, 20 μm; D, F, 10 μm.  
 
Crim1 may alter epicardial adhesion junctions. 
The observed epicardial defects, namely epicardial blistering and a non-uniform epicardium, and 
the increase in epicardial EMT, may be suggestive of defects in cell adhesion. β-catenin is a crucial 
component of intercellular adhesion complexes, and has been shown to interact indirectly with 
Crim1 (Ponferrada et al., 2012). Therefore, we assessed localisation of β-catenin (Wu et al., 2010) 
in Crim1
+/+ 
wildtype and Crim1
∆flox/∆flox
 mutant hearts at 13.5 dpc. We found that there was an 
increase in the percentage of epicardial cells that displayed a concentrated accumulation of β-
catenin at epicardial cell-cell junctions in Crim1
+/+ 
hearts (Figure 3.14A-G), suggesting that Crim1 
may play a role in stabilising intercellular junctions. We also looked for changes in f-actin in 
Crim1
∆flox/∆flox
 hearts, but f-actin morphology in the myocardium appeared comparable between 
mutant and wildtype (Figure 3.15A-F). 
 
 
Figure 3.14: Changes in β-catenin accumulation at epicardial cell junctions in the absence of 
Crim1. 
A-F, Confocal images of ventricular sections of 13.5 dpc hearts from Crim1
+/+
 (A, B, C) and Crim1
Δflox/Δflox
(D, E, F) 
embryos stained for β-catenin (red).A, B, merged images of DAPI (blue) and MF20 (green) to delineate the epicardium 
with the β-catenin (red) from B, C and E, F respectively. C, F, magnified views of boxed regions in B and E. Note β-
catenin distribution at epicardial cell-cell junctions of Crim1
+/+
 hearts (arrows, C, F). G, the percentage of epicardial 
cells with an accumulation of β-catenin at cell junctions (n=5-6). cm, compact myocardium; ep, epicardium; s.ep, sub 
epicardium.n.s., not significant. *, P<0.05. Scale bars, A,D, 10 μm.  
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Figure 3.15: No visible change in filamentous actin morphology in the epicardium or 
myocardium of Crim1
Δflox/Δflox
 hearts at 13.5 dpc.  
A-F, Representative confocal images of ventricular sections of 13.5 dpc hearts from Crim1
+/+
(A, B, C) and 
Crim1
Δflox/Δflox
 (D, E, F) hearts at 13.5 dpc.A, D merged images of DAPI (blue) and MF20 (green) to delineate the 
myocardium with Phalloidin (red) from B and E, respectively (n=4-5). C, F, magnified views of boxed regions in B and 
E respectively. Scale bars A – F, 20 µm. 
 
CRIM1 can bind to other CRIM1 molecules, and further confer junctional stability. 
CRIM1 has been shown, via immunoprecipitation, to self-associate and form complexes where 
multiple CRIM1 molecules are present (Wilkinson et al., 2003, Ponferrada et al., 2012). We further 
examined this using a Protein Fragment Complementation Assay. HEK293 cells were transfected 
with Zipper-V1 only, Zipper-V2 only, AT1R(Angiotensin II Type 1 Receptor)-V1 only and β-
Arrestin-V2 only, and, both Zipper-V1 + Zipper-V2 and AT1R-V1 + β-Arrestin-V2. Only cells with 
both constructs displayed strong fluorescence (Figure 3.16G-I), indicating stable complementation 
and function of V1 and V2 fragments.  
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Figure 3.16: Protein Complementation Assay as tested with AT1-V1 and β-Arrestin-V2 
 A-C, HEK293 cells transfected with AT1-V1 (no fluorescence). D-F HEK293 cells transfected with β-Arrestin-V2 
(no fluorescence). G-I HEK293 cells transfected with both AT1-V1 and β-Arrestin-V2 (fluorescence observed). A-F 
images were captured using a 10x objective, zoomed 4 times. G-I images used a 10x objective. Scale bars A-F, 50 μm; 
G-1, 160 μm. 
 
We then generated CRIM1-V1 and CRIM1-V2 clones and used these to transfect HEK293 cells. 
Fluorescence was observed, confirming the interaction (Figure 3.17A-F). It is known from other 
studies that CRIM1 localizes in the Golgi and ER, as well as on the plasma membrane (Glienke, 
Sturz et al. 2002, Wilkinson, Kolle et al. 2003). To confirm the cellular localization of CRIM1, 
immunofluorescence was performed on the transfected samples using anti-Myc and anti-CRIM1 
antibodies, and compared with the control N-terminal Myc-tagged CRIM1-Green Fluorescent 
Protein (GFP) clone. The constructs CRIM1-GFP, CRIM1-V1 and CRIM1-V2, both when co-
transfected and transfected individually, have a similar localization pattern compared to the control 
(Figure 3.18A-E, Figure 3.19A-C). In another experiment, live CHO cells were transfected with N-
terminal Myc-tagged CRIM1-GFP. Since the GFP is cytoplasmic and the Myc tag at the N-
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terminus; a proportion of CRIM1 molecules are at the cell surface, and the Myc-tag will be 
extracellular. As the experiment was performed on chilled, live cells, the plasma membrane is 
impermeable to antibodies; therefore only the cell surface, extracellular Myc tag is detected. While 
no double staining was performed to confirm the localization of CRIM1, the staining pattern 
visualized by GFP expression indicates that it is expressed in these compartments. This implies that 
if CRIM1 molecules are present at epicardial junctions, theymay confer stability at these junctions 
via associating with other CRIM1 moleculeson adjacent epicardial cells (Figure 3.20). 
 
 
Figure 3.17: Protein Complementation Assay as tested with CRIM1-V1 and CRIM1-V2 
A, B HEK293 cells transfected with CRIM1-V1 (no fluorescence). C, D HEK293 cells transfected with CRIM1-V2 (no 
fluorescence). E, F HEK293 cells transfected with both CRIM1-V1 and CRIM1-V2 (fluorescence observed). Scale bars 
A-F, 50 μm. 
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Figure 3.18: Cellular localization of CRIM1 
A-T, Cellular localization of Crim1. A-D, E-H, No fluorescence observed when CRIM1-V1 and CRIM1-V2 are 
transfected individually. I-P, Fluorescence observed when CRIM1-V1 and CRIM1-V2 are co-transfected, and also 
stained for α-Myc and α-CRIM1 antibodies. Observe localization of CRIM1 using the α-CRIM1 and α-Myc antibodies 
compared to control, across panels J, N, R. Q-T, HEK293 cells transfected with CRIM1-GFPtagged control. Scale bars 
A-T, 50 μm. 
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Figure 3.19: Magnified images showing CRIM1 localization 
A-C, Confocal images showing that CRIM1 is localized to the endoplasmic reticulum  (ER) and golgi. A, B, magnified 
images of PCA with CRIM1-V1 and CRIM1-V2 showing CRIM1 localization. C, Immunofluorescence performed on 
live, chilled CHO cells under non-permeabilising conditions. Cells were transfected with N-terminal Myc-tagged 
CRIM1-GFPand subjected to immunofluorescence to the Myc epitope (green, GFP; more prominent in golgi and ER, 
red, Myc tag; extracellular), indicating CRIM1 localization in the ER and golgi. Scale bars A,B, 50 μm; C, 4 μm. 
 67 
 
Figure 3.20: CRIM1 may confer stability at epicardial cell junctions 
Schematic representation of epicardial cell junctions with adhesion and bridging molecules along with CRIM1, which 
may serve as a stabilization mechanism at these junctions and restrain epicardial EMT. 
 
Modulation of growth factor activity by Crim1. 
To assess a role for Crim1 in regulating the activity of growth factors, indirect immunofluorescence 
for phospho-SMAD2 and phospho-SMAD1/5 to assess canonical TGFβ and BMP signalling, 
respectively, was performed. At 13.0dpc, Crim1
∆flox/∆flox
 hearts showed comparable levels of 
ventricular compact mycoardial phospho-SMAD2 relative to controls (Figure 3.21A, B, E-H). 
However, there was a reduced level of phospho-SMAD2 in the epicardium of Crim1
∆flox/∆flox
 hearts 
at 13.0dpc (Figure 3.21A-D, E, F). At this stage, there was no change in the levels of phospho-
SMAD1/5 in the ventricular compact myocardium or the epicardium of Crim1
∆flox/∆flox
 hearts 
relative to controls, suggesting canonical BMP signalling was unchanged in Crim1
∆flox/∆flox
 hearts at 
13.0 dpc (Figure 3.22A-H). Despite the increased epicardial EMT and invasion resulting from the 
epicardial-restricted loss of Crim1 function, these results suggested that canonical TGFβ signalling 
was reduced in the epicardium of Crim1
∆flox/∆flox
 hearts.  
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Figure 3.21: Reduction in canonical TGFβ signalling in the absence of Crim1 
A-F, Confocal images of ventricular sections of 13.0 dpc hearts from Crim1
+/Δflox
 (A, B) and Crim1
Δflox/Δflox
(E, F) 
embryos stained for phospho-SMAD2/3 (white).A, B, merged images of DAPI (blue) and actin (green) to delineate the 
myocardium with the phospho-SMAD2/3 (white) from B and F, respectively. C, D, G, and H, There was a reduction in 
phospho-SMAD2 signal intensity in epicardial cells of left and right ventricles of Crim1
Δflox/Δflox
hearts, but the levels in 
compact myocardial cells was unchanged (n=4–5). cm, compact myocardium; ep, epicardium; s.ep, subepicardium.n.s., 
not significant. *, P<0.05. Scale bars, A-B, E-F, 10 μm.  
 
 
Figure 3.22: No change in canonical BMP signalling in the absence of Crim1 
A-F, Confocal images of ventricular sections of 13.0 dpc hearts from Crim1
+/Δflox
 (A, B) and Crim1
Δflox/Δflox
 (E, F) 
embryos stained for phospho-SMAD1/5 (white). A and E, merged images of DAPI (blue) and actin (green) to delineate 
the myocardium with the phosphoSMAD1/5 (white) from A and E, respectively. C, D, G, H, Quantification of the 
average signal intensity/cell after indirect immunofluorescence to detect phospho-SMAD1/5 showed there was no 
change in the levels in the epicardium or compact myocardium of left and right ventricles of Crim1
Δflox/Δflox
 hearts in 
comparison to controls (n=5). cm, compact myocardium; ep, epicardium; n.s., not significant. Scale bars, A, B, E, F 10 
µm. 
 
We also assessed whether there were changes in the effectors phospho-AKT and phospho-ERK1/2 
that are known to act downstream of a number of growth factors as another representation of 
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misregulated signalling. Levels of phospho-AKT in the epicardium and myocardium were 
comparable (Figure 3.23A-H) between mutants and controls, as were the levels of epicardial 
phospho-ERK1/2 (Figure 3.24A, B, E-H). However, we observed that there was an increase in 
levels of phospho-ERK1/2 in the ventricular compact myocardium of Crim1
∆flox/∆flox
 hearts relative 
to controls (Figure 3.24A-D, E, F). This indicates that Crim1 does not play a role in the regulation 
of growth factors within the epicardium, but that it could serve a paracrine function in modulating 
the development of the myocardium by controlling the activity of epicardium-derived molecules. 
However, further analysis needs to be performed by using cardiac tissue homogenates at relevant 
embryonic ages in Western blot experiments, which will helps us quantify and confirm the growth 
factor signalling changes observed upon immuno-staining. 
 
 
Figure 3.23: No change in phospho-AKT levels in the absence of Crim1 
A-D, Confocal images of ventricular sections of 13.5 dpc hearts from Crim1
+/+
 (A, B) and Crim1
Δflox/Δflox
 (C, D) 
embryos stained for phospho-AKT (red). Quantification of signal intensity per cell to detect phospho-AKT levels 
revealed no change in the levels in the epicardium or compact myocardium of left and right ventricles of Crim1
Δflox/Δflox
 
hearts in comparison to controls (n=5-6). cm, compact myocardium; ep, epicardium; n.s., not significant. Scale bars, A, 
B, C, D, 50 µm. 
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Figure 3.24: Increase in myocardial phospho-ERK1/2 levels in the absence of Crim1 
A-F, Confocal images of ventricular sections of 13.5 dpc hearts from Crim1
+/+
 (A, B) and Crim1
Δflox/Δflox
(E, F) embryos 
stained for phospho-ERK1/2 (red). C, D, G and H, There was an increase in phospho-ERK1/2 signal intensity in 
compact myocardial cells of left and right ventricles of Crim1
Δflox/Δflox
hearts, but the levels in epicardial cells was 
unchanged (n=8-6). cm, compact myocardium; ep, epicardium; n.s., not significant. *, P<0.05. Scale bars, A-B, E-F, 50 
μm.  
 
Loss of Crim1 results in decreased proliferation of intramyocardial cells. 
Proliferation of EPDCs was assessed in control Crim1
+/FLOX
; +/Wt1-CreERT2; R26R and mutant 
Crim1
FLOX/FLOX
; +/Wt1CreERT2; R26R heart sections at 15.5 dpc using pHH3 (Figure 3.25A, B). 
Quantification of pHH3-positive cells that were X-Gal-positive in the myocardium of left and right 
ventricles revealed a significant reduction in proliferation of intramyocardial cells in the mutant 
(Figure 3.25A, B, D). Quantification of pHH3-positive cells among X-Gal-positive epicardial cells, 
however, revealed comparable results (Figure 3.25A-C). This demonstrates that deleting Crim1 
from the epicardium can perturb proliferation of EPDCs, and confirms the cell-autonomous role of 
Crim1. 
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Figure 3.25: Decrease in the number of proliferating EPDCs in the absence of epicardial 
Crim1 
A, B, Phospho-Histone H3 immunohistochemistry on X-Gal stained Crim1
+/FLOX
; + /WT1-CreERT2; R26R and 
Crim1
FLOX/FLOX
; + /WT1-CreERT2; R26R sections at 15.5 dpc, counter stained with 1% DAB followed by NFR staining 
for visualisation of nuclei, showing (A) pHH3- and X-Gal-positive nuclei (arrow) and (B), a PHH3-positive nucleus 
(open arrowhead). C, D Quantification of proliferating EPDCs showing no change in the epicardium, but a significant 
reduction in the number of pHH3-positive EPDCs in mutant hearts compared to control in the myocardium (n = 6–4). 
*P < 0.05. n.s., not significant; LV, left ventricle. Scale bars, A,B 50 μm. 
 
Crim1 may control fate specification of EPDCs, particularly into the fibroblast lineage. 
Having observed a reduction in proliferation of EPDCs residing in the myocardium, we next 
investigated whether there were any changes in epicardial cell fate into vascular smooth muscle, 
cardiomyocyte or fibroblast lineages. We performed immunofluorescence experiments on 
Crim1
∆flox/∆flox 
and Crim1
+/+ 
hearts at 17.5 dpc using periostin and transgelin as markers but found 
no observable changes between the two genotypes (Figure 3.26A-H). We next performed qPCR 
analyses on ventricular tissue extracted from Crim1
∆flox/∆flox 
and Crim1
+/+ 
hearts at 17.5 dpc, using 
markers for these cell types. There were no significant changes observed, although a trend for the 
fibroblast marker Collagen1a reduction in Crim1
∆flox/∆flox 
samples was observed (Figure3.26 I, 
Trend P = 0.0556).  
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Figure 3.26: Assessing expression levels of different cell lineage markersin the absence of 
Crim1  
A-I, No change in cardiac fibroblasts, coronary vascular smooth muscle cells or cardiomyocytes in Crim1
Δflox/Δflox
 hearts 
at 17.5dpc. A–H, Representative confocal images of whole-heart sections (A, E, C, G) and magnified views of the 
myocardium (B, F, D, H) of Crim1
+/+
 (A-D) and Crim1
Δflox/Δflox
 (E-H) heart stained with DAPI (blue), and Periostin 
(red) (A-B, E-F) and Transgelin (red) (C-D, G-H). I, qPCR with fibroblast, smooth muscle and cardiomyocyte markers 
showing no significant difference in fold change between Crim1
+/+ 
and Crim1
Δflox/Δflox
 ventricular samples at 17.5 dpc 
(n=4-5).  
 
To further analyse this, we performed immunohistochemical analyses on control Crim1
+/FLOX
; 
+/Wt1-CreERT2; R26R and mutant Crim1
FLOX/FLOX
; +/Wt1CreERT2; R26R heart sections at 17.5 
dpc, using periostin, a fibroblast marker (Figure 3.27A-C). We observed a reduction in periostin 
expression upon quantification of X-Gal- and periostin-positive cells in the myocardium of mutant 
hearts, which indicates that the number of fibroblasts is decreased in the absence of epicardial 
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Crim1 (Figure 3.27A-E). This implies a potential role for Crim1 in determining the fate of EPDCs, 
specifically committed to the fibroblast lineage.  
 
 
Figure 3.27: Decrease in the number of periostin-positive EPDCs in the absence of epicardial 
Crim1 
A-C, Periostin immunohistochemistry on X-Gal stained Crim1
+/FLOX
; + /WT1-CreERT2; R26R and Crim1
FLOX/FLOX
; + 
/WT1-CreERT2; R26R sections at 17.5 dpc, counter stained with 1%DAB followed by Hematoxylin staining, showing 
(A), a periostin- and X-Gal-positive cardiac fibroblast (arrow), (B), an X-Gal-positive EPDC (open arrowhead) and (C) 
a periostin-positive cardiac fibroblast (double open arrowheads). D, E, quantification of % periostin-positive cells 
among X-Gal-positive myocardial cells in left and right ventricles, showing a decrease in number of cardiac fibroblasts 
(n = 3–5). *P < 0.05. n.s., not significant; LV, left ventricle; RV, right ventricle. Scale bars, A–C, 10 μm. 
 
Discussion. 
Crim1 is a type-I transmembrane protein found to be expressed in a spatially and temporally 
restricted manner in a number of cell types during development and homeostasis, and important for 
different aspects of organogenesis (Kolle et al., 2000, Pennisi et al., 2007, Wilkinson et al., 2007, 
Lovicu et al., 2000, Kinna et al., 2006). By employing the use of various transgenic mouse lines, 
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including tissue-restricted mutants, we sought to determine the role of Crim1 in heart development. 
Crim1 expression begins in the proepicardium, and although it is dispensable for proepicardial 
specification and outgrowth, its expression continues in the epicardium and epicardium-derived 
lineages.  
 
There is much effort being put into how to harness the potential of the largely quiescent adult 
mammalian epicardium, and activate and mobilize it in response to myocardial damage, so as to 
introduce therapies to reduce the societal burden of cardiovascular disease. This includes re-
expression of embryonic epicardial genes and the release of paracrine and autocrine factors from 
the epicardium or epicardium-derived cells (Zhou et al., 2011a, Smart et al., 2007, Smart and Riley, 
2012). 
 
The epicardium is known to contribute important components of the developing heart, and activated 
epicardial cells have been demonstrated to commit to the fibroblast and smooth muscle cell lineages 
following myocardial damage (van Wijk et al., 2012, Duan et al., 2012, Limana et al., 2011, Huang 
et al., 2012, Zhou et al., 2011a). Additionally, the epicardium provides instructive molecules to the 
developing myocardium, and appears to aid its growth and expansion in a paracrine manner. 
 
Hearts of Crim1
∆flox/∆flox
 mutants displayed abnormal epicardial morphology at 13.5 dpc, indicative 
of epicardial EMT and adhesion defects. Further investigations involving epicardium-specific 
Crim1 deletion confirmed increased epicardial EMT and invasion of EPDCs into the myocardium. 
Moreover, primary epicardial cultures showed increased migration in the absence of Crim1. The 
distribution of β-catenin at epicardial cell junctions was also altered. Furthermore, CRIM1 has also 
been shown to be localized to junctional complexes at points of cell-to-cell contact of microvascular 
endothelial cells when stimulated with lipopolysaccharide (Glienke, Sturz et al. 2002).Taken 
together with previous studies implicating the interaction of the cytoplasmic domain of Xenopus 
Crim1 with β-catenin and N-cadherin in the formation and maintenance of cadherin-dependent 
complexes at epithelial cell junctions, we can infer a role for Crim1 in stabilizing junctional 
complexes (Ponferrada et al., 2012), not only in epicardial cells, but also in endothelial cells. The 
binding of Crim1 to β-catenin at junctional complexes could also impede Wnt signalling, and the 
link between the two molecules especially in the context of developmental interactions between the 
epicardium and myocardium, is an attractive avenue that is yet to be explored.  Additionally, the 
fact that multiple CRIM1 molecules can self-associate, lends further credibility to its role in 
increasing junctional stability. 
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Some cystine-knot growth factors that promote epicardial EMT and invasion (such as PDGFs, 
BMPs, and TGF) (Morabito et al., 2001, Smith et al., 2011, Sánchez and Barnett, 2012) can be 
bound by CRIM1 (Wilkinson et al., 2003). The lack of changes in canonical BMP signalling via the 
SMAD1/5 pathway, along with no significant differences in AKT and ERK1/2 signalling in the 
epicardium of Crim1
∆flox/∆flox
 hearts, indicates that Crim1 may play a role other than epicardial 
growth factor regulation. Furthermore, the paradoxical reduction in TGF signalling in the 
epicardium could imply an uncoupling of these pathways and epicardial EMT. 
 
The underlying mechanisms involved in regulation of myocardial development via modulation of 
epicardial and myocardial signalling molecules is unclear. Mouse mutants where epicardial 
formation is perturbed, such as VCAM-1, 4 integrin, WT1 knockouts, and mouse lines with 
altered retinoic acid signalling, show secondary myocardial defects during development (Yang et 
al., 1995, Moore et al., 1999, Kwee et al., 1995, Chen et al., 2002). Additionally, hypoplastic 
ventricles with abnormal compact myocardium are also observed in avian embryos in which 
epicardium formation was obstructed microsurgically (Pennisi et al., 2003, Männer, 1993, 
Gittenberger-de Groot et al., 2000). 
 
We observed a reduced compact myocardial thickness in Crim1 null hearts at 13.0 dpc. Further 
investigations revealed that myocardial loss of Crim1 did not affect compact myocardium 
development through changes in proliferation and apoptosis of cardiomyocytes, which is consistent 
with the finding that the thickness of compact myocardium was not significantly altered. This 
indirectly implies the importance of epicardial Crim1 for compact myocardium development and 
suggests non-cell-autonomous requirements for epicardial Crim1 in myocardial development. 
However, epicardial loss of Crim1 also did not recapitulate this phenotype, and this could be 
attributed to incomplete penetrance of the WT1Cre-ERT2 line during development. Taken together 
with the fact that reciprocal signalling between both the epicardium and the myocardium is required 
for the development of the myocardium, this suggests a requirement for both epicardial and 
myocardial Crim1 for myocardial development. Cardiomyocytes comprise an important part of the 
myocardium and are responsive to a number of signalling molecules via expression of surface 
receptors that are able to bind mitogens (Sucov et al., 2009). Coincident with this, epicardial IGFs 
and PDGFs have indeed been shown to act as epicardial mitogenic factors that stimulate the 
proliferation of cardiomyocytes and subsequently ventricular development (Kang et al., 2008, Li et 
al., 2011). 
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Crim1 possesses an IGFBP domain with highest sequence similarity to IGFBP-7 (Kolle et al., 
2000). Since IGFBPs are known to regulate the activity of IGFs (Hwa et al., 1999), Crim1 could 
also possibly serve to bind IGFs and regulate downstream signalling. This would be consistent with 
our observation that ERK1/2 signalling in the myocardium of Crim1
∆flox/∆flox
hearts is increased.  
Thus Crim1 could mediate epicardial growth factor sequestration, and this is in accordance with our 
observation demonstrating increased ERK1/2 signalling in the compact myocardium of 
Crim1
∆Flox/∆Flox
 hearts. The lack of Crim1 would mean that untethered growth factors are free to 
signal to the adjacent myocardium. A number of growth factors, however, activate downstream 
ERK1/2 signalling, and whether this activation is transient or prolonged can lead to different 
outcomes (Mebratu and Tesfaigzi, 2009).  Therefore, the increase in ERK1/2 signalling could either 
have a pro- or anti-apoptotic effect, and much depends on both the triggering ligand and the 
downstream effectors. Crim1 may be required to modulate growth factor activity in a timely manner 
for proper myocardial maturation to ensue.   
 
This hypothesis is exemplified in a study by Wilkinson et al. who showed that Crim1 is co-
expressed with VEGF-A in the podocytes of the renal glomerulus (Wilkinson et al., 2007), 
consistent with a role in tethering epicardium-derived growth factors. In mice lacking Crim1, there 
was an increased diffusion of VEGF-A away from the podocytes and a concomitant activation of 
the VEGF-A receptor Flk1 in adjacent vascular endothelial cells, further substantiating the role of 
Crim1 in growth factor binding and regulation via its CRRs (Wilkinson et al., 2007) and potentially 
the IGFBP domain as well. The processing and secretion of BMPs has also been shown to be 
reduced in the absence of CRIM1, and thus, in Crim1
∆Flox/∆Flox
 hearts, there could be increased 
growth factor production and concomitant signalling. This could subsequently cause a co-activation 
of apoptosis and proliferation in the myocardium of mutant hearts and result in a high myocardial 
cell turnover. However, the context-dependent agonistic or antagonistic functions of Crim1 must be 
noted, which could be dependent on both the cell type within the heart and also the stage of 
development concerned. 
 
The growth factors that Crim1 could bind and modulate during the process of myocardial 
maturation can be assessed by immunoprecipitation of endogenous Crim1 and associated growth 
factors at the specific stages of cardiogenesis when the myocardium is developing, for example, 
between 10.5 and 15.5 dpc. This would help us understand the temporal regulation of growth 
factors by Crim1, in the context of myocardial maturation. 
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Although the underlying mechanisms that controls the development of the myocardium is not 
transparent, regulation of signalling molecules from the epicardium appears to be crucial for 
myocardial development. Furthermore, though there was an increased migration of EPDCs into the 
myocardium in the case of Crim1
FLOX/FLOX
; WT1-Cre and Crim1
FLOX/FLOX
;WT1-CreERT2 hearts, 
their proliferative ability was diminished. Alongside, there also exists a potential role for Crim1 in 
determining specification of EPDCs into the fibroblast lineage. Cardiac fibroblasts are important 
residents of the myocardium, especially in the case of cardiac repair and performance following 
myocardial damage (Souders et al., 2009, Camelliti et al., 2005). While we observe a reduction in 
the number of fibroblasts, it is not known whether the EPDCs that have migrated into the 
myocardium remain undifferentiated or commit to the coronary vascular smooth muscle cell 
lineage, altering the balance between cardiac fibroblasts and vascular smooth muscle cells; thus this 
remains an attractive avenue to be explored. 
 
In summary, the data collectively validates essential roles for Crim1 in heart development, in both 
autocrine and paracrine ways. These include epicardial EMT and invasion, proliferation and fate 
specification of EPDCs, and modulation of growth factor activity. Another critical role identified in 
heart development includes regulating compact myocardial development, likely through regulation 
of epicardium-derived paracrine factors. Though previously thought to be a quiescent lining that 
surrounds the myocardium, recent experiments demonstrate that epicardial genes can be reactivated 
and regulated to release factors from the epicardium or EPDCs in response to injury or disease 
(Smart and Riley, 2012). Thus, Crim1 may likely provide a potential avenue for future molecular 
and cellular therapeutic interventions for cardiac regeneration and repair. 
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Chapter 4 
 
 
Examining the cell-autonomous role of Crim1 in the 
coronary vasculature, specifically in endothelial cells. 
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Introduction. 
Cardiac ischemia, which occurs due to reduced blood supplyto the heart, is a feature of coronary 
artery or ischemic heart disease. Any irregularities in blood vessel function, usually caused due to 
endothelial cell abnormalities, can ultimately lead to myocardial infarction and impairment of heart 
muscle function (Hansson 2005). In order to understand the pathogenesis of cardiovascular disease 
and overcome its burden, we need to examine the functional biology of the network of factors that 
regulate it at the tissue, molecular and cellular level. 
 
Endothelial cells have not received muchattention in the past due to the misconception that they are 
an inactive monolayer lining blood vessel walls. However, they have recently been shown to have 
crucial roles in angiogenesis and vasculogenesis, regulation of vessel tone and permeability(Aird 
2007, Aird 2012). Detailed studies on endothelial cells that have their origins in different tissue and 
vascular beds have made it possible for us to understand endothelial cell heterogeneity (Aird 2012). 
Within the heart, there are a number of endothelial cell subtypes that display differential gene 
expression and, subsequently, function (Hendrickx, Doggen et al. 2004). For example, the inner 
lining of the heart chambers and valves comprise endocardial endothelial cells, microvascular 
endothelial cells line smaller myocardial vessels, and macrovascular endothelial cells line larger 
coronary vessels. 
 
The source of cardiac endothelial cells is somewhat controversial. The use of lineage tracing has 
revealed that the proepicardial organ in avian models is a source of endothelial cells (Mikawa and 
Gourdie 1996, Pérez-Pomares, Carmona et al. 2002), but in murine models, is not a significant 
contributor of endothelial cells to the coronary vasculature (Cai, Martin et al. 2008, Zhou, von Gise 
et al. 2008). However, by using fate-mapping studies in mice, Katz and colleagues have shown that 
different subcompartments within the proepicardium do give rise to the coronary endothelium 
(Katz, Singh et al. 2012). Another study presents the possibility of endothelial cells migrating to the 
proepicardium from the sinus venosus and liver bud, with the proepicardium facilitating the passage 
of these cells to the developing heart (Cossette 2011). Coronary endothelial cells have also been 
shown to have epicardial and subepicardial origins (Riley 2012, Tian, Hu et al. 2013). Coronary 
venous endothelial cells have been shown to arise from the sinus venosus (Red-Horse, Ueno et al. 
2010), as well has have endocardial origins (Wu, Zhang et al. 2012). A small population of these 
cells, by de-differentiation, also form coronary artery endothelial cells (Red-Horse, Ueno et al. 
2010), though Wu and colleagues suggest that the major source for coronary arterial endothelial 
cells appears to be the endocardium (Wu, Zhang et al. 2012). However, it has most recently been 
confirmed in an elegant study that employed genetic labelling and lineage tracing using a number of 
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transgenic mouse lines that a large population of intramyocardial endothelial cells derives from the 
sinus venosus in the developing mouse heart, and that the endocardium contributes only minimally 
to coronary arterial endothelial cells (Zhang, Pu et al. 2016). 
 
Origins notwithstanding, the role that endothelial cells play in vasculature development and 
homeostasis (Coultas, Chawengsaksophak et al. 2005, Aird 2012), and regulating responses to 
inflammation, has had widespread acceptance (Pate, Damarla et al. 2010). These cells are known to 
produce a large number of cytokines, growth factors and other molecules, while also being 
responsive to the same.  
 
What are the growth factors that play an important role in endothelial cell biology? BMP-2, -4 and -
9 have crucial roles in endothelial cell development (Dyer, Pi et al. 2014), and signal predominantly 
via binding to type I BMP receptors ALK2, ALK3 and ALK6 (BMPRs), which in turn 
phosphorylate and activate their downstream mediators, SMAD1, -5 and -8 (SMAD1/5/8) 
(Kawabata, Imamura et al. 1998). Signalling can also occur via or in combination with other 
receptors, such as the TGF receptor ALK1 (Brown, Zhao et al. 2005, Scharpfenecker, van Dinther 
et al. 2007). Some ligand-receptor interactions also require the presence of co-receptors; endoglin is 
one such glycoprotein that is present predominantly on endothelial cells (Cheifetz, Bellon et al. 
1992, Brown, Zhao et al. 2005). Absence of each of these components – the ligands, receptors or 
downstream mediators – results in defective cardiac and vasculature development (Mishina, Suzuki 
et al. 1995, Yang, Castilla et al. 1999, Goumans and Mummery 2000, Lechleider, Ryan et al. 2001, 
Liu, Selever et al. 2004).  
 
As with the case for most growth factors, BMPs exert dual roles depending on the site and time of 
expression, and also the cell type concerned. For example, smooth muscle cell proliferation in both 
rat aortic smooth muscle cells and pulmonary artery smooth muscle cells is hindered by BMP-2 
(Nakaoka, Gonda et al. 1997, Morrell, Yang et al. 2001). BMP-9 has also been shown to impede 
both proliferation and angiogenesis in bovine aortic endothelial cells (Scharpfenecker, van Dinther 
et al. 2007). Conversely, BMP-2 has been shown to have a positive effect on the survival of 
pulmonary artery endothelial cells (Teichert-Kuliszewska, Kutryk et al. 2006). In human aortic 
endothelial cells, BMP-2 also stimulates proliferation and tube formation, mediating an angiogenic 
response (Langenfeld and Langenfeld 2004). Absence of BMP-4 causes impaired formation of 
branchial arch arteries (Liu, Selever et al. 2004). Furthermore, BMP-4 has also been shown to 
increase cell number and proliferation of human microvascular endothelial cells while suppressing 
apoptosis, and also to stimulate angiogenesis via VEGF receptors (Suzuki, Montagne et al. 2008).  
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Similarly, BMP-9 has been found to increase endothelial cell proliferation via phospho-SMAD1/5 
in mouse embryonic-stem-cell-derived endothelial cells in vitro, and angiogenesis in vivo(Suzuki, 
Ohga et al. 2010). Regulation of BMP signal transduction occurs at a number of levels, and in 
multiple ways (Wilkinson, Kolle et al. 2003, Umulis, O'Connor et al. 2009). Well-known 
antagonists include the cysteine-rich domain containing chordin (Larraín, Bachiller et al. 2000)and 
noggin (Zimmerman, De Jesus-Escobar et al. 1996, Groppe, Greenwald et al. 2002), and the agonist 
crossveinless-2 (Zhang, Patterson et al. 2010). 
 
How does Crim1 function in relation to cardiac and endothelial cell development? It contains six 
CRRs, via which it potentially binds growth factors such as TGFβ, BMP and VEGF when both are 
co-expressed in the same cell (Wilkinson, Kolle et al. 2003, Wilkinson, Gilbert et al. 2007). The 
association of CRIM1 and BMPs has been studied the most, although the exact mechanisms 
through which a downstream effect is mediated, is not fully understood. Also, whether the binding 
leads to growth factor signalling being positively or negatively regulated is also not transparent. For 
example, crm-1, a Crim1 homolog in C.elegans, plays an agonistic role in the BMP-like DBL-1 
pathway (Fung, Chi Fat et al. 2007). However, Crimpy, another BMP homolog in Drosophila, 
impedes BMP signalling at neuromuscular junctions of motorneurons (James and Broihier 2011). 
Similarly, in vitro studies have revealed that CRIM1 antagonizes both the production and secretion 
of mature BMPs (Wilkinson, Kolle et al. 2003). 
 
Another growth factor that has received attention in the context of Crim1 binding is VEGF. This 
growth factor has a pervasive role in endothelial cell function, and its interaction with Crim1 in 
cultured endothelial cells as well as in the murine retina has been studied (Glienke, Sturz et al. 
2002, Fan, Ponferrada et al. 2014). Initially it was shown that in HUVECs, CRIM1 has a crucial 
role in endothelial cell capillary network formation, indicating a likely involvement in cell-cell 
contact formation (Glienke, Sturz et al. 2002). Coincident to this, CRIM1 was shown to localize at 
points of cell contact at the plasma membrane of microvascular endothelial cells (Glienke, Sturz et 
al. 2002). In vivo, loss of Crim1 has been shown to impede retinal vascular development, with a 
reduction in vascularized area alongside reduced endothelial cell proliferation (Fan, Ponferrada et 
al. 2014). CRIM1 has been previously shown to bind VEGF-A (Wilkinson, Gilbert et al. 2007), an 
indispensible factor for angiogenesis, and conditional deletion of Vegfa or Crim1 alone resulted in 
impaired angiogenesis, but deletion of both Vegfa and Crim1 caused a more severe phenotypic 
defect, indicating that Crim1 and VEGF-A function along a similar pathway (Fan, Ponferrada et al. 
2014). Furthermore, it has also been demonstrated that CRIM1 is necessary for HUVEC viability, 
and that it can regulate the autocrine activity of VEGF-A (Fan, Ponferrada et al. 2014). 
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In this chapter, we explore the modulation of BMPs by Crim1 in cardiac endothelial cell function. 
In the heart, Crim1 is expressed in the epicardium at all stages of development, and also in coronary 
vascular smooth muscle and endothelial cells (Iyer, Chou et al. 2016). In the current study, we 
reveal a role for Crim1 in cardiac microvascular endothelial cell development in vivo and in vitro; 
specifically, a dysregulation of BMP signalling is evident in the absence of Crim1. We also report 
the misexpression of a number disease-related endothelial genes in the absence of CRIM1, 
collectively defining a cell-autonomous role in normal endothelial cell function in the heart. 
 
Materials and methods. 
Ethics Statement. 
Please refer to the Materials and General Methods chapter for the detailed ethics statement. 
 
Animal Breeding. 
The mouse lines used in this study were the Crim1
FLOX
conditional knock-out (Chiu, York et al. 
2012), the Crim1
Δflox
line (Chiu, York et al. 2012), the ROSA26 Cre reporter line (R26R;(Soriano 
1999), and Tie2-Cre line (Kisanuki, Hammer et al. 2001). Embryos were obtained from timed 
matings between Crim1
+/Δflox
intercrosses to produce Crim1
Δflox/Δflox
, Crim1
+/Δflox 
andCrim1
+/+
mice 
or Crim1
FLOX/FLOX
; R26R females mated with Crim1
+/FLOX
; Tie2-Cre males to produce 
Crim1
FLOX/FLOX
; R26R; Tie2-Cre and Crim1
+/FLOX
; R26R; Tie2-Cre mice.The presence of a 
vaginal plug was regarded as 0.5 dpc. 
 
Sample preparation. 
Embryonic hearts were dissected, photographed in whole-mount as required, and prepared by 
paraffin or cryo-embedding and sectioning, for immunohistochemical analyses as detailed in the 
Materials and General Methods chapter. 
 
Antibodies and lectin. 
Primary antibodies/lectin used in the study were: rabbit polyclonal anti-phospho-Histone H3 
(pSer10; #06-570, Millipore); rabbit monoclonal anti-cleaved caspase 3 (activated caspase 3; 
#9664, Cell Signaling Technology); rabbit monoclonal anti-phospho-Smad1/5 (pSer463/pSer465; 
Invitrogen #700047); rabbit polyclonal anti-phospho-Smad2 (pSer465/pSer467; Millipore 
AB3849); total SMAD1/5/8/9 (NB100-56656;Novus Biologicals); rat monoclonal anti-CD31 
(PECAM-1; BD Pharmingen #550274); Angiogenesis Sampler kit (#8696; Cell Signalling); total 
AKT (#9272; Cell Signalling); total ERK1/2 (sc-93; Santa Cruz); rabbit monoclonal HA tag 
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(#3724; Cell Signalling); mouse monocolonal myc tag (#2276; Cell Signalling); GAPDH (#2118; 
Cell Signalling); -tubulin (#2146; Cell Signalling) and Isolectin B4 (#MP21410; Invitrogen).  
Secondary antibodies used for immunofluorescence experiments were Alexa Fluor-488, and 594-
conjugated secondary antibodies (Invitrogen). Secondary antibodies used for 
immunohistochemistry experiments were anti-rabbit HRP (Promega; #W4011), anti-mouse HRP 
(Promega; #W4021), anti-rabbit biotin (Sigma; # B7389). 
 
Cell Culture. 
HCMVECs (Lonza, CC-7030) were cultured in EGM-2MV BulletKit media (Lonza, CC-3202) and 
pooled HUVECs (CC-2519) were cultured in EGM-2 BulletKit media CC-3162). Cells before 
passage six were used in all experiments. shRNA targeting CRIM1 mRNA (Fan et al, 2014) was 
acquired from TRC Mission Library (TRCN0000063862, Invitrogen). Lentiviral particles were 
synthesized by transfecting CRIM1 shRNA, scrambled shRNA and the lentiviral packaging vectors 
into HEK293T cells using Lipofectamine 2000. The supernatant containing lentiviral particles was 
collected at 24 and 48 hours after transfection. Cells at 80% confluence were then incubated with 
lentiviral particles along with 8 μg/ml polybrene for 48 hours and then treated with 2 μg/ml 
puromycin for 48 hours to enrich the infected cell population. After puromycin removal, cells were 
used in subsequent experiments.  
 
For experiments not involving external stimulation with growth factors (BMP-2/4), HCMVECs 
were cultured in EGM-2MV and EGM-2 complete medium. To examine the effect of exogenous 
growth factor stimulation and inhibitor treatment, cells were starved in serum-free basal media 
without growth factors for 2 hours, and treated with LDN193189 (1mM)(Yu, Deng et al. 2008) for 
30 minutes. This was done prior to stimulation with BMP-2 and BMP-4 (100 ng/ml) for ten minutes 
(Star, Giovinazzo et al. 2009).  
 
Trypan Blue Viability Assay. 
5,000 scrambled shRNA Control and CRIM1-knockdown CMVECs and 16,000 scrambled shRNA 
Control and CRIM1-knockdown HUVECs were plated into wells of a 24-well plate at time zero, in 
EGM-2MV and EGM-2 complete medium. The number of viable cells was counted at two time 
points namely 24 hours and 48 hours based on Trypan Blue exclusion. 
 
Quantitative RT-PCR and q-PCR Array. 
RNA was extracted using the RNeasy Mini Kit (Qiagen) and stored at -80°C. cDNA was prepared 
using RT
2
 First Strand Kit (Qiagen) according to manufacturer’s protocol. Quantitative PCR to 
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assess percentage CRIM1 knockdown was performed with QuantiFast SYBR Green PCR kit 
(Qiagen). The RT
2
 SYBR Green ROX qPCR Mastermix was used for Profiler PCR Array (Plate E). 
Signals were detected using the Roche LightCycler and Applied Biosystems QuantStudio 7 system 
and gene expression levels were calculated using the standard curve method. Gene analyses were 
performed using the Qiagen Gene Globe Data Analysis Center and the Ingenuity Pathway Analysis. 
 
Plasmid Constructs. 
GFP and CRIM1 open reading frames were cloned into the pLVX-Puro lentiviral construct as per 
manufacturer’s instructions (Clontech).  
 
CRIM1 overexpression. 
The 2A peptide sequence is a self-processing viral peptide bridge that can separate different protein 
coding sequences in a single ORF transcription unit (Ryan, King et al. 1991). Using these 2A 
peptide constructs it has been shown that quantitative co-expression of heterologous proteins, 
driven by one promoter is possible for both in vitro and in vivo analysis (Tang, Ehrlich et al. 2009). 
 
For creating CRIM1 lentiviral constructs using 2A peptide, two individual PCRs were carried out. 
The first fragment was generated by attB1 sequence linked to Crim1 CDS and with the reverse 
complement of half of a 2A peptide sequence linked to reverse complement of GHR C-terminus 
without the stop codon. The second fragment was generated by using half of 2A peptide linked with 
GFP start codon and attB2 sequence linked with reverse complement of GFP C-terminus sequence 
with a stop codon between attB2 and GFP.   
 
Primer sequences were as follows: 
attB1-CRIM1 Fwd 1 
5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGTACTTGGTGGCGGGGGACAG 
 
CRIM1-HAtag-2Cc1 Rev 1 
5’-
GTTTTCCTCCACGTCGCCGCAGGTGAGCAGGCTTCCCCTGCCCTCAGCGTAATCTGGAA
CATCGTATGGGTACACTGTTTGGTAGAAATTGTCTGCCTGTAGATGG 
 
2Ac1-GFP Fwd 2 
5'-
ACCTGCGGCGACGTGGAGGAAAACCCTGGCCCCGCCCCAGGATCCATGGTGAGCAAG
GGCGAGGAGCTG 
 
GFP-attB2 Rev 2 
5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTTTACTTGTACAGCTCGTCCATGCCGAGAG 
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The portion of DNA sequence of 2A peptide was kept overlapping between the two PCRs while 
designing the Rev primer1 and Fwd primer2. This common region between the two PCR products 
was on the same principle as overlap extension PCR cloning (Bryksin and Matsumura 2013). The 
final PCR fragment containing CRIM1-2A-GFP flanked by attB sites was cloned in to pLenti-PGK-
Puro DEST (plasmid# 19068, Addgene) by Gateway Cloning (as per manufacturer's guidelines, 
Thermofisher). pLenti-PGK-GFP-puro (Plasmid#19070, Addgene) was used as control plasmid.  
 
qPCR primers for analysis of effect of CRIM1 overexpression. 
hCasp1-Fwd 5’-TGTTCCTGTGATGTGGAGGAAA-3’ 
hCasp1-Rvs 5’-CATCTGGCTGCTCAAATGAAAA-3’ 
 
hCCL5-Fwd 5’-AGCCTCTCCCACAGGTACCA-3’ 
hCCL5-Rvs 5’-GGCAGTAGCAATGAGGATGACA-3’ 
 
hCx3cl-Fwd 5’-CCCGGAGCTGTGGTAGTAATTC-3’ 
hCx3cl-Rvs 5’-ACTAGACACAGGCCAGAGGAGTTC-3’ 
 
hIL1B-Fwd 5’-TTAAAGCCCGCCTGACAGA-3’ 
hIL1B-Rvs 5’-GCGAATGACAGAGGGTTTCTTAG-3’ 
 
hKIT-Fwd 5’-GCTTTTATACTACCGACCTGGTTTTT-3’ 
hKIT-Rvs 5’-GGGAGGCCTTCTCTCCAATT-3’ 
 
hSELE-Fwd 5’-AAGCCTAAACCTTTGGGTGAAAA-3’ 
hSELE-Rvs AAGTGAGAGCTGAGAGAAACTGTGAA 
 
hSerpine1-Fwd 5’-GCTTTTGTGTGCCTGGTAGAAA-3’ 
hSerpine1-Rvs 5’-GGCAGGCAGTACAAGAGTGATG-3’ 
 
hTNSF10-Fwd 5’-CATCAAGGAGTGGGCATTCA-3’ 
hTNSF10-Rvs  5’-TGACCAGTTCACCATTCCTCAA-3’ 
 
hTYMP-Fwd 5’-GCGGACGGAATCCTATATGC-3’ 
hTYMP-Rvs 5’-TGAGAATGGAGGCTGTGATGAG-3’ 
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hVCAM-Fwd 5’-CACTCCGCGGTATCTGCAT-3’ 
hVCAM-Rvs 5’-TGTGCCTGGGAGGGTATTCA-3’ 
 
Data documentation, quantification and analyses. 
Bright-field and fluorescent images were captured as outlined in the Materials and General Methods 
chapter, and images were adjusted using Adobe Photoshop software.  
 
Signal intensity was determined using the Integration function of the Olympus Fluoview Software 
and the number of DAPI-positive nuclei in the demarcated area was quantified using the ImageJ 
software. 
 
For quantification of coronary endothelial cell numbers, 40x images were acquired of the left and 
right mid-ventricular myocardial free wall from at least three non-consecutive sections of each 
sample on a laser scanning confocal microscope. PECAM-1 positive cells were counted and divided 
by total cell number to determine the PECAM-1 positive percentage. Endocardial and trabecular 
endothelial cells were not included in the quantification.  
 
For quantification of proliferating and dying endothelial cells, 40x images were acquired of the left 
and right mid-ventricular myocardial free wall from at least three non-consecutive sections of each 
sample on a laser scanning confocal microscope. PHH3-and-CC3 PECAM-1-positive cells were 
counted and divided by PECAM-1-positive cell number to determine percentages of proliferating 
and dying endothelial cells respectively. PHH3- and CC3-positive and PECAM-1-negative cells 
were also counted to investigate a paracrine effect.  
 
For quantification of intensity of phospho-SMAD2 and phospho-SMAD1/5 levels, at least two non-
consecutive sections for each sample were imaged using a laser scanning confocal microscope. To 
determine total signal intensity in, and area of, the specified region of interest, Olympus Fluoview 
software was used.  
 
Signal intensity within specifically endothelial cells was determined using the IMARIS software 
(ver 8.2.0). Channel 1 was set to DAPI, channel 2 to PECAM-1, and channel 3 to phospho-SMAD 
1/5 or phospho-SMAD 2, based on the fluorescent dyes. A surface for channel 2 was created. 
Channel 1 for that surface was masked. This created ‘Channel 4’, which was PECAM-1 plus the 
DAPI associated with that PECAM-1. A surface for channel 4 was created. Channel 3 for that 
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surface was masked. This created ‘Channel 5’, which was PECAM-1 + DAPI associated with that 
PECAM-1, + phospho-SMAD associated with that DAPI. A surface for Channel 5 was created. All 
non-endothelial cells were deselected and intensity of phospho-SMAD within only endothelial cells 
was obtained.   
 
Experiments were repeated three times, and each time in duplicate, for CRIM1 knockdown 
quantitation and the results were averaged and compared to controls. For the endothelial biology 
qPCR array, 4 separate biological samples were used in duplicate (as a technical replicate).  
 
Overexpression experiments were performed in triplicate, and relative expression was normalised to 
β2-microglobulin. All P-values were evaluated by a two-tailed, unpaired t-test. 
 
To determine statistical significance between pooled data from mutant and control groups a two-
tailed, unpaired Student’s t-test was used. Quantified data shown are mean ± standard deviation. 
GraphPad Prism v6.0 was used to conduct all analyses and generate graphs. 
 
Results. 
Crim1 deletion results in abnormal coronary vasculature development. 
That Crim1 is necessary for normal heart development has been established previously, with 
Crim1
Δflox/Δflox 
hearts exhibiting a range of defects including reduced ventricular size and 
irregular epicardia (Iyer, Chou et al. 2016). Crossing Crim1
+/Δflox 
mice to produce Crim1
Δflox/Δflox 
mutants did not reveal abnormal vasculature development upon whole mount PECAM staining at 
13.5 dpc (Figure 4.1A,B, D, E); however, vascular malformations at 17.5 dpc were observed 
(Figure 4.1C,F).  
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Figure 4.1: Loss of Crim1 results in malformed coronary vasculature at 17.5 dpc 
A, B, D, E, Whole mount PECAM staining showing no significant differences in vasculature formation between 
Crim1
+/+ 
(A, B) and Crim1
Δflox/Δflox 
(D, E) hearts at 13.5 dpc. B, E, higher magnifications of boxed areas in (A) and (D).  
(n=3). C, F, Whole-mount views of 17.5 dpc embryonic hearts fromCrim1
+/+ 
(C) and Crim1
Δflox/Δflox 
(F) embryos. Note 
the malformed coronary vessels in the Crim1
∆flox/∆flox
 heart (F). (n=3). Scale bars, C, F, 400 μm. 
 
To analyse any defects arising from endothelial cell anomalies, we assessed whether there were 
any changes in endothelial cell endowment in these mutant hearts. To do this we immunostained 
cryosections from Crim1
+/+
,Crim1
+/Δflox
andCrim1
Δflox/Δflox
hearts with PECAM-1, a marker for 
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endothelial cells.We observed a reduction in the number of endothelial cells in the ventricular 
compact myocardium of Crim1
Δflox/Δflox
hearts at 17.5 dpc (Figure 4.2A-F).  
 
 
Figure 4.2: Reduced number of coronary vascular endothelial cells in Crim1
∆flox/∆flox 
hearts 
A-D, Confocal images of sections of 17.5 dpc hearts from Crim1
+/+
 and Crim1
+/∆flox
 (A, B) and Crim1
∆flox/∆flox
 (C, D) 
embryos stained with PECAM-1 (red). A, C, merged confocal images of DAPI (blue) and the PECAM-1 stain (red).E, 
F, There was a reduced percentage of PECAM-1+ endothelial cells (y-axis) in the ventricular myocardium of 
Crim1
∆flox/∆flox
 hearts (n=4). RV, right ventricle; ep, epicardium; en, endocardium. *P<0.05. Scale bars A, C, 50 μm. 
 
Cell autonomous role for Crim1 in endothelial cell development. 
To address whether this was due to a cell-autonomous role of Crim1, we crossed Crim1
FLOX/FLOX
; 
R26R mice with the Crim1
+/FLOX
; Tie2-Cre line for the deletion of Crim1 from specifically the 
endothelial cells. This line has been previously used and restricted to endothelial cells (Kisanuki, 
Hammer et al. 2001, Koni, Joshi et al. 2001). We confirmed this by both X-Gal staining and also 
histochemical analyses using Isolectin B4 as a marker of endothelial cells (Figure 4.3A-G). 
There was extensive overlap between the blue cells that had lost Crim1, and Isolectin-B4-
positive endothelial cells (Figure 4.3F, G). At 17.5 dpc, we also observed a decrease in 
endothelial cell endowment in Crim1
FLOX/FLOX
; R26R; Tie2-Cre mutant hearts compared to 
Crim1
+/FLOX
; R26R; Tie2-Cre controls (Figure 4.4A-F).  
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Figure 4.3: Efficiency of the Tie-2Cre line 
A-G, Efficiency of the Tie2-Cre line. A, X-Gal-stained Crim1
+/FLOX
; Tie2-Cre; R26R heart at 17.5dpc displaying lacZ 
expression in the vasculature upon Cre-mediated excision of Crim1.B, C, Higher magnification of vasculature in (A). 
D, E, Histological sections after nuclear fast red staining showing Cre-mediated loss of Crim1 in coronary vascular 
endothelial cells at 15.5 dpc. F, G, Histological sections showing overlap between endothelial marker Isolectin B4 and 
X-Gal at 15.5 dpc, confirming efficiency of Tie2Cre line. Scale bars, A, 500 μm; B, 300 μm; C, 150 μm; D, F, 200 μm; 
E, G, 20 μm. 
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Figure 4.4: Reduced number of coronary vascular endothelial cells in Crim1
FLOX/FLOX
; Tie2-
Cre hearts 
A-D, Confocal images of sections of 17.5 dpc hearts from Crim1
+/FLOX
; Tie2-Cre; R26R (A, B) and Crim1
FLOX/FLOX
; 
Tie2-Cre; R26R (C, D) embryos stained with PECAM-1 (red). A, C, merged confocal images of DAPI (blue) and the 
PECAM-1 stain, which is specific for endothelial cells (red).E, F, There was a reduced percentage of PECAM-1+ 
endothelial cells (y-axis) in the ventricular compact myocardium of both ventricles of Crim1
FLOX/FLOX
; Tie2-Cre; R26R 
hearts. (n=9-7). RV, right ventricle; ep, epicardium; en, endocardium. *P<0.05 Scale bars A, C, 50 μm. 
 
This decrease could be either due to a decrease in proliferation or an increase in apoptosis, and 
thus we investigated both, using PHH3 (Yang 2011)and CC3(Barbosky, Lawrence et al. 2006) as 
corresponding markers for proliferation and apoptosis respectively.  While there was a 
limitedincrease in apoptosis in the left ventricles of Crim1
FLOX/FLOX
; R26R; Tie2-Cre mutant hearts 
(Figure 4.5A-F), there was no change in the number of proliferating endothelial cells (Figure 4.6A-
D). This could be because PHH3 marks only a small population of proliferating cells. To address 
this concern, we also assessed proliferation using the marker Ki67(Yang 2011), which marks all 
phases of the cell cycle except for the resting phase (Figure 4.7A-D) and can thus be used to 
completely rule out that the observed reduction in number of endothelial cells is not due to a 
proliferation defect. There was still no change in the number of proliferating endothelial cells. 
There was also no change in the apoptosis or proliferation of adjacent non-endothelial cells in 
experiments employing CC3 (Figure 4.8A, B) and PHH3 (Figure 4.8C, D). Interestingly, while 
Crim1
Δflox/Δflox 
mice displayed embryonic lethality, Crim1
FLOX/FLOX
; R26R; Tie2-Cre mice 
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survived into adulthood without any apparent external phenotypic anomalies (data not shown; 
n=9). 
 
 
Figure 4.5: Limited apoptosis of endothelial cells in Crim1
FLOX/FLOX
; Tie2-Cre heartsas 
assessed using CC3 
A-D, Confocal images of ventricular sections of 17.5 dpc hearts from Crim1
+/FLOX
; Tie2-Cre (A, 
B)andCrim1
FLOX/FLOX
; Tie2-Cre (C, D) embryos immunostained with PECAM-1 and CC3. A-D, Merged images of 
DAPI (blue), CC3 (red) and PECAM-1 (green), with higher magnification images showing a non endothelial cell 
undergoing apoptosis (B), and an endothelial cell undergoing apoptosis (D).  E, F, Increase in endothelial cell 
apoptosis in the left ventricles of Crim1
FLOX/FLOX
; Tie2-Cre hearts. (n=6-7). LV, left ventricle; en, endocardium; ep, 
epicardium. *P<0.05. Scale bars A, C, 50 μm, B, D 10 μm. 
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Figure 4.6: No change in proliferation of endothelial cells in Crim1
FLOX/FLOX
; Tie2-Cre heartsas 
assessed with PHH3 
A-D, No change in proliferation of endothelial cells in ventricles of Crim1
+/FLOX
; Tie2-Cre hearts. A, B, Confocal 
images of ventricular sections of 17.5 dpc hearts from Crim1
+/FLOX
; Tie2-Cre (A)andCrim1
FLOX/FLOX
; Tie2-Cre (B) 
embryos immunostained with PECAM-1 (green) and PHH3 (red).  C, D, No change in percentage of PHH3-
positive endothelial cells (y-axis) in both ventricles of Crim1
FLOX/FLOX
; Tie2-Cre hearts (n=9-7). LV, left ventricle; 
en, endocardium; ep, epicardium; n.s, not significant. Scale bars, A, B, 50 μm. 
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Figure 4.7: No change in proliferation of endothelial cells in Crim1
FLOX/FLOX
; Tie2-Cre hearts 
as assessed with Ki67 
A-D, No change in proliferation of endothelial cells in ventricles of Crim1
+/FLOX
; Tie2-Cre hearts. A, B, Confocal 
images of ventricular sections of 17.5 dpc hearts from Crim1
+/FLOX
; Tie2-Cre (A)andCrim1
FLOX/FLOX
; Tie2-Cre (B) 
embryos immunostained with PECAM-1 (red) and Ki67 (green).  C, D, No change in percentage of Ki67-positive 
endothelial cells (y-axis) in both ventricles of Crim1
FLOX/FLOX
; Tie2-Cre hearts (n=5-6). LV, left ventricle; en, 
endocardium; ep, epicardium; n.s, not significant. Scale bars, A, B, 50 μm. 
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Figure 4.8: No change in apoptosis and proliferation of non-endothelial cells in 
Crim1
FLOX/FLOX
; Tie2-Cre hearts as assessed with CC3 and PHH3 
A, B, No change in apoptosis of CC3-positive non-endothelial cells in both ventricles of Crim1
FLOX/FLOX
; Tie2-Cre 
hearts compared to controls (n=6-7). C, D, No change in proliferation of PHH3-positive non-endothelial cells in 
both ventricles of Crim1
FLOX/FLOX
; Tie2-Cre hearts compared to controls (n=9-7).  n.s., non significant.  
 
Growth factor signalling is perturbed in the absence of Crim1. 
Growth factors are known to regulate cell development and survival in both normal and diseased 
states in a number of ways, although most of these are complex and poorly understood. CRIM1 is a 
versatile protein that can bind a number of growth factors such as TGFβ, BMPs and VEGF 
(Wilkinson, Kolle et al. 2003, Wilkinson, Gilbert et al. 2007). The interactions and function of 
Crim1 and VEGF in retinal vascular endothelial cells as been studied (Fan, Ponferrada et al. 
2014). Thus we next assessed whether loss of Crim1 would impact BMP signal transduction 
within coronary vascular endothelial cells. We performed indirect immunofluorescence for 
PECAM-1 and phospho-SMAD1/5 on Crim1
Δflox/Δflox 
hearts at 17.5 dpc, as a proxy to assess 
canonical BMP signalling (Figure 4.9A-D). This revealed a reduction in phospho-SMAD1/5 in 
all cells of the ventricular compact myocardium as well as in specifically endothelial cells of the 
left ventricle, although a trend is visible in the right ventricle. (Figure 4.9E-H).  
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Figure 4.9: Decrease in canonical BMP signalling in cells of Crim1
∆flox/∆flox
hearts as assessed 
with phospho-SMAD1/5 
A-D, Confocal images of ventricular sections of 17.5 dpc hearts from Crim1
+/+
, Crim1
 +/Δflox
 (A, B) and 
Crim1
Δflox/Δflox 
(C, D) embryos, immunostained for PECAM-1 and phospho-SMAD1/5. (A, C) Merged images of 
DAPI (blue), PECAM-1 (red) and phospho-SMAD1/5 (green). (E, F) Reduction in phospho-SMAD1/5 levels in all 
 98 
cells of both ventricles of Crim1
Δflox/Δflox 
hearts and (G H) endothelial cells of the left ventricles of Crim1
Δflox/Δflox 
hearts (n=4). RV, right ventricle; ep, epicardium; en, endocardium. *P<0.05, Scale bars A-D, 50 μm. 
 
Examination of CRIM1 function in vitro. 
Our findings to date using the Crim1
+/Δflox
, Crim1
+/FLOX
; Tie2-Cre, and Crim1
FLOX/FLOX
; R26R 
mouse lines suggested that Crim1 plays is essential for coronary endothelial cell development 
and BMP signalling, in vivo. To further probe the role of Crim1 in endothelial cells, we 
employed in vitro assays using both HUVECs and HCMVECs. First, we mediated the knockdown 
of CRIM1 using lentiviral shRNA, in HCMVECs (Figure 4.10A), using an shRNA targeting CRIM1 
that has been previously used for the efficient knockdown of CRIM1 in HUVECs (Fan, Ponferrada 
et al. 2014). We were able to achieve CRIM1 knockdown by approximately 75% at the transcript 
level, compared to scrambled shRNA controls (Figure 4.10A). Our hypothesis was that loss of 
CRIM1 would lead to a decrease in cell viability, and also impact growth factor signalling within 
endothelial cells. To examine this, we assessed the viability of HCMVECs and HUVECs lacking 
CRIM1, and found a reduction in viable cell number as well as percentage viability in HCMVECs, 
and a reduction in viable cell number but not percentage viability in HUVECs, as measured by the 
Trypan Blue Viability Assay (Figure 4.10B, C, D, E). This suggests a functional requirement of 
CRIM1 in maintaining the ability of HCMVECs to survive.  
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Figure 4.10: CRIM1 knockdown in HCMVECs and its effect on cell viability 
A, Approximately 75% CRIM1 knockdown in HCMVECs (n=3). B, C, Trypan Blue Viability Assay demonstrating 
decrease in viablecell number and percentage viability in CRIM1 knockdown HCMVECs compared to control after 24 
and 48 hours respectively, after plating 5000 cells per well of a 24 well plate (n = 3, and each n represents an average of 
3 replicates). D, E, Trypan Blue Viability Assay demonstrating decrease in viable cell number but not percentage 
viability in CRIM1 knockdown HUVECs compared to control after 24 and 48 hours respectively, after plating 16000 
cells per well of a 24 well plate (n = 3, and each n represents an average of 3 replicates). *P<0.05, **P<0.01, 
****P<0.0001. 
 
Dysregulation of canonical BMP signalling in the absence of CRIM1 in vitro. 
We have observed a decrease in endothelial phospho-SMAD1/5 signalling in left ventricles of 
Crim1
Δflox/Δflox 
mutants (Figure 4.9G). To investigate the effect that loss of CRIM1 function has 
on canonical BMP signalling in HCMVECs, we assessed the phosphorylation of downstream 
effectors SMAD1/5, AKT and ERK1/2 as proxies for downstream signal transduction (Figure 
4.11A). While there was no change in either phospho-ERK1/2 or phospho-AKT levels, there was 
a significant decrease in phospho-SMAD1/5 levels in CRIM1 knockdown lysates compared to 
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scrambled shRNA controls (Figure 4.11B). This is consistent with our in vivo observations on 
Crim1
Δflox/Δflox 
mutants (Figure 4.9). 
 
 
Figure 4.11: CRIM1 knockdown in HCMVECs results in decreased phospho-SMAD1/5 
activity 
A, B, Reduction in pSMAD1/5 levels as a proxy to assess BMP signalling in CRIM1 knockdown HCMVECs, but no 
change in pERK1/2 and pAKT levels, compared to scrambled shRNA control HCMVECs (n=4-7). Representative blot 
chosen*P<0.05 
 
Misregulation of genes involved in endothelial stress response, apoptosis and cell adhesion 
in HCMVECs lacking CRIM1. 
Certain growth factors, such as BMPs, are known to have an impact on endothelial disease 
states, including inflammatory responses and responses to stress and injury (Lowery and 
deCaestecker 2010). CRIM1 has been shown to interact with many of these growth factors 
(Wilkinson, Kolle et al. 2003, Wilkinson, Gilbert et al. 2007). Furthermore, we have observed 
aberrant BMP signalling in endothelial cells in the absence of Crim1. Additionally, vascular 
malformations are also a potential consequence of chronic inflammation and stress. The effect of 
CRIM1 ablation on HCMVEC genes has not been studied, and hence, I hypothesised that loss of 
CRIM1 would result in misregulation of endothelial genes that are critical to endothelial cell 
development and function. Using a Human Endothelial Cell Biology qPCR array, I performed a 
quantitative assay testing a panel of 84 genes involved in endothelial disease progression. This 
revealed that 29 genes involved in endothelial cell function are greater than two-fold up or 
downregulated (Figure 4.12, Table 4.1).  
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Figure 4.12: Effect of CRIM1 knockdown on endothelial gene expression as assessed by a 
human endothelial cell biology array 
A, Scatterplot displaying misregulation of 29 genes out of 84, involved in endothelial cell function, with a fold-change 
cut-off of 2. The scatter plot compares the normalized expression of every gene on the array between the two selected 
groups by plotting them against one another to quickly visualize large gene expression changes. The central line 
indicates unchanged gene expression. The dotted lines indicate the selected fold regulation threshold. Data points 
beyond the dotted lines in the upper left and lower right sections meet the selected fold regulation threshold. (n = 4, 
with 2 technical repeats i.e 4 independent experiments performed in duplicate). 
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Table 4.1: List of all 84 endothelial genes assessed in the human endothelial cell biology array, 
with fold regulation and P values. Significant genes are highlighted in bold font. 
 
NUMBER GENE REFSEQ FOLD REGULATION P-VALUE 
1 ACE NM_000789 1.0909 0.290151 
2 ADAM17 NM_003183 -2.5219 0.00018 
3 AGT NM_000029 -1.4969 0.076943 
4 AGTR1 NM_031850 -1.1724 0.522084 
5 ALOX5 NM_000698 1.0231 0.969908 
6 ANGPT1 NM_001146 -1.8019 0.007017 
7 ANXA5 NM_001154 -2.2338 0.000006 
8 APOE NM_000041 -1.6211 0.044427 
9 BAX NM_004324 -1.0566 0.281637 
10 BCL2 NM_000633 -1.5905 0.030518 
11 BCL2L1 NM_138578 -1.3774 0.000041 
12 CALCA NM_001741 1.0374 0.488782 
13 CASP1 NM_033292 5.1266 0.00003 
14 CASP3 NM_004346 1.0501 0.424219 
15 CAV1 NM_001753 -2.0448 0.000345 
16 CCL2 NM_002982 1.1958 0.04106 
17 CCL5 NM_002985 15.0637 0.000131 
18 CDH5 NM_001795 -1.4064 0.000322 
19 CFLAR NM_003879 -1.0154 0.820888 
20 COL18A1 NM_030582 -1.3561 0.007195 
21 CX3CL1 NM_002996 6.139 0.026342 
22 EDN1 NM_001955 -1.8019 0.000243 
23 EDN2 NM_001956 1.0073 0.925998 
24 EDNRA NM_001957 -1.431 0.154058 
25 ENG NM_000118 -1.2393 0.007858 
26 F2R NM_001992 1.32 0.01127 
27 F3 NM_001993 3.7529 0.000074 
28 FAS NM_000043 1.8797 0.000744 
29 FASLG NM_000639 1.0374 0.488782 
30 FGF1 NM_000800 1.32 0.277886 
31 FGF2 NM_002006 -1.0566 0.535619 
32 FLT1 NM_002019 -1.1266 0.145134 
33 FN1 NM_002026 -2.2611 0.0004 
34 HIF1A NM_001530 -1.0457 0.107155 
35 HMOX1 NM_002133 -1.1247 0.142892 
36 ICAM1 NM_000201 1.7207 0.000004 
37 IL11 NM_000641 -2.117 0.013737 
38 IL1B NM_000576 7.0153 0.001666 
39 IL3 NM_000588 1.0374 0.488782 
40 IL6 NM_000600 1.7752 0.002456 
41 IL7 NM_000880 1.6621 0.124883 
42 ITGA5 NM_002205 -1.2414 0.001696 
43 ITGAV NM_002210 -2.3983 0.00012 
44 ITGB1 NM_002211 -2.8669 0.000001 
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45 ITGB3 NM_000212 -1.5099 0.003451 
46 KDR NM_002253 -1.0996 0.224994 
47 KIT NM_000222 -3.7373 0.000736 
48 KLK3 NM_001648 -1.0845 0.479634 
49 MMP1 NM_002421 -1.5204 0.000071 
50 MMP2 NM_004530 -1.2986 0.012208 
51 MMP9 NM_004994 2.247 0.008745 
52 NOS3 NM_000603 1.0629 0.378124 
53 NPPB NM_002521 -3.0042 0.007349 
54 NPR1 NM_000906 1.8188 0.005741 
55 OCLN NM_002538 -2.3367 0 
56 PDGFRA NM_006206 -1.456 0.104707 
57 PECAM1 NM_000442 1.0091 0.766073 
58 PF4 NM_002619 -4.2047 0.030872 
59 PGF NM_002632 -1.7255 0.000027 
60 PLAT NM_000930 -1.4459 0.126347 
61 PLAU NM_002658 1.0556 0.288138 
62 PLG NM_000301 1.0374 0.488782 
63 PROCR NM_006404 -2.3327 0.000002 
64 PTGIS NM_000961 -2.0028 0.008857 
65 PTGS2 NM_000963 2.6126 0.000009 
66 PTK2 NM_005607 -1.3967 0.000021 
67 SELE NM_000450 7.0641 0.000001 
68 SELL NM_000655 1.6364 0.000056 
69 SELPLG NM_003006 -2.1803 0.029765 
70 SERPINE1 NM_000602 -4.6251 0.000001 
71 SOD1 NM_000454 -1.7863 0.000009 
72 SPHK1 NM_021972 -2.1391 0.000192 
73 TEK NM_000459 -2.2532 0 
74 TFPI NM_006287 -1.2986 0.000011 
75 TGFB1 NM_000660 -1.1092 0.093609 
76 THBD NM_000361 -2.4487 0.000072 
77 THBS1 NM_003246 -1.5878 0.000133 
78 TIMP1 NM_003254 1.3269 0.004462 
79 TNF NM_000594 1.7752 0.0015 
80 TNFSF10 NM_003810 9.5666 0.000001 
81 TYMP NM_001953 4.494 0.000058 
82 VCAM1 NM_001078 5.056 0 
83 VEGFA NM_003376 -1.0677 0.210602 
84 VWF NM_000552 -1.2117 0.025954 
 
When these genes were further analysed using Ingenuity Pathway Analysis, we observed that 
those involved in inflammation such as pro-inflammatory cytokines produced in response to 
stress, such as CCL5, CX3CL1, IL11 and IL1B, adhesion molecules such as VCAM1 and SELE 
which are induced after endothelial cell activation, and molecules involved in cell death, such as 
CASP1, TNFSF10, PF4, CAV1 and IL11, were enriched (Figure 4.13B, Table 4.1). Chronic 
inflammatory conditions can lead tovascular malformations as seen in Crim1
Δflox/Δflox 
mice, and 
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eventually lead to irreversible multiple organ defects(Pennisi, Wilkinson et al. 2007). This could 
be one of the causes for embryonic lethality observed in Crim1 conditional null mice(Chiu, York 
et al. 2012). 
 
In the case of genes associated with cellular infiltration, ILIB, VCAM1, PTGS2, CCL5, SELE, 
F3, CASP1, which increase infiltration, were upregulated, and CAV1, SERPINE1, FN1, ADAM17 
and THBD, which decrease cellular infiltration, were downregulated. Genes associated with 
inflammation were predicted to be enriched based on upregulation of IL1B and VCAM1, and 
downregulation of OCLN, THBD and IL11. Specifically, there was an increase in expression of 
endothelial genes involved in recruitment of phagocytes, monocytes and leukocytes, and 
infiltration by cells such as monocytes, neutrophils, leukocytes and granulocytes (Figure 4.13B, 
Table 4.1), which is characteristic of cellular recruitment to sites of injury and stress and an 
inflammatory response. Similarly, genes associated with cytolysis were predicted to be 
increased, due to an upregulation of IL1B, TNFSF10, CASP1 and CX3CL1, and downregulation 
of PF4, CAV1 and IL11. This is consistent with invivo data indicating a reduction in endothelial 
cell numbers in the absence of Crim1as observed using endothelium-specific mutants and 
conditional null mice, as well as in vitro data which indicates reduced HCMVEC viability. 
 
Genes associated with vascular lesions were predicted to be enriched (Fig. 4.13B, Table 3), 
consistent with an upregulated expression of endothelial genes such as IL1B, VCAM1, PTGS2, 
CX3CL1 and SELE. Genes associated with size of vascular lesions were also predicted to be 
increased based on increase in endothelial expression of IL1B, VCAM1, PTGS2, SELE, CX3CL1, 
MMP9 and CASP1, and downregulation of CAV1, ANXA5 and THBD. Pertinent to other 
cardiovascular diseases, genes associated with heart failure and infarction were predicted to be 
increased based on misregulation of endothelial genes such as CAV1, ANXA5, PTGS2, THBD, ILIB, 
F3 and MMP9 (Fig. 4.13C, Table 4.1).  
 
Additionally, upstream factors such as TNF and TNF family members, CD40, IL17 and RELA (of 
the NFB family) which have been shown to stimulate inflammation (Galkina and Ley 2009, 
Lawrence 2009) were predicted to be activated based on changes in downstream effector genes 
(Figure 4.13A). Specifically, in the case of TNF, 16 genes had an expression direction consistent 
with activation of TNF. VCAM1, SELE, IL1B, CCL5, TYMP, PTGS2, F3, TNFSF10, MMP9 and 
CX3CL1 which are known to be upregulated by TNF were upregulated in the dataset, and thus TNF 
was predicted to be activated. THBD, SPHK1, OCLN, KIT andCAV1 which are known to be 
downregulated by TNF are downregulated in the dataset, and thus, TNF is predicted to be activated. 
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RELA is predicted to be activated based on upregulation of VCAM1, SELE, PTGS2, MMP9, IL1B 
and CCL5. IL17A is predicted to be activated based on upregulation of VCAM1, SELE, PTGS2, 
MMP9, IL1B, CX3CL1 and CCL5, and downregulation of THBD and OCLN (Fig. 4.13A, Table 
4.1). 
 
 
4.13: Ingenuity Pathway Analysis of misregulated endothelial genes in CRIM1 knockdown 
HCMVECs 
A-C, IPA analysis of genes misregulated in the human endothelial cell biology qPCR array, indicating predicted activity 
by upstream regulators such as TNF, RELA, IL17A (A), a heightened inflammatory response and cell death (B), along 
with a predicted increase in heart failure, infarction and vascular lesions (C) based on endothelial gene expression. Z 
scores > 2 are significant. 
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Effect of CRIM1 overexpression on endothelial genes. 
Having observed that CRIM1 ablation causesgene expression changes that have been correlated 
with heightened inflammatory response and cell death, we hypothesized that CRIM1 
overexpression could ameliorate these results by having an opposite effect on the expression of 
these endothelial genes. To address this hypothesis, we cloned CRIM1 in HCMVECs using 
Gateway Technology,to overexpress CRIM1, confirming that there was greater than a 2-fold 
increase in CRIM1 expression compared to GFP-only controls (Figure 4.14A).  
 
 
4.14: CRIM1 overexpression in HCMVECs 
A, CRIM1 overexpression in HCMVECs as compared to GFP-only control. (n=3). **P<0.01. 
 
We then tested the expression of 10 genes that were more than three-fold up or downregulated in 
the absence of CRIM1, including CASP1, CCL5, CX3CL1, IL1B, KIT, SELE, SERPINE1, 
TNFSF10, TYMP and VCAM1 (Table 4.2).We found that the presence of CRIM1 had an 
attenuating effect on the expression of many of these genes compared to CRIM1 knockdown 
(Figure 4.15A), and could likely abrogate inflammation and promote survival of endothelial 
cells.For example, the expression of pro-inflammatory and pro-apoptotic markers like CCL5, 
IL1-B, SELE, TNFSF10 and VCAM-1, which is increased in CRIM1 knockdown HCMVECs, is 
reduced in HCMVECs in which CRIM1 was overexpressed.The limited ability of the 
endothelium to repair itself has made it critical to uncover molecules that can counter or prevent 
endothelial dysfunction. Thus, the presence of Crim1 could counter the pathophysiology of 
various diseases that are directly involved with endothelial abnormalities, such as 
atherothrombosis, hypertension and kidney failure, while maintaining homeostasis of the 
cardiovascular system and heart function on the whole(Pennisi, Wilkinson et al. 2007, 
Rajendran, Rengarajan et al. 2013, Morbidelli, Donnini et al. 2016). 
  
 107 
Table 4.2: 10 endothelial genes had more than a 3-fold regulation in the CRIM1 knockdown assay. 
These 10 genes were assessed again in HMCVECs that had CRIM1 overexpressed, revealing a 
change in fold regulation upon CRIM1 overexpression that is mostly beneficial in the context of 
endothelial cell inflammation and death. 
 
NUMBER GENE FOLD REGULATION P-VALUE 
1 SERPINE1 1.315 0.101 
2 VCAM1 1.46 0.0039 
3 TYMP 1.90 0.0018 
4 KIT 2.529 0.0005 
5 CX3CL1 14.407 0.0086 
6 CCL5 3.46 0.0011 
7 CASP1 1.64 0.1340 
8 IL1B -3.07 0.0028 
9 SELE -2.614 0.003 
10 TNFSF10 2.566 0.0001 
 
 
 
4.15: Effect of CRIM1 overexpression in HCMVECs compared to CRIM1 knockdown 
HCMVECs 
A, Overexpression of CRIM1 ameliorated the effect of CRIM1 knockdown in HCMVECs as assessed using 10 
endothelial genes that had more than a 3-fold change upon initial CRIM1 knockdown in HCMVECs. (n=3). 
 
Cell-autonomous role for Crim1 in regulating BMP signalling, in vivo. 
Having observed a reduction in BMP signalling in endothelial cells of Crim1 conditional null 
mutants and HCMVECs that have lost CRIM1, we further investigated whether this was a cell-
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autonomous defect by using Crim1
FLOX/FLOX
; R26R; Tie2-Cre mutant hearts. However, contrary 
to expectations, we found that there was a marked increase in phospho-SMAD1/5 in mutants 
compared to Crim1
+/FLOX
; R26R; Tie2-Cre controls (Figure 4.16A-J), in all cells (Figure 4.16G, 
H) as well as exclusively endothelial cells (Figure 4.16I, J).  
 
 
Figure 4.16: Increase in canonical BMP signalling in cells of Crim1
FLOX/FLOX
; Tie2-Cre hearts 
as assessed with phospho-SMAD1/5 
A-F, Confocal images of ventricular sections of 17.5 dpc hearts from ventricles of Crim1
+/FLOX
; Tie2-Cre (A-
C)andCrim1
FLOX/FLOX
; Tie2-Cre (D-F)hearts, immunostained for PECAM-1 and phospho-SMAD1/5.A, C, D, 
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F,Merged images of DAPI (blue), PECAM-1 (green) and pSMAD1/5 (red). C, F, Magnified images showing vessel 
with increased phospho-SMAD1/5 levels within endothelial cells in Crim1
FLOX/FLOX
; Tie2-Cre  hearts (F) compared 
to control (C). G, H, Increase in phospho-SMAD1/5 signalling in Crim1
FLOX/FLOX
; Tie2-Crehearts in all cells. I, J, 
Increase in phospho-SMAD1/5 signalling in Crim1
FLOX/FLOX
; Tie2-Crehearts in endothelial cells. (n=6). RV, right 
ventricle; ep, epicardium; en, endocardium. *P<0.05. Scale bars A, B, D, E, 50 μm, C, F, 10 μm. 
 
We also examined phospho-SMAD2 levels in mutant hearts compared to controls but there was 
no significant change, indicating that canonical TGFβ signalling is largely independent of Crim1 
(Figure 4.17A-F). 
 
 
Figure 4.17: No change in canonical TGF signalling in endothelial cells of Crim1FLOX/FLOX; 
Tie2-Cre hearts as assessed with phospho-SMAD2 
A-F, No change in phospho-SMAD2 levels as a proxy to assess canonical TGF signalling in ventricles of Crim1+/FLOX; 
Tie2-Cre andCrim1
FLOX/FLOX
; Tie2-Cre hearts. A-D, Confocal images of ventricular sections of 17.5 dpc hearts 
fromCrim1
+/FLOX
; Tie2-Cre (A, B) and Crim1
FLOX/FLOX
; Tie2-Cre(C, D) embryos, immunostained for PECAM-1 and 
phospho-SMAD2.A, C, Merged images of DAPI (blue), PECAM-1 (green) and pSMAD1/5 (red).E, F No change in 
phospho-SMAD2 levels in Crim1
FLOX/FLOX
; Tie2-Creendothelial cells (n=4-6).LV, left ventricle; en, endocardium; 
ep, epicardium. Scale bars, A, C, 50 μm. 
 
Increase in phospho-SMAD1/5 signalling may not directly be due to paracrine stimulation 
by BMP2/BMP4. 
In light of the fact that there was an increase in phospho-SMAD1/5 levels in Crim1
FLOX/FLOX
; 
R26R; Tie2-Cre hearts at 17.5 dpc (Figure 4.16A-J), it could indicate that in these mutants, the 
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ventricular cells that retain Crim1 function could provide BMP stimulation so as to 
overcompensate for endothelial loss of Crim1. To address this hypothesis further, we stimulated 
HUVECs that had CRIM1 ablated with exogenous BMP2 and BMP4. Addition of BMP2 and 
BMP4 did not cause an increase in phospho-SMAD1/5 levels CRIM1 knockdown HUVECs 
compared to scrambled shRNA controls (Figure 4.18A, B). We also treated the cells with 
LDN193189, an inhibitor of BMP receptors ALK2 and ALK3 that mediate downstream BMP 
signalling, along with BMP2 and BMP4. Addition of LDN alone suppressed phospho-SMAD1/5 
signalling in only CRIM1 knockdown HUVECs (Figure 4.18A, B). Addition of exogenous 
BMP2 and BMP4 to LDN-treated cells did not significantly increase phospho-SMAD1/5 levels 
between CRIM1 knockdown and control cells, indicating that LDN is efficient in inhibiting 
downstream signalling via ALK2/3 (Figure 4.18B). Thus, our data indicates that there could be 
another member of the BMP family that is responsible for the endothelial increase in phospho-
SMAD1/5 that was observed in Crim1
FLOX/FLOX
; R26R; Tie2-Cre hearts. 
 
 
Figure 4.18: Addition of exogenous BMP-2/4 does not exert a paracrine effect on CRIM1 
knockdown HUVECs 
A, Change in pSMAD1/5 levels as a proxy to assess BMP signalling in the presence of inhibitor LDN193189 and 
exogenous BMP-2/4. B, Compared to PBS-treated scrambled shRNA control HUVECs, there is an increase in 
pSMAD1/5 upon treatment of scrambled shRNA control HUVECs with exogenous BMP-2 and decrease in pSMAD1/5 
in PBS-treated, LDN-treated, LDN + BMP-2 treated, and LDN + BMP-4 treated CRIM1 knockdown HUVECs, by way 
of a 1-way ANOVA (significance represented by #). Using t-tests, we see a decrease in pSMAD1/5 in PBS-treated 
CRIM1 knockdown HUVECs, and also in LDN-treated, LDN + BMP-2 treated, LDN + BMP-4 treated, BMP-2 CRIM1 
knockdown HUVECs, compared to their respective scrambled shRNA control HUVECs (significance represented by *) 
(n=3).Representative blot chosen.*
/#
P<0.05, **P<0.01, ***
/###
P<0.001. 
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Discussion. 
We have investigated the function of Crim1 in coronary endothelial cell development in vivo, 
using both constitutive nulls and tissue-restricted knockouts. Specifically, the number of 
coronary vascular endothelial cells was reduced, and this was also observed in vitro in 
HCMVECs lacking CRIM1, which display decreased viability. However, further experiments are 
required to discern whether the loss of CRIM1 promotes apoptotic or necrotic endothelial cell 
death. We also provide evidence that in coronary endothelial cells, Crim1 modulates BMP 
signalling, as demonstrated by changes in downstream phospho-SMAD1/5 levels. Finally, we 
describe changes in endothelial gene expression, characteristic of endothelial dysfunction and 
disease, which may either cause, or result in, diminished endothelial cell numbers and disrupted 
growth factor signalling collectively. While we have described both a knockdown and 
overexpression of CRIM1 in HCMVECs, both these will have to be confirmed at the protein 
level by Western blotting in future experiments. 
 
Cardiac endothelial cells are in close contact with other cells of the heart, importantly the 
cardiomyocytes and vascular smooth muscle cells (Brutsaert, Fransen et al. 1998). Essential factors 
produced by both endocardial and myocardial vessel endothelial cells have been shown to influence 
cardiomyocyte survival (Narmoneva, Vukmirovic et al. 2004), and also smooth muscle and 
cardiomyocyte performance (Brutsaert, Fransen et al. 1998, Brutsaert 2003). Reciprocal signalling 
between these cells is required for proper cardiac development (Brutsaert 2003, Hsieh, Davis et al. 
2006). The regenerative potential of the heart has received considerable focus in recent years and 
there exist a variety of strategies aimed at engineering cardiac tissue (Narmoneva, Vukmirovic et al. 
2004). Neovascularization is a critical process that aids myocardial regeneration following injury 
(Porrello, Mahmoud et al. 2013), and studies have shown that the interaction of cardiomyocytes and 
endothelial cells leads to enhanced cardiomyocyte network formation, coordinated beating, and 
overall spatial organization (Narmoneva, Vukmirovic et al. 2004). We reveal a reduction in 
endothelial cell number in the compact myocardium of constitutive and tissue-restricted mutants,in 
vivo. This is further confirmed in vitro, where there is a decrease in the number of viable HUVECs 
and HCMVECs in the absence of CRIM1. Moreover, in HCMVECs, inducers of apoptosis, such as 
CASP1 and TNFSF10 are upregulated, and molecules such as PF4, CAV1 and IL11, which 
decrease cell death, are downregulated.In light of this, a reduction in the number of endothelial 
cells in the absence of Crim1, as seen in both constitutive nulls as well as endothelial-restricted 
mutants, could imply sub-optimal conditions for the functioning of surrounding coronary smooth 
muscle cells and cardiomyocytes. It would be of interest to assess endothelial cell death in 
conditional nulls, as well as in surrounding cells, to further investigate this hypothesis. Additionally, 
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it would be worthwhile to assess vessel length and number of branchpoints in both embryonic and 
adult hearts lacking Crim1, to further examine the role of Crim1 in causing abnormal vessel 
morphology. While we did not find any discernable differences in the vasculature of 
Crim1
Δflox/Δflox
hearts at earlier time points, more detailed analysis needs to be performed using a 
larger sample size, while also assessing apoptosis and proliferation of these cells. 
 
The VWC domains in Crim1 are similar to those present in secreted proteins such as chordin (Sasai, 
Lu et al. 1994) that has been shown to function as BMP antagonists. Though Crim1 has been shown 
to antagonize BMP-7 and BMP-4 (Wilkinson, Kolle et al. 2003), its role in the heart appears to be 
different. Growth factor modulation by CRIM1 can occur via its various domains, but whether it 
acts as an agonist or antagonist is thus likely dependent on its environment and developmental 
context (Wilkinson, Kolle et al. 2003, Fung, Chi Fat et al. 2007, James and Broihier 2011).BMPs 2 
and 4 are produced by endothelial cells, smooth muscle cells and cardiomyocytes and have both 
autocrine and paracrine functions on the same targets, via activation of smad1/5/8 (Morrell, Bloch 
et al. 2016). Inflammation and atherogenesis are stimulated due to heightened BMP signalling, 
especially by BMPs 2 and 4 (Jo, Song et al. 2006, Derwall, Malhotra et al. 2012, Morrell, Bloch et 
al. 2016). This implies that when BMP signalling is inhibited, both inflammation and atherogenesis 
are reduced. However, we observe an increase inexpression of markers associated with 
inflammation, accompanying reduced BMP signalling via the phospho-SMAD1/5 pathway in 
CRIM1 knockdown HCMVECs. Moreover, in conditional nulls, BMP signalling is also decreased. 
This is coincident with other studies that imply a protective effect of BMP-2 in atherosclerotic 
plaques(Nakaoka, Gonda et al. 1997), and BMP-9 in promoting vascular stability and preventing 
the death of pulmonary artery endothelial cells (Long, Ormiston et al. 2015). Contrary to these two 
models, in Crim1
FLOX/FLOX
;Tie2-Cre mice, BMP signaling via the phospho-SMAD1/5 pathway is 
increased. A caveat of this study, however, is that inflammation in Tie2-Cre mutants was not 
assessed. Irrespective of this, it may be likely that other cells in the myocardium that retain Crim1, 
could produce BMPs which would bind to receptors on endothelial cells, and activate downstream 
signaling. Furthermore, any differences observed in our studies and others could be a result of 
different characteristics displayed by endothelial cells arising from distinctive vascular networks 
from different areas (Aird 2007). Another explanation could be that because BMPs are required for 
endothelial cell development (Langenfeld and Langenfeld 2004, Liu, Selever et al. 2004, Suzuki, 
Montagne et al. 2008), any decrease in BMP signaling, could lead to a manifestation of endothelial 
stress, and any inflammatory responses and gene changes associated with this could be a secondary 
pathology. 
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There was no obvious external phenotypic defect, or change in animal health, in adult Tie2-Cre 
mutants. Thus, it would be interesting to subject Crim1
FLOX/FLOX
;Tie2-Cre mice to stress, injury or 
diet-dependent load to the metabolic system, and assess their response. We hypothesize that these 
mutants would be more prone to inflammation and subsequently, artherosclerotic lesions, based on 
our current observations. Another path to explore is the crossbreeding of Crim1 mutant mice with 
ApoE
-/-
 or LDLr
-/-
mice, which are the most extensively used in atherosclerosis and hyperlipidemia 
research,to directly examine the role of Crim1 in vascular inflammation and atherogenesis. As 
previously mentioned, other growth factors and molecules secreted by surrounding cell types may 
compensate for the loss of Crim1 function in specifically endothelial cells, leading to the lack of an 
outward phenotype in the adulttissue-restricted mice, exacerbated only upon environmental 
changes. 
 
The role that endothelial cells play in the development of atherosclerosis, which is a leading cause 
of coronary artery disease and risk factor for myocardial infarction, is firmly established, and 
dependent on endothelium activation (Hansson 2005). This activation of the endothelium is a result 
of both a response to, and a secretion of a large number of factors that in turn lead to the recruitment 
of leukocytes, neutrophils and granulocytes, eliciting an inflammatory response (Figure 4.19). It is 
evident from our results that there is a misregulation of these factors, including cell adhesion 
molecules, interleukins and other chemokines, when CRIM1 is ablated. CX3CL1, specifically 
expressed in endothelial cells, may be a marker for artherosclerosis (Umehara, Bloom et al. 2004), 
and is upregulated in CRIM1-deficient endothelial cells. Coincident with a chronic inflammatory 
state that often precedes atherogenesis, pro-inflammatory mediators like IL1-B, SELE, CCL5 and 
VCAM-1 are also upregulated, and this likely by regulators such as TNFs and RELA (of the NFB) 
family that function upstream of these genes (Gearing and Newman 1993, Hajra, Evans et al. 2000, 
Aird 2007, Galkina and Ley 2009, Frostegård 2013, Gimbrone and García-Cardeña 2016). It has 
been previously established that a pro-inflammatory response and secretion of cytokines by 
endothelial cells stimulates vascular smooth muscle cell proliferation, and that aberrant proliferation 
promotes plaque and lesion formation (Rudijanto 2007). CRIM1 knockdown HCMVECs may also 
possessthe potential to increase smooth muscle cell proliferation based on an increased expression 
of endothelial genes such as CCL5, CX3CL1(Perros, Dorfmuller et al. 2007), ILIB and TNFSF10; 
this proliferation is characteristic of atherosclerosis progression (Rudijanto 2007), and could 
implicate CRIM1 in this disease.  Furthermore, CRIM1 overexpression could have a therapeutic 
effect in attenuating a pro-inflammatory state based on the comparison of the expression of target 
genes examined in our study, making it an exciting avenue for future research. 
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Figure 4.19: Schematic representation of endothelial proinflammatory activation 
In lesion-prone regions of the arterial vasculature, the actions of proinflammatory agonists (eg, interleukin [IL]-1, tumor 
necrosis factor [TNF], and endotoxin), oxidized lipoproteins (ox-LDL) and advanced glycation end products (AGE), as 
well as biomechanical stimulation by disturbed blood flow, leads to endothelial activation. These biochemical and 
biomechanical stimuli signal predominantly via the pleiotropic transcription factor nuclear factor-κB (NF-κB), resulting 
in a coordinated program of genetic regulation within the endothelial cell. This includes the cell surface expression of 
adhesion molecules (eg, vascular cell adhesion molecule-1 [VCAM-1), secreted and membrane-associated chemokines 
(eg, monocyte chemotractant protein [MCP]-1 and fractalkine (CX3CL1), and prothrombotic mediators (eg, tissue 
factor [TF], vonWillebrand Factor [vWF], and plasminogen activator inhibitor [PAI]-1 (called SERPINE1 in humans)). 
These events foster the selective recruitment of monocytes and various types of T lymphocytes, which become resident 
in the subendothelial space. The concerted actions of activated endothelial cells, smooth muscle cells, 
monocyte/macrophages, and lymphocytes result in the production of a complex paracrine milieu of cytokines, growth 
factors, and reactive oxygen species (ROS) within the vessel wall, which perpetuates a chronic proinflammatory state 
and fosters atherosclerotic lesion progression. IL-R, TNF-R indicates receptor(s) for IL-1, TNF; Ox-LDL-R, receptor 
for oxidized LDL; RAGE, receptor for AGE; and TLRs, Toll-like receptors (Illustration Credit: Ben Smith). (Adapted 
from (Gimbrone and García-Cardeña 2016)). 
 
In conclusion, in Crim1-mutant mice we observed a reduced number of endothelial cells and 
dysregulation of the phospho-SMAD1/5 pathway involved in BMP signal transduction. 
Subsequently, we have elucidated that the BMP pathway is aberrant in CRIM1 mutant human 
cardiac endothelial cells; this will help provide novel information on the specific roles played by 
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different growth factors in coronary vascular endothelial cell development in the future. The 
absence of CRIM1 also perturbs the expression of a large number of genes involved in progression 
of endothelial disease states. Collectively, our findings provide a basis for understanding the 
molecular mechanisms of Crim1 dysfunction in endothelial cells of the heart and identify Crim1 to 
be a critical regulator of endothelial cell function. 
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Chapter 5 
 
 
Investigating whether the IGFBP domain of CRIM1 can 
serve to bind IGFs and modulate downstream signalling 
 
  
 117 
Author contributions 
Primers for generation of CRIM1 deletion constructs using InFusion cloning were designed by Dr. 
Aaron Smith. 
Western blotting was performed in association with Dr. Yash Chhabra. 
All densitometry quantifications were performed blinded by Dr. Yash Chhabra. 
  
 118 
Introduction 
A large number of growth factors function cooperatively to mediate a variety of cellular processes, 
and their timely regulation is crucial for proper development to ensue. This makes it essential for us 
to investigate novel modulators of these growth factors, to uncover mechanisms by which 
developmental aberrations that occur due to impaired growth factor signalling can be alleviated. 
CRIM1 possesses six CRRs, via which it has been shown to bind growth factors such as BMPs, 
TGFβ and VEGF (Wilkinson et al., 2003, Wilkinson et al., 2007), along with an IGFBP-like 
domain whose functional relevance is not yet known (Kolle et al., 2000). In light of this, we 
hypothesize that CRIM1 can bind another family of growth factors, the IGFs, via its CRRs and its 
IGFBP domain.  
 
While VEGFs and BMPs receive maximum attention in the context of endothelial cell biology, 
another essential growth factor that is required for normal endothelial cell function is the IGF. Both 
autocrine and paracrine functions for IGFs are known, and their cellular effects are widespread 
(Jones and Clemmons, 1995). Two IGF ligands exist, IGF-1 and IGF-2, which bind to the IGF-1 
and IGF-2 receptors. These also bind to the insulin receptor, based on similar sequence homology 
(Jones and Clemmons, 1995). The IGF receptor is a heterotetramer, with the 2 extracellular α 
subunits participating in ligand binding and the two intracellular β subunits possessing tyrosine 
kinase activity (Laustsen et al., 2007), and triggers a signalling cascade upon phosphorylation, 
leading to the activation of the MAPK, ERK1/2 and AKT pathways (Baserga, 1999) and 
consequently, multiple cellular responses including cell proliferation, death, differentiation and 
overall function (Jones and Clemmons, 1995).  
 
Differential alternative splicing of the IGF-1 gene produces transcripts coding for different IGF-1 
precursor polypeptides; these Ea, Eb and Ec variants of IGF-1 add to the diversity of this growth 
factor (Delafontaine et al., 2004). Most of the actions mediated by IGF-1 are a result of the binding 
of the mature IGF-1 peptide to the IGF receptor; the bioactive IGF-1 peptide is generated upon 
post-translational modifications involving removal of the C-terminal E peptides (Hede et al., 2012).  
The significance of each of these peptides is unclear; however, their existence in different tissues 
implies the complex role of these IGF-1 isoforms under varying conditions (Philippou et al., 2014). 
Interestingly, the IGF-1 Eb peptide, also called mechano-growth factor (MGF), has been shown to 
improve cardiac function and preserve blood supply to heart muscle (Carpenter et al., 2008). 
 
The amount of IGF-1 and IGF-2 produced by endothelial cells is low, but their IGF-1 receptor 
expression is abundant (Delafontaine et al., 2004, Back et al., 2012). Endothelial cells also express 
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IGF Binding proteins, which modulate IGF activity (Hwa et al., 1999). This occurs locally, or is 
systemic, based on endocrine control over circulating IGFs (Yamada and Lee, 2009). The 
bioavailability of IGFs is controlled by IGFBPs, as is their half-life. IGFBPs can also sequester 
IGFs, thereby limiting the activation of IGF receptors, or act as vehicles for IGF trafficking (Hwa et 
al., 1999). It is important to note that both the IGF receptor and IGFBPs contain cysteine-rich 
regions that are required for binding IGFs (Lee et al., 1997,Keyhanfar et al., 2007). 
 
Thus, the CRRs are a common thread that likely link the binding of IGF-1 to the IGFR, IGFBPs, 
and potentially, CRIM1. Furthermore, IGFs secreted from the epicardium have been shown to 
influence development of the ventricular chambers in the embryo (Li et al., 2011). In light of the 
fact that Crim1 is strongly expressed in the epicardium, and that it has both CRRs and an IGFBP 
domain, led us to hypothesize that it can bind IGFs, and modulate their activity. 
 
In the current chapter, we reveal for the first time, that CRIM1 can indeed bind IGF-1. Moreover, 
the examination of the phosphorylation status of the IGF-1 receptor in the absence of CRIM1 also 
shows that CRIM1 modulates IGF-1 signalling in human cardiac endothelial cells. Taken together, 
our studies demonstrate aputative role for CRIM1 in regulating the activity of yet another family of 
growth factors, the IGFs.  
 
Materials and methods 
Cell Culture 
H-CMVECs and pooled HUVECs were cultured in EGM-2MV and EGM-2 BulletKit media 
respectively. Cells before passage six were used in all experiments.  Lentiviral particles containing 
shRNA targetingCRIM1 mRNA were synthesized, and used to infect cell populations as described 
previously.Prior to examining the effect of exogenous IGF-1 stimulation, cells were starved in 
serum-free basal media without growth factors for 2 hours. 
 
Antibodies 
Primary antibodies used in the study were: phospho-IGF-1Rβ (#3024S; Cell Signalling), phospho-
AKT (#4060; Cell Signalling); phospho-ERK1/2 (#4370; Cell Signalling); total AKT (#9272; Cell 
Signalling); total ERK1/2 (sc-93; Santa Cruz); total IGF-1R (sc-712; Santa Cruz); GAPDH (#2118; 
Cell Signalling); -tubulin (#2146, Cell Signalling); rabbit monoclonal HA tag (#3724; Cell 
Signalling); mouse monocolonal myc tag (#2276; Cell Signalling); normal mouse IgG2a isotype 
control (#02-6200; Thermo Fisher Scientific).  Secondary antibodies were rabbit HRP (#W4011; 
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Promega), mouse HRP (#W4021; Promega), IgG mouse IRDYE (#926-32212; Licor) and IgG 
rabbit IRDYE (#926-68073; Licor). 
 
Generation of deletion constructs 
Full-length myc-tagged CRIM1(Wilkinson et al., 2003) was used as a template to generate myc-
tagged CRIM1 deletion constructs. Primers were designed as follows: 
 
CRIM1-3.1-InF-RV-F 
5’-TGGAATTCTGCAGATATGTACTTGGTGGCGGGG-3’ 
 
CRIM1-3.1-InF-RV-R 
5’-GCCACTGTGCTGGATTCATAGGTCTTCTTCTGA-3’ 
 
CRIM1-IGFBPsplice-InF-F 
5’-GAGAACTGGACTGATGAC-3’ 
 
CRIM1-IGFBPsplice-InF-R 
5’-ATCAGTGCAGTTCTCCGCCCGGGTGCCGGAGCGCGC-3’ 
 
CRIM1-D1-2-IF-F 
5’-GAAGAACCAACCATCATC-3’ 
  
CRIM1-D1-2-IF-R 
5’-GATGGTTGGTTCTTCGGCTGGCTTTGTATCATTAAC-3’ 
  
CRIM1-D3-6-IF-F 
5’-CCAGAAATGTATGTCCCA-3’ 
  
CRIM1-D3-6-IF-R 
5’-GACATACATTTCTGGAGTGCCCGACAGGATGGGTGG-3’ 
  
CRIM1-D1-6-IF-R 
5’-GACATACATTTCTGGGGCTGGCTTTGTATCATTAAC-3’ 
 
Cloning was performed using the In-Fusion Kit (#638910). Ensembl transcript ID CRIM1-001 
ENST00000280527 was used as a reference for analysis. For CRIM1ΔIGFBP, amino acids 34-111 
(bp 102 – 333) were deleted, for CRIM1Δ1-2, amino acids 335 – 456 (bp 1005 – 1367) were 
deleted. For CRIM1Δ3-6, amino acids 607 – 873 (bp 1821 – 2619) were deleted. For CRIM1Δ1-6, 
amino acids 335 – 873 (bp 1005 – 2619) were deleted. For CRIM1ΔIGFBPΔ1-6, amino acids 34 – 
111 (bp 102 – 333) and amino acids 335 – 873 (bp 1005 – 2619) were deleted. Constructs were 
sequenced to confirm deletion.  
 
Briefly, the vector pcDNA3.1 was linearized by ECORV digestion, gel purified and run on a gel to 
check for complete digestion. Wildtype CRIM1 was generated using InFusion primers, run on a gel 
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to check the size of product, and ligated using the InFusion kit. The Ligation was performed at 
50°C for 15 minutes and placed on ice. The ligated mixture was used to transform competent cells, 
and plated on agar plates containing Ampicillin. Colonies were observed the next day, and picked 
for plasmid mini-prep experiments. The colonies were also digested with restriction enzymes 
HindIII and XhoI, which are non-cutters of CRIM1 and single, unique cutters of pcDNA3.1. Bands 
were observed at the right sizes. The protocol was repeated for generation of all deletion constructs.  
 
Co-Immunoprecipitation 
HEK293 at 80% confluence were transfected with full length myc-tagged CRIM1(Wilkinson et al., 
2003), myc-tagged CRIM1 deletion constructs, and HA-tagged IGF-1 Ea and IGF-1 Eb constructs 
(Hede et al., 2012) using Lipofectamine 2000 (Invitrogen). After 24 hours, the cells were lysed in 
RIPA containing protease inhibitor and phosphatase inhibitor on ice. Immunoprecipitation was 
performed by the addition of α-myc antibody for 2 hours at 4°C, followed by addition of 30 μL of 
Protein A Agarose (Roche, # 11719408001). The mix was further incubated for 1 hour at 4°C. The 
beads were pelleted and washed five times with cold PBS 0.1% Triton X-100. Protein was eluted by 
addition of SDS-PAGE loading buffer and boiled for 4 minutes.  
 
Western Blotting 
Control and CRIM1-knockdown HCMVECs were lysed in RIPA buffer containing protease 
inhibitor and phosphatase inhibitor. The lysates were heated at 95°C for 4 minutes with SDS-PAGE 
loading sample buffer, run on a 10% SDS-polyacrylamide gel and transferred onto PVDF 
membranes. Membranes were blocked in 5% BSA, probed with primary and secondary antibodies 
and detected using ECL. 
 
Data Documentation, Quantification and Analysis 
Immunoblots were visualised either with a chemi-luminescent reagent (Merck Millipore) via 
exposure to X-ray film, or by using the Licor scanner. All densitometry quantitation was performed 
on immunoblots using ImageJ software. All test values were normalised to respective loading and 
experimental controls and graphed with Prism 6. 
 
Specifically for COIP quantification, IP-myc intensity = x. IB-HA intensity = y. y/x = z. total cell 
lysate-CRIM1/GAPDH =a. total cell lysate-IGF/GAPDH = b. a/b=c. z/c = plotted values for 
assessing binding of IGF-1 Eb to different CRIM1 deletion constructs. IP refers to CRIM1 
pulldown with Myc, and IB refers to probing for IGF-HA. 
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Statistical significance between pooled data from mutant and control groups was determined using a 
two-tailed, unpaired Student’s t-test or a standard one-way ANOVA with Dunnett’s post-test, as 
specified in the figure legend. For coimmunoprecipitation quantification, a standard one-way 
ANOVA with Dunnett’s post-test was used. Quantified data shown are mean ± standard deviation. 
GraphPad Prism v6.0 was used to conduct all analyses and generate graphs. 
 
Results 
CRIM1 can bind IGF-1 
Although evidence suggests that CRIM1 can bind IGFs, based on the presence of the IGFBP 
domain of CRIM1 as well as its CRRs, such an interaction has never been reported. Thus,we 
hypothesised that CRIM1 could bind IGFs and modulate their activity. To address this, we first 
investigated whether CRIM1 could interact with IGF-1 intracellularly when transiently co-
transfected in HEK293 cells. Two splice variants of IGF-1, IGF-1 Ea-HA and IGF-1 Eb-HA, were 
co-immunoprecipitated with CRIM1-myc (Figure 5.1A). This suggests that full-length CRIM1 can 
bind to IGFs.  
 
 
Figure 5.1: COIP revealing that CRIM1 can bind IGF-1 Ea and IGF-1 Eb constructs 
A, HEK293 cells transiently transfected with full length CRIM1-myc and IGF-1 Ea-HA and IGF-1 Eb-HA. 
Immunoprecipitation performed with anti-myc and immunoblotting with anti-HA. IB bands were detected only when 
both CRIM1 and IGF-1 Ea/Eb were co-transfected. (n=3). 
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Generation of CRIM1 deletion constructs 
CRIM1 possesses six CR motifs, in addition to an IGFBP-like domain, and could thus bind IGFs 
via these domains as well. To investigate this, myc-tagged CRIM1 WT and deletion constructs were 
generated as outlined in the Materials and Methods section. Specifically, deletion constructs 
lacking the IGFBP domain, CRRs 1-2, 3-6, 1-6 and 1-6 along with the IGFBP domain were 
made (Figure 5.2). Product sizes were confirmed on a gel (Figure 5.3A-C), and constructs were 
sequenced to confirm deletions.  
 
 
Figure 5.2: Schematic representation of CRIM1 deletion constructs 
A, Representation of CRIM1 deletion constructs as generated using InFusion cloning.  1. Full length CRIM1, 2. 
CRIM1IGFBP lacking the IGFBP domain, 3.CRIM1lacking CRRs 1 and 2, 4. CRIM1lacking CRRs 3, 4, 5 
and 6, 5. CRIM1lacking all six CRRs. 6. .CRIM1IGFBPlacking the IGFBP domain and all six CRRs. 
Key: 
Green box – IGFBP domain 
Orange box – RGD motif 
Grey box – VWFC domain 
Red box – antistasin domain 
Black double line – trannsmembrane domain 
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Figure 5.3: Generation of CRIM1 deletion constructs 
A-C, Gel images of CRIM1 deletion constructs after restriction digestion with appropriate enzymes to confirm correct 
ligation and sizes of the constructs after InFusion cloning. 
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CRIM1 binds IGF-1 via its IGFBP-like domain, and CRRs 3-6 
Full length CRIM1-myc and all CRIM1-myc-tagged deletion constructs were co-transfected in 
HEK293 cells with IGF-1Eb-HA, due to its suggested role in the heart (Carpenter et al., 2008). In 
each case, IGF-1 Eb-HA was immunoprecipitated with CRIM1, but at varying levels. There was a 
significant decrease in IGF binding in the CRIM1 construct lacking the IGFBP domain, and 
CRRs 3-6 (Figure 5.4A, B). In the construct lacking all six CRRs, binding was significantly 
reduced, and almost absent in the construct lacking the IGFBP domain in addition to the six 
CRRs (Figure 5.4 A,B). This confirmed that as in the case of BMPs, VEGF and PDGF, the 
CRRs are required to mediate the binding of CRIM1 to IGF-1, along with the IGFBP domain.  
 
 
Figure 5.4A:Binding of IGF-1 Eb to CRIM1 deletion constructs 
A, HEK293 cells transiently co-transfected with full length CRIM1-myc, CRIM1IGFBP-
myc,CRIM1mycCRIM1mycCRIM1mycand CRIM1IGFBPmyc, and IGF-1 Eb-HA. 
Control cells transiently co-transfected with only CRIM1-myc and only IGF-1 Eb-HA. Immunoprecipitation performed 
with anti-myc and immunoblotting with anti-HA. IB bands were detected only when both CRIM1 and IGF-1 Ea/Eb 
were co-transfected. (Three independent IPs performed. Representative blot chosen).IgG controls were utilized in the 
first out of the three independent experiments performed, along with ‘no antibody’ controls and CRIM1-Myc-only and 
IGF-HA-only transfection controls, which were used in all three experiments. 
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Figure 5.4B: CRIM1 binds IGF-1 Eb via the IGFBP domain and CRRs 3-6 
B, CRIM1 binds IGF-1 Eb via the IGFBP domain and CRRs 3-6, as indicated by 1-way ANOVA analysis, which 
reveals that deletion of the IGFBP domain and CRRs 3-6 of CRIM1 significantly reduces binding of CRIM1 to IGF-1 
Eb. Deletion of CRRs 1-2 does not affect binding to IGF-1 Eb. (n=3). **P<0.01, ***P<0.001 
 
Interaction of CRIM1 with IGFs, and modulation of IGF signalling 
Using IGF-1 receptor phosphorylation as a proxy for IGF signal transduction, we examined 
whether CRIM1 could regulate the same. The level of phospho-IGF-1Rβ was significantly 
reduced in CRIM1 knockdown HCMVEC protein lysates (Figure 5.5 A,B), implying that CRIM1 
could serve to bind and present IGFs to their receptors, thereby increasing downstream 
signalling. Levels of phospho-AKT were unchanged (Figure 4.13A, B), indicating that 
endogenous IGF-1 may signal via another downstream pathway.   
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Figure 5.5: CRIM1 modulates IGF-1 signalling in HCMVECs 
Reduction in phospho-IGF-1 Rlevels as a proxy to assess IGF-1 signalling in CRIM1 knockdown H-CMVECs, 
indicating misregulation of the IGF-1 pathway in the absence of CRIM1 (n=3). **P<0.01 
 
Effect of IGF-1 stimulation in the absence of CRIM1 
The level of endogenous IGF-1 expression in endothelial cells is low (Tucci et al., 1998. 
Therefore, we sought to determine whether addition of exogenous IGF-1 would have an effect on 
IGF-1 signal transduction in the presence and absence of CRIM1. This would allow us to assess 
whether CRIM1 can regulate IGF-1 signalling when the growth factor is supplied by an external 
source. Therefore we stimulated HUVECs with recombinant IGF-1 to assess phosphorylation of 
the IGF receptor (Figure 5.6A-C). We also examined AKT phosphorylation in IGF-1 stimulated 
HUVECs, in the presence and absence of CRIM1 (Figure 5.6A, D, E). We found that phospho-
IGF-1Rβ levels continued to be low in both unstimulated and stimulated CRIM1 knockdown 
cells (Figure 5.6 B, C), but interestingly, levels of phospho-AKT, which were unchanged in 
unstimulated CRIM1 knockdown and control HCMVECs (Figure 4.13A, B) and HUVEC lysates 
(Figure 5.6D), were also decreased in IGF-1 stimulated CRIM1 knockdown HUVECs (Figure 
5.6E). Furthermore, addition of IGF1 to scrambled shRNA control cells also increased phospho-
AKT levels compared to untreated cells (data not shown), implying that the AKT pathway is 
employed when a sufficient amount of IGF-1 is present. 
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Figure 5.6: Change in downstream IGF signalling upon treatment of CRIM1 knockdown 
HUVECs with exogenous IGF-1 
A, CRIM1 knockdown and control scrambled shRNA HUVECs treated with exogenous IGF-1. B, In unstimulated 
CRIM1 knockdown HUVECs, levels of phospho-IGF-1Rwere reduced. C, In both CRIM1 knockdown and control 
scrambled shRNA HUVECs, level of phospho-IGF-1Rwere increased compared to unstimulated conditions, but 
CRIM1 knockdown HUVECs still displayed lower levels of phospho-IGF-1RD, In unstimulated CRIM1 knockdown 
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HUVECs, levels of phospho-AKT were unchanged compared controls. E, In IGF-1 stimulated CRIM1 knockdown and 
control scrambled shRNA HUVECs, levels of phospho-AKT were increased compared to unstimulated conditions, 
accompanied by a decrease in phospho-AKT in CRIM1 knockdown HUVECs compared to control. (n=2). 
Representative blot chosen*P<0.05, **P<0.01 
 
Discussion 
IGFBPs mainly function as regulators of IGFs (Hwa et al., 1999); thus, the presence of an IGFBP 
domain in CRIM1 suggested that it would solely mediate binding to IGFs. CRRs are known to 
mediate binding of TGFβ superfamily members to other proteins that modulate their function 
(Larraín et al., 2000).  Furthermore, it has also been revealed that cysteine-rich regions, which are 
present in the IGF receptor and IGFBPs as well, are essential for IGF binding (Lee et al., 
1997,Keyhanfar et al., 2007). This is the first study revealing that CRIM1 can bind IGF-1, via both 
its IGFBP domain and CRRs 3-6. It is noteworthy that IGFBP-7 of the IGFBP family has the 
highest sequence similarity to CRIM1 (Kolle et al, 2000). We have demonstrated that like IGFBPs, 
CRIM1 modulates IGF signalling, but the mechanism by which it does so, is not yet established. 
This is a novel finding, which will have implications in most tissues and organs, due to the 
involvement of IGFs in governing development and regulation of normal physiology, homeostasis 
and disease states. 
 
How does our finding impact vascular development and disease? Neovascularization in murine 
retinas was reduced upon IGF-1 receptor inhibition, and this occurred in part due to a reduction in 
VEGF-induced MAPK activation (Smith et al., 1999). Moreover, there was a decrease in 
endothelial cells in human fetal lung explants when IGF signalling was disrupted by blocking the 
IGF receptor (Han et al., 2003). IGF-1 has previously been known to enhance angiogenesis, likely 
through enhancing the expression of other angiogenic factors such as VEGFs and TGF(Punglia et 
al., 1997, Miele et al., 2000), and exogenously administered IGF-1 was found to have a protective 
function against myocardial ischemia (Lisa et al., 2011). Interestingly, it has been found that low 
levels of IGF in circulation are associated with coronary artery disease (Spallarossa et al., 1996), 
and an increased risk of ischemic heart disease (Juul et al., 2002).  
 
HCMVECS have been shown to be IGF-1-responsive, but not sensitive to insulin, possibly due to 
the abundance of IGF-1Rs on these cells (Chisalita and Arnqvist, 2004). The role of IGF-1 in 
restraining atherosclerosis has been revealed, by reducing senescence in vascular endothelial cells, 
caused by oxidative stress (Higashi et al., 2013). Similarly, IGF-1 infusion was demonstrated to 
counter inflammation and atherosclerosis progression in mouse models, further confirming its role 
as an anti-atherogenic factor (Sukhanov et al., 2007). IGF-1 has also been shown to reduce the 
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expression of IL1B and TNFconsequently abrogating a pro-inflammatory response (Spies et al., 
2001). 
 
Similarly, IGF-1 was found to decrease levels of proteins implicated in cellular ageing (Torella et 
al., 2004). The senescence of cardiac stem cells, which leads to them being unable to form new 
myocyte populations, impedes myocardial regeneration. However, when the expression of IGF-1 
was increased, cardiac stem cells re-entered the cell cycle and displayed improved telomerase 
activity and delayed senescence (Torella et al., 2004). Furthermore, this is seemingly caused by a 
reduction in phospho-AKT, which is also rescued in part by IGF-1 overexpression (Torella et al., 
2004). Therefore, the IGF-1 pathway in cardiac stem cells is likely an effective route to counter 
cardiac ageing and enhance myocardial regeneration (Torella et al., 2004). Other studies also 
implicate IGF-1 in cardiomyocyte survival after infarction, by preventing further cell death in the 
myocardium (Li et al., 1997). We have demonstrated that an absence of CRIM1 leads to reduced 
IGF-1 signalling; this implies that CRIM1 serves as an agonist of IGF-1, and furthermore, the 
presence of CRIM1 also enhances AKT levels upon IGF-1 stimulation. 
 
The role of Crim1 in the epicardium and myocardium of nascent hearts in relation to IGF 
modulation has not been studied. This can be further explored by using Crim1-and-IGF double 
knockouts and assessing myocardial development to determine whether Crim1 and IGFs function 
along similar pathways. Additionally, we can investigate whether CRIM1 modulates IGF-1 in 
cultured epicardial cells. 
 
We have demonstrated that an absence of CRIM1 leads to reduced IGF-1 signalling; this implies 
that CRIM1 serves as an agonist of IGF-1. A decrease in IGF-1R phosphorylation as seen in CRIM1 
knockdown H-CMVECs does not necessarily indicate a decrease in levels of secreted or circulating 
IGFs, but might mean that IGF-1 requires to be presented to its receptor effectively to mediate 
downstream signalling. Another avenue to explore in the future would be to assess whether absence 
of CRIM1 reduces the amount of secreted, mature IGF-1. Also, it would be interesting to assess 
whether overexpression of CRIM1 increases IGF-1 signalling. 
 
A caveat of this study and other studies performed examining the binding of CRIM1 to various 
growth factors is that both were co-expressed by the same cell (Wilkinson et al., 2003, Wilkinson et 
al., 2007). Thus, it is essential to examine the interaction of CRIM1 and growth factors produced by 
different cells. This will heavily influence any interpretations, and provide insight into the role of 
CRIM1 in growth factor modulation, as well its biological relevance in development and disease. In 
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light of all evidences suggesting that IGF-1 protects against ventricular and endothelial dysfunction, 
and progression of atherosclerosis(Higashi et al., 2014), our data posits a novel mechanism by 
which CRIM1 and IGF-1 could function in tandem as cardioprotective factors. This could constitute 
a unique approach to developing new therapies to prevent vascular disease or improve outcomes 
after ischemic myocardial damage.  
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The role of Crim1 in developmental organogenesis is well-established. However, the mechanism 
through which it acts remains unclear, most critically with respect to its role in mediating growth 
factor signalling in different developmental contexts. For example, in C. elegans, crm-1 acts as an 
non-cell-autonomous agonist of a BMP-like pathway, specifically the DBL-1 pathway (Fung et al., 
2007). It is not known whether this occurs through a ligand- or receptor-based interaction. In 
contrast, in Drosophila, the homolog of Crim1, CRIMPY, antagonises the function of the BMP 
ligand, Glass bottom boat (Gbb), in motorneurons at the neuromuscular junction (NMJ), restraining 
its expansion (James and Broihier, 2011). Synaptic development appears to be regulated by a 
preferential association of the full-length Gbb precursor with CRIMPY, and Gbb is then secreted 
from the motorneuron terminal (James and Broihier, 2011). Similarly, in transfected COS7 cells, 
CRIM1 binds to and antagonistically modulates the processing of pre-BMPs and the secretion of 
mature BMPs(Wilkinson et al., 2003). Thus, the function of Crim1 in organogenesis is context-
dependent; prominent variables influencing its overall biological function include the timing and 
location of Crim1 expression and interactions with local growth factors.We have sought to 
determine the role played by Crim1 in cardiac development by employing various transgenic mouse 
lines, including tissue-restricted mutants.  
 
Crim1 in epicardial development 
There is much interest in harnessing the potential of the mostly quiescent adult mammalian 
epicardium. Its activation and mobilisation in response to myocardial and ischemic damage, 
including through re-expression of embryonic epicardial genes, releasing paracrine and autocrine 
factors from the epicardium or epicardium-derived cells, and through therapeutic revascularization 
that could contribute to the coronary vasculature, is crucial to repair following injury or stress 
(Smart et al., 2007, Zhou et al., 2011a). The expression of Crim1 in the epicardium and epicardium-
derived lineages is noteworthy. There is significant contribution from epicardium-derived cells to 
the developing heart, as well as to the fibroblast and smooth muscle cell lineages following 
myocardial damage (van Wijk et al., 2012, Duan et al., 2012, Limana et al., 2011, Huang et al., 
2012, Zhou et al., 2011a). Furthermore, the epicardium aids the growth and expansion of the 
developing myocardium in a paracrine manner through provision of signalling cues and reciprocal 
signalling. 
 
Aberrations in epicardial morphology during the early stages of heart development in 
Crim1
∆flox/∆flox
mutants imply defective epicardialEMT as well as adhesion. This was confirmed by 
employing the use of transgenic models displaying epicardium-specific Crim1 deletion, which 
showed increased epicardial EMT and EPDC invasion into the myocardium. Moreover, in the 
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absence of Crim1, an increased migration of primary epicardial cultures was demonstrated. 
Additionally, βcatenin distribution at epicardial cell junctions was altered. Combined with the 
results of previous studies implicating the indirect interaction of the cytoplasmic domain of 
Xenopus Crim1 β-catenin and N-cadherin in the formation and maintenance of cadherin-dependent 
complexes at epithelial cell junctions (Ponferrada et al., 2012), it may be inferred that Crim1 plays a 
role in stabilising junctional complexes. The link between these two molecules in the context of 
interactions between the epicardium and myocardium during development is an attractive avenue of 
research that has not yet been explored. Using primary epicardial cells and ablating Crim1, β-
catenin localisation at junctions can be assessed. Crim1 binding to β-catenin at junctional 
complexes may also impede Wnt signalling. Levels of both phosphorylated and non-phosphorylated 
β-catenin require to be assessed by western blotting - upon binding of Wnt ligands to their receptors 
and triggering a signalling cascade, the level of non-phosphorylated β-catenin increases, which then 
translocates into the nucleus to mediate transcription of regulatory genes. An increased amount of 
β-catenin tethered at cell junctions by Crim1 might reduce available protein for nuclear 
translocation, thus impeding Wnt signalling. Furthermore, levels of Wnt-target genes such as 
Axin2,Nanog,Sox2,Sox9and others can also be assessed using qPCR, to determine the impact of loss 
of Crim1 on Wnt signal transduction. 
 
The increased migration of EPDCs into the myocardium at 15.5 dpc, however, does not translate to 
an increase number of endothelial cells in the ventricular myocardium of mutant hearts at 17.5 dpc. 
This is because only a small proportion of EPDCs give rise to endothelial cells (Mikawa and 
Gourdie, 1996, Gittenberger-de Groot et al., 1998). Furthermore, the EPDCs that have migrated into 
the myocardium could also remain in an undifferentiated state. Stringent analyses of numbers of 
differentiated derivaties from the epicardium, vascular smooth muscle cells and fibroblasts, will 
also need to be performed, so as to confirm this hypothesis. 
 
Crim1 in myocardial development 
The underlying mechanisms involved in regulation of myocardial development via modulation of 
epicardial and myocardial signaling molecules remain uncertain. Epicardial IGFs and PDGFs have 
been shown to act as epicardialmitogenic factors that stimulate the proliferation of cardiomyocytes 
and ventricular development (Kang et al., 2008, Li et al., 2011). The effect of loss of Crim1 in the 
context of PDGF signalling has not yet been assessed; this could be determined by analyzing levels 
of phosphorylation of the PDGF receptor, and also downstream effectors such as ERK1/2 and AKT. 
Crim1 could act as a co-receptor in the cells expressing it. Alternately, Crim1 could mediate 
epicardial growth factor sequestration, and the absence of Crim1 could mean that the growth factors 
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that are not tethered to the cell surface are free to signal to the adjacent myocardium. Wilkinson and 
colleagues supported this hypothesis with their finding that in mice lacking Crim1, VEGF-A 
diffused away from the podocytes, where Crim1 and VEGF-A are co-expressed, and resulted in a 
simultaneous increased activation of the VEGF-A receptor in adjacent vascular endothelial cells 
(Wilkinson et al., 2007). 
 
While the underlying controlling mechanisms of myocardial development remain unclear, 
epicardial signalling molecule regulation appears to be crucial in this process. Furthermore, 
although an increased migration of EPDCs into the myocardial was observed in cases of 
Crim1
FLOX/FLOX
;WT1-Cre and Crim1
FLOX/FLOX
;WT1-CreERT2 hearts, overall proliferative ability of 
EPDCs was reduced, indicating an important role for Crim1 in the development of the myocardium. 
In cardiac remodelling and function following myocardial damage, cardiac fibroblasts play an 
important role (Duan et al., 2012). Thus, another attractive future research avenue involves 
investigation of the mechanisms by which Crim1 may potentially reactivate the adult myocardium 
following myocardial damage, particularly through modulation of growth factors such as BMPs, 
TGFβ, VEGF, IGF and PDGF. Future research into therapeutic interventions to improve cardiac 
function after myocardial damage is aided by our recent observation that the number of cardiac 
fibroblasts is reduced in the absence of Crim1, as epicardial cells are stimulated to produce 
fibroblasts and smooth muscle cells by myocardial injury (Limana et al., 2011, Zhou et al., 2011a, 
Duan et al., 2012, Huang et al., 2012, van Wijk et al., 2012). While we observed a reduction in the 
number of fibroblasts, it is not known whether the EPDCs that have migrated into the myocardium 
remain undifferentiated or commit to the coronary vascular smooth muscle cell lineage; thus this 
remains an interesting prospect to be explored, making it essential to assess the number of coronary 
vascular smooth muscle cells in the same WT1-CreERT2 mice used for assessing fibroblast number. 
Using in vitro studies involving primary epicardial cells that have lost Crim1, and assessing cell 
fate, will also aid in our understanding of whether it contributes to lineage specification.  
 
The limited regenerative capacity of the adult myocardium has led to research into new 
technologies investigating the possibility of generating cardiomyocytes from induced stem cells. 
However, in order to make this process feasible, clarification of the pertinent growth factors and 
signalling molecules is essential. Molecules such as BMPs regulate stem cell renewal and 
differentiation into cardiomyocytes, and also provide links to other signalling pathways to further 
modulate gene expression of transcription factors (van Wijk et al., 2007, Varga and Wrana, 2005a). 
Since Crim1 can regulate BMP signalling, the interactions between CRIM1 and BMP signalling 
during in vitro development of cardiomyocytes could be a valuable area of investigation.  
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Crim1 in endothelial cell development and function 
In the absence of Crim1, the coronary vasculature is malformed. Looking forward, it will be 
important to perform morphometric investigations of the vascular network for patterning defects, by 
assessing vessel length and vascular diameter, as well as branch point number and number of blind-
ending vessels. In vivo, we show an overall reduction in endothelial cell numbers and vascularized 
area. In vitro, this is further confirmed, with a decrease in viable HUVEC and HCMVEC numbers 
when CRIM1 is ablated. However, in vivo studies were performed only at 17.5 dpc embryos, 
making it essential to analyse whether endothelial cell endowment, accompanied by apoptosis and 
proliferation, are affected at earlier stages as well. The number of apoptotic endothelial cells in our 
immunofluorescence analyses was extremely low; this could be due to CC3 being an unsuitable 
apoptosis marker in our experiments. A better detection of apoptosis in tissue sections as well as in 
HCMVECs using TUNEL assay would provide more insight into how CRIM1 affects viability of 
endothelial cells. Furthermore, it would be crucial to distinguish between necrotic and apoptotic 
endothelial cell populations by using methods such as Propidium Iodide staining, to elucidate the 
extent to which Crim1 influences each of these phenomena. 
 
Smooth muscle cells play an important role in vascular function and pathophysiology. Endothelial 
cells supply PDGF-B, required for the endothelial-cell-mediated recruitment of vascular smooth 
muscle cells to developing vessels (Van den Akker et al., 2008). It would be of interest to perform 
immunofluorescence labelling with Transgelin, a vascular smooth muscle cell marker, to assess the 
integrity of vessel walls, as well as degree of pericyte coverage of coronary vessels, based on vessel 
contact with pericytes, in the hearts of mice with an endothelial-restricted deletion of Crim1. 
Alongside this analysis, activation of the PDGF receptor on adjacent smooth muscle cells can also 
be investigated. Additionally, the presence of Crim1 at endothelial cell junctions makes it 
worthwhile to investigate endothelial cell permeability in vivo by using published protocols such as 
the intravenous injection of Evans Blue in mice so as to assess the possible extravasation of the dye 
in nearby vascularized tissue due to increased endothelial permeability (Radu and Chernoff 2013) 
 
Adult Tie2-Cre mutants did not display any obvious external phenotypic changes or health 
deficiencies, suggesting that decrease in number of endothelial cells does not impede survival. 
However, a more stringent phenotypic analysis will have to be performed. It would therefore be 
of interest to investigate the response of Crim1
FLOX/FLOX
;Tie2-Cre mice to stress, injury or diet-
dependent metabolic loading, as other growth factors and molecules from surrounding cell types 
may compensate for deficient Crim1 function in endothelial cells in these mice. Endothelial cells 
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play a firmly established role in the development of atherosclerosis. This is the leading cause of 
coronary artery disease and therefore myocardial infarction, and is dependent on activation of the 
endothelium (Hansson, 2005). This activation is a response to a large number of factors, some of 
which are secreted by the endothelium itself, which in turn results in leukocyte, neutrophil and 
granulocyte recruitment, leading to an inflammatory response. It is also important to confirm the 
relevant gene changes observed upon CRIM1 knockdown in HCMVECs, at the protein level by 
Western blotting.  It would also be interesting to assess inflammation in adult Tie2-Cre mutants, 
given that loss of CRIM1 in HCMVECs caused an upregulation of genes involved in the 
inflammatory response. The limited ability of the endothelium to repair itself has made it critical 
to uncover molecules that can counter or prevent endothelial dysfunction. Thus, the presence of 
CRIM1 could counter the pathophysiology of various diseases that are directly involved with 
endothelial abnormalities. 
 
CRIM1 and IGF interactions in endothelial cells. 
This study is the first to show that CRIM1 can bind IGF-1 via both the IGFBP domain and CRRs 3-
6, as performed in HEK293 cells. We have demonstrated that IGF signalling in HUVECs is 
modulated by CRIM1, and thus that CRIM1 potentially functions as an agonist of IGF-1, but the 
mechanism by which this occurs remains to be established. Decreased IGF-1R phosphorylation, 
seen in CRIM1-knockdown HCMVECs may not necessarily indicate reduced IGF levels, but may 
in fact indicate specific and effective presentation of IGF-1 to the receptor is required to mediate 
downstream signalling. The impact of this on vascular development and disease is currently 
unknown. IGF-1 plays a role in limiting atherosclerosis by reducing oxidative stress and thus 
senescence in vascular endothelial cell (Higashi et al., 2013). Similarly, infusion of IGF-1 was 
shown to counter the progress of inflammation and atherosclerosis in murine models, confirming it 
as an anti-atherosclerotic factor (Sukhanov et al., 2007). Furthemore, an IGF-1-mediated reduction 
in IL1B and TNFα expression has been demonstrated with a resultant abrogation of pro-
inflammatory response (Spies et al., 2001). IGF-1 receptor inhibition also reduced murine retinal 
neovascularisation, partly due to reduced VEGF-induced MAPK activation (Smith et al., 1999). A 
decrease in endothelial cells was also seen upon disruption of IGF signalling through receptor 
blockade in human fetal lung explants (Han et al., 2003). Thus, based on existing evidences, there is 
a likelihood that CRIM1 and IGF-1 function together in endothelial cells to restrain inflammation 
and atherosclerosis, and maintain endothelial cell numbers as well. This can be further investigated 
by using IGF-1 ablated HCMVECs, and CRIM1 and IGF-1 double knockdown HCMVECs, and 
assessing whether they both function along a similar atheroprotective pathway by assessing severity 
of phenotype and endothelial gene expression. Furthermore, similar double knockdown in vivo 
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studies employing Tie2-Cre mice could also be a powerful tool in assessing whether Crim1 and 
IGF-1 function in tandem to mediate their protective function in the context of inflammation and 
atherosclerosis. 
 
The ectodomain of Crim1 has been shown to be cleaved(Wilkinson et al., 2003)by matrix 
metalloproteinases(Butler et al., 2008); thus it could exist in circulation and mediate growth factor 
regulation in a paracrine manner. Further, it would be interesting to assess the relationship between 
CRIM1 and secreted mature IGF-1 levels and function, specifically, whether or not overexpression 
of CRIM1 results in increased IGF-1 signalling. Limitations of this study, as with others that have 
investigated the binding of CRIM1 to growth factors, include the fact that both are co-expressed by 
the same cell (Wilkinson et al., 2003, Wilkinson et al., 2007). It is therefore essential to examine 
how CRIM1 interacts with growth factors produced by different cells, as this will provide insight 
into CRIM1’s role in modulating these factors as well as its biological relevance in development 
and pathological conditions. Our data posits a novel mechanism by which CRIM1 and IGF-1 
function synergistically as cardioprotective factors. Novel therapies to prevent cardiovascular 
disease or restore myocardial function after ischaemic damage may be developed using these 
unique findings. 
 
Putative role of CRIM1 in other diseases 
In the context of other disorders highlighting potential roles for CRIM1 in humans, analysis of 
serum from patients with chronic heart failure has shown increased CRIM1 levels and fibrosis-
associated secreted factors compared to other pathological disorders. This indicates a positive 
correlation between CRIM1 and pro-fibrotic activity (Eleuteri et al., 2014). Furthermore, increased 
CRIM1 expression has been demonstrated in drug-resistant leukaemia cells, implicating CRIM1 as 
a potential marker for drug resistance (Prenkert et al., 2010). Intronic regions of CRIM1 and ZEB2 
are downregulated in breast cancer epithelial cells (Kim et al., 2015), and CRIM1 overexpression is 
seen in gastric cancer tissues (Lim et al., 2014). It is also a suggested target of the Hippo pathway 
(Lim et al., 2014). These glimpses of the overarching role of CRIM1 in cancer biology and disease 
may provide further impetus for investigating the role of this gene in pathological conditions. 
Developmental studies have suggested that CRIM1 may be the fulcrum for many critical signalling 
pathways, and as such, manipulating its expression may reveal targets for modulation of cellular 
proliferation, differentiation and repair following injury and tumorigenesis. 
 
Thus, while our findings take us a step closer to understanding the role of CRIM1 in the heart and 
identify CRIM1 to be a critical regulator of epicardial and myocardial development and coronary 
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endothelial cell function, there are further questions pertaining to its role that have been raised. Its 
extensive crosstalk with other major signalling pathways in the same cell or tissue type needs to be 
further explored, as a better understanding of the molecular mechanisms of CRIM1 dysfunction in 
within the various cells of the heart may facilitate the development of innovative therapies, 
especially in the context of myocardial repair and coronary vascular disease. 
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Abstract 
The epicardium has a critical role during embryonic development, contributing epicardium-derived 
lineages to the heart, as well as providing regulatory and trophic signals necessary for myocardial 
development. Crim1 is a unique trans-membrane protein expressed by epicardial and epicardially-
derived cells but its role in cardiogenesis is unknown. Using knockout mouse models, we observe 
that loss of Crim1 leads to congenital heart defects including epicardial defects and hypoplastic 
ventricular compact myocardium. Epicardium-restricted deletion of Crim1 results in increased 
epithelial-to-mesenchymal transition and invasion of the myocardium in vivo, and an increased 
migration of primary epicardial cells.  Furthermore, Crim1 appears to be necessary for the 
proliferation of epicardium-derived cells (EPDCs) and for their subsequent differentiation into 
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cardiac fibroblasts. It is also required for normal levels of cardiomyocyte proliferation and 
apoptosis, consistent with a role in regulating epicardium-derived trophic factors that act on the 
myocardium. Mechanistically, Crim1 may also modulate key developmentally expressed growth 
factors such as TGFβs, as changes in the downstream effectors phospho-SMAD2 and phospho-
ERK1/2 are observed in the absence of Crim1. Collectively, our data demonstrates that Crim1 is 
essential for cell-autonomous and paracrine aspects of heart development. 
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Introduction 
During development, the heart is invested with cells of the proepicardium (PE), a structure that will 
give rise to the epicardium, myocardial fibroblasts, cells of the coronary vasculature and some cells 
of the valves 
1-4
. A critical step in the formation of these epicardium-derived lineages is the 
epithelial-to-mesenchymal transition (EMT) that epicardial cells must undergo to occupy the sub-
epicardial space or to invade the myocardium. Some factors implicated in promoting epicardial 
EMT and invasion include FGFs, PDGF-A/B, TGFβ-1/2/3, and BMP-2 5-8, while these processes 
are restrained by NF1 
9
 and WT1 
10
. However, the molecular factors that control epicardial EMT 
and myocardial invasion, and the differentiation of epicardium-derived lineages, are incompletely 
understood. 
 
Crim1 is a type-I transmembrane protein that is broadly expressed during development and which 
has been shown to regulate embryonic development of multiple organ systems 
11-14
. We have 
previously demonstrated embryonic lethality in mice homozygous for the Crim1
KST264
genetrap and 
Crim1
∆flox
 null alleles 
11,15
, and that homozygous Crim1
KST264/KST264
mice display defects in organ 
systems including the kidney, limb, eye and placenta. These mice die perinatally on a C57BL6 
background 
11
. The Crim1
∆flox/∆flox
 mice display similar defects but there exist variations in severity 
and penetrance of the phenotypes, likely due to differences in the type of mutation used to generate 
each mouse line 
15
. The Crim1
∆flox
 homozygotes are also embryonic lethal on the C57BL6 
background 
15
. The underlying role of this molecule in vivo is complex, and likely involves 
interactions with growth factors and the extracellular milieu. Crim1 is homologous to the BMP-
regulating protein Chordin, and contains six von Willebrand factor, type C-like cysteine-rich repeats 
(CRRs) through which it binds a broad range growth factors including TGFβ, BMP, VEGF and 
PDGF, when Crim1 is co-expressed in the same cell as the growth factor 
12,13
. Moreover, Crim1 can 
variably have an agonistic or antagonistic effect on BMP signaling 
13,16,17
, although this activity 
may be context-dependent. In the heart, it is expressed in PE-derived lineages, including the 
epicardium, and coronary vasculature 
11
, however, its role in cardiogenesis, along with the growth 
factors it interacts with at different stages, is unclear. 
 
In this study, we demonstrate essential autocrine and paracrine roles for Crim1 in heart 
development. Crim1 loss-of-function and genetrap mice display congenital heart defects such as 
ventricular septal defects, epicardial defects and hypoplastic ventricular myocardium. We reveal an 
involvement of Crim1 in regulating epicardial cell migration into the myocardium both in vivo and 
in vitro. Crim1 also limits EMT in a manner independent of canonical TGFβ signaling, but possibly 
via an interaction with β-catenin, a crucial component of adherens junctions, which has been 
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previously shown to complex indirectly with Crim1 
18
. Interestingly, the cells that have lost Crim1 
and have taken up residence in the myocardium, proliferate less, and give rise to a reduced number 
of cardiac fibroblasts, suggesting a further cell-autonomous role for Crim1 in fate specification of 
cells derived from the epicardium. We also provide evidence that upon loss of Crim1 function, 
compact myocardial development is aberrant, likely due to epicardial loss of Crim1, indicative of a 
paracrine role. Collectively, these findings illustrate how Crim1 and other factors function in 
tandem to regulate heart development. 
 
Results 
Expression of Crim1 during heart development using a genetrap reporter 
To investigate Crim1 expression in the developing heart, we used a genetrap line for Crim1, 
Crim1
KST26411
 that allowed the use of a LacZ reporter under the control of the Crim1 locus. We 
observed Crim1 expression in the proepicardium at 9.5 days post coitum (dpc), and in the 
epicardium at all stages during cardiac development (Fig. 1A-M). Crim1 was also expressed in 
coronary vascular smooth muscle and coronary endothelial cells, as reported previously 
11
. Crim1 
expression in the endocardium and valve leaflets was confirmed by performing X-Gal staining 
coupled with immunohistochemical analyses against periostin, a mesenchymal cell marker 
(Supplementary Fig. 1A-E), and Crim1 expression in coronary vascular smooth muscle cells was 
confirmed using transgelin double labelling (Supplementary Fig. 1F). The dynamic expression 
pattern observed suggests that Crim1 plays a role in heart development. 
 
Developmental defects in hearts of Crim1 mutant embryos. 
The expression pattern of Crim1 led us to investigate whether there were heart defects exhibited by 
Crim1 mutant mice. Examination of hearts from embryos homozygous for the Crim1
KST264
 genetrap 
mutant (Supplementary Fig. 2A-L) revealed epicardial malformations and blebbing (Supplementary 
Fig. 2J-L), as well as a reduced ventricular size (Supplementary Fig. 2A-C) and muscular 
ventricular septal defects (Supplementary Fig. 2D-I). Similarly, Crim1
∆flox/∆flox
 embryonic hearts had 
reduced ventricle size at 14.5 dpc (Fig. 2A-B, D-E), and distended atria and reduced ventricular size 
at 17.0 dpc (Fig. 2C, F). Histological analysis of Crim1
∆flox/∆flox
 hearts at 13.5 dpc revealed abnormal 
epicardial morphology, including epicardial blistering (Fig. 2G-I, N), findings supported by 
scanning electron microscopic analysis of Crim1
∆flox/∆flox
 hearts, which revealed a loss of the regular, 
cobblestone appearance of the epicardium (Fig. 2J-M).  
 
These phenotypes may have arisen from deficits in early PE formation. To address this, we used in 
situ hybridization on Crim1
∆flox/∆flox
 embryos for the PE markers Gata4 and Tbx18. We found that 
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PE formation and morphology, and PE marker expression, was similar between Crim1
∆flox/∆flox
 and 
control embryos (Supplementary Fig. 3), indicating that Crim1 is not necessary for initial outgrowth 
of the PE. From this we infer that Crim1 may regulate adhesion or migration at a later time point 
within the developing epicardium. 
 
Crim1 is necessary for normal compact myocardial development.  
As we had observed a reduction in ventricular size at 14.5 dpc in Crim1
∆flox/∆flox
 hearts, we 
investigated whether there were any changes in thickness of the compact myocardium at 13.0 dpc 
(when the myocardium has started to develop) that could underlie this phenotype. We observed a 
reduced compact myocardial thickness in Crim1
∆flox/∆flox
 hearts at 13.0 dpc, a finding that was not 
due to changes in cell density (Fig. 3A-D). Interestingly, this phenotype is shared by other mutants 
that lack epicardium or epicardium-derived factors 
19
. To further examine the nature of this defect, 
we analyzed the proliferation marker phospho-histone H3 (pHH3; Fig. 3E-F) and the apoptotic 
marker cleaved caspase 3 (CC3; Fig. 3I-J). We found an almost two-fold increase in proliferation, 
and a four-fold increase in apoptosis in the compact myocardium of Crim1
∆flox/∆flox
 hearts (Fig. 3H, 
L). No change was observed in proliferation or apoptosis in epicardial or sub-epicardial cells of 
Crim1
∆flox/∆flox
 hearts at this age (Fig. 3G-, K). This suggests that the loss of Crim1 culminates in 
elevated cell death within the compact myocardium during development, but whether it is an 
autocrine effect of Crim1 expressed within the compact myocardium, or epicardially-expressed 
Crim1 acting in a paracrine manner, is unknown.  
 
To address this question, we analyzed the potential autocrine role of Crim1 in compact myocardial 
development by deleting Crim1 from the cardiomyocytes in the myocardium of the developing 
heart using the Mlc2v-Cre line. This line is efficient and restricted to ventricular cardiomyocytes 
20-
23
. Cardiomyocyte proliferation and survival upon myocardial loss of Crim1 in the ventricular 
myocardium were examined using pHH3 and CC3 immunocytochemistry, respectively. 
Quantification of cells expressing both X-Gal and pHH3, or cells expressing X-Gal and CC3 in the 
compact myocardium at 13.5 dpc revealed no significant differences in the number of either pHH3- 
and CC3-positive cells between control and mutant hearts (Supplementary Fig. 4). Moreover, no 
significant change in compact myocardium thickness was observed in these mice (Supplementary 
Fig. 4). From this, and the fact that the compact myocardium phenotype is observed before the 
epicardial cells have undergone EMT and invaded the compact myocardium, we infer that the 
myocardial deletion of Crim1 does not give rise to deficits in the compact myocardium, but rather 
that epicardial Crim1 regulates the development of the myocardium in a paracrine fashion. In order 
to substantiate this, we crossed the conditional Crim1
FLOX
 line to a strain that would enable 
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inducible ablation of Crim1 from the epicardium (WT1-CreERT2). The WT1-CreERT2 line has 
previously been shown to be specific to the epicardium and epicardium-derived lineages 
24
.  We 
further corroborated this by immunohistochemical analysis using the cardiomyocyte marker MF20, 
which revealed limited overlap between the X-Gal staining and MF20 immunoreactivity 
(Supplementary Fig. 5D-E). Two doses of Tamoxifen were administered at 9.5 dpc and 10.5 dpc 
prior to harvesting the embryos, and epicardial-restricted Cre activity as assessed by the R26R LacZ 
reporter was confirmed in embryonic hearts from 12.5 dpc (Fig. 4F-G, J-K, and data not shown). 
Unlike the hearts of Crim1
∆flox/∆flox
 mice,the phenotype of reduced myocardial wall thickness was 
not recapitulated in the WT1-CreERT2 hearts at 15.5 dpc (data not shown). This could be due to 
incomplete penetrance and variable expressivity; a common occurrence with Cre lines, including 
the WT1-CreERT2 line 
24
. Indeed, upon quantification of the percentage of epicardial cells that had 
lost Crim1 (pooled genotypes, n=6; data not shown), we saw that in the left and right ventricles, 
there were still 62.5% of epicardial cells in which Crim1 was not ablated, which could compensate 
for any myocardial defects that may have arisen with a complete lack of Crim1. 
 
Cell-autonomous requirement for Crim1 to control epicardial migration and myocardial 
invasion in vitro and in vivo. 
Given the potential role for epicardially-derived Crim1 in regulating myocardial development, as 
well as the epicardial defects observed in the hearts of conditional null and genetrap mutant 
embryos, we next examined the role of Crim1 in epicardial development. We first sought to 
determine whether Crim1 mutant epicardial cells exhibited migration defects. To do this we 
cultured primary embryonic epicardial cells from the Crim1
KST264
 genetrap line in a transwell 
migration assay (modified Boyden chamber assay). The Crim1
KST264
 allele in these experiments 
allowed us to monitor the continued expression of Crim1 by X-Gal staining in representative 
examples of explant cultures. In all cases, ubiquitous Crim1-LacZ expression was observed in 
primary epicardial cells (data not shown). We found that primary epicardial cultures from 
Crim1
KST264/KST264
 hearts, immunostained with WT1 as an epicardial marker to confirm epicardial 
identity after enrichment (Fig. 4D), exhibited an increased rate of migration relative to heterozygote 
controls (Fig. 4A–E), suggesting that the loss of Crim1 from the developing epicardium resulted in 
increased epicardial migration.  
 
To confirm these observations in vivo, and to also investigate changes in EMT, we used the WT1-
CreERT2 line and assessed the location of X-Gal-positive cells at 15.5 dpc in Crim1
FLOX/FLOX
;WT1-
CreERT2; R26R and littermate heterozygous controls, determining whether labelled cells remained 
epicardial, or had undergone EMT and migrated to the sub-epicardium or to an intramural 
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myocardial location. We found that loss of Crim1 in epicardial cells resulted in an increase in the 
number of epicardial cells that had undergone EMT and invaded the myocardium of the right 
ventricle relative to controls (Fig. 4F-M). This finding was confirmed using a second Cre driver, 
namely WT1-Cre
25
 (data not shown). These in vivo data indicate that the loss of Crim1 in the 
epicardium results in increased epicardial EMT, and are consistent with the primary epicardial 
culture migration experiments indicating that the loss of Crim1 function results in increased 
epicardial cell migration. 
 
To gain insight into the mechanism by which Crim1 may regulate EMT and the migration of 
epicardial cells, we next investigated whether growth factor signalling in both the epicardium and 
the myocardium is perturbed in Crim1-deficient mice. Numerous growth factors have been 
implicated in epicardial EMT, including TGFβ and BMPs (acting via TGFβ receptors 5-8). As Crim1 
has been shown to bind such growth factors in cell culture binding experiments 
12,13,26
, and 
potentially regulate their activity in vivo
12,26
, we examined whether there were changes in canonical 
TGFβ or BMP signalling at the time of epicardial EMT and invasion, using the Crim1Δflox line. To 
do this we performed indirect immunofluorescence for phospho-SMAD2 and phospho-SMAD1/5 
as proxies to assess canonical TGFβ and BMP signalling, respectively. We also investigated 
whether there were changes in downstream effectors such as ERK1/2 and AKT as further read-outs 
of aberrant signal transduction. There was a reduced level of phospho-SMAD2 in the epicardium of 
Crim1
∆flox/∆flox
 hearts at 13.0 dpc (77% and 69% of control values for the left and right ventricular 
epicardium, respectively) (Fig. 5A-B, E-F, C-D). Despite the increased epicardial EMT and 
invasion suggested by the epicardial-restricted loss of Crim1 function, these results suggest that 
canonical TGFβ signalling was reduced in the epicardium of Crim1∆flox/∆flox hearts. There was no 
change in levels of phospho-SMAD1/5 (Supplementary Fig. 6A-H), phospho-AKT (Supplementary 
Fig. 6I-P) and phospho-ERK1/2 (Fig. 5I-J, M-N, K-L) in the epicardium of Crim1
∆flox/∆flox
 hearts 
relative to wildtype controls. At 13.0 dpc, Crim1
∆flox/∆flox
 hearts showed comparable levels of 
ventricular compact myocardial phospho-SMAD2 (Fig. 5A-B, E-F, G-H), phospho-SMAD1/5 
(Supplementary Fig. 6A-H) and phospho-AKT (Supplementary Fig. 6I-P) relative to controls. 
However, we observed that there was an increase in both the number of phospho-ERK1/2 positive 
cells (for example, 29% of cells were phospho-Erk1/2-positive in the left ventricle of the mutant, 
compared to 6% in the left ventricle of the control; P < 0.05, t-test), as well as an increase in the 
phospho-ERK1/2 signal intensity per cell in the ventricular compact myocardium of mutant hearts 
relative to controls (Fig. 5I-J, M-N, O-P). There was also no significant difference in the distance 
that pERK1/2 positive cells were from the epicardium in both control and mutant hearts (data not 
shown). Together with the lack of compact myocardial changes observed in the myocardium-
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restricted Crim1knock-out, this indicates that Crim1 could play a paracrine role in regulating 
myocardial development, likely through the regulation of epicardium-derived factors. 
 
The adhesion molecule β-catenin is an important regulator of epithelial stability and EMT, and 
Crim1 has been shown to interact indirectly with β-catenin 18. To investigate the role of Crim1 in 
altering EMT and migration, we analyzed the localisation of β-catenin 27 in Crim1+/+ and 
Crim1
∆flox/∆flox
 hearts at 13.5 dpc. We found that there was a decrease in the percentage of epicardial 
cells that displayed an accumulation of β-catenin at epicardial cell-cell junctions in mutant hearts 
(Fig. 5Q-W). When considered in light of the findings that increased EMT and myocardial invasion 
occurs in the hearts of Crim1 mutant mice, this finding suggests that Crim1 normally regulates the 
stability of intercellular junctions within the epicardium. Analysis of filamentous actin to assess the 
cytoskeletal remodelling that accompanies EMT and migration revealed no visible changes in stress 
fibre morphology between mutant and wildtype hearts at 13.5 dpc (Supplementary Fig. 7). The data 
reveal a cell-autonomous role for Crim1 in controlling epicardial migration, EMT and invasion in 
primary cell culture and in vivo, which appears to rely on interactions with β-catenin.  
 
Cell-autonomous requirement for Crim1 to control proliferation and fate specification of 
EPDCs. 
The increase in the number of EPDCs that had migrated into the myocardium prompted us to 
further investigate the proliferative ability and differentiation potential of these EPDCs. We used 
the WT1-CreERT2 and Crim1
FLOX
; R26R lines and assessed EPDC proliferation at 15.5 dpc using 
pHH3 (Fig. 6A-B). Quantification of X-Gal expressing cells that were pHH3-positive in the 
myocardium of left and right ventricles revealed a significant reduction in proliferation of 
intramyocardial cells in Crim1
FLOX/FLOX
; +/WT1-CreERT2;R26R hearts (Fig. 6D). Quantification of 
pHH3-positive cells among X-Gal-positive epicardial cells, however, revealed comparable results 
(Fig. 6C). This demonstrates that deleting Crim1 from the epicardium can perturb proliferation of 
epicardium-derived cells, even though there is increased migration into the myocardium.  
 
To address whether changes in epicardial cell fate occurred due to loss of Crim1, we performed 
qPCR analyses on ventricular tissue from 17.5 dpc Crim1
∆flox/∆flox
 and Crim1
+/+
 hearts using 
vascular smooth muscle, fibroblast and cardiomyocyte markers. No significant changes in these 
markers were observed, although there was a trend for a reduction in the fibroblast marker 
Collagen1a (P=0.0556; Supplementary Fig. 8A). To specifically examine the effect of epicardial 
Crim1 deletion on the differentiation of EPDCs into cardiac fibroblasts, we used the WT1-CreERT2 
line to perform IHC using periostin, another fibroblast marker, on heterozygote control and mutant 
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WT1-CreERT2 heart sections at 17.5 dpc. Quantification of the proportion of periostin- and X-Gal-
positive cells in the myocardium revealed a significant decrease in the expression of periostin in the 
left and right ventricles of the mutant (Fig. 6E-I). This suggests that the number of cardiac 
fibroblasts were reduced, and the secretory phenotype of cardiac fibroblasts was perturbed upon 
epicardial Crim1 loss-of-function, indicating a possible cell-autonomous requirement for Crim1 to 
regulate fate specification of EPDCs into fibroblasts. 
 
Discussion 
The epicardium gives rise to crucial components of the developing heart, and while the 
differentiation of EPDCs into cardiomyocytes and coronary endothelial cells remains a 
controversial topic, reactivated epicardial cells after myocardial damage have been shown to give 
rise to fibroblast and smooth muscle cells
28-32
. The epicardium also has a critical role in providing 
instructive cues and trophic factors for the developing myocardium. Although certain epicardium-
derived factors are believed to act on the myocardium in a paracrine manner, the nature of this 
interaction is not entirely understood. Here, we demonstrate an essential role for Crim1 in the 
epicardium during heart development. Crim1 appears to regulate epicardial EMT and invasion, fate 
specification of EPDCs into cardiac fibroblasts, and modulation of growth factor activity. As a 
result, we infer that Crim1 controls compact myocardial development via regulation of epicardium-
derived paracrine factors.  
 
Crim1 is expressed in a large number of tissues in a spatially and temporally regulated manner and 
has been shown to have diverse extracellular and intracellular functions 
11-14,18,33,34
. This study 
focused determining the role of Crim1 in the cardiogenesis by using different transgenic mouse 
lines. We have observed that Crim1 expression in the heart begins in the proepicardium, although it 
is not necessary for PE specification, and continues in the epicardium and epicardium-derived 
lineages. Crim1
KST264/KST264
homozygotes showed a disrupted epicardial layer, reduced ventricular 
size, and prominent ventricular septal defects. Hearts of both Crim1
∆flox/∆flox
 and 
Crim1
KST264/KST264
homozygotes at 13.5 dpc showed irregular epicardial morphology indicative of 
EMT and adhesion defects. Indeed, epicardial deletion of Crim1 resulted in an increase in epicardial 
cell EMT and myocardial invasion. Similarly, primary epicardial cultures showed increased 
migration upon loss of Crim1. However, epicardial cells lacking Crim1 also showed reduced 
proliferation and an overall reduction in cardiac fibroblast marker expression. Overall this suggests 
that loss of Crim1 in epicardial cells affects cell phenotype, proliferation and fate.  
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Growth factors like BMPs and TGFβs that can be bound by Crim1 promote epicardial EMT and 
invasion 
5,7,8
. Canonical BMP signalling via the SMAD1/5 pathway, AKT signalling and ERK1/2 in 
the epicardium appear to be largely independent of Crim1 in Crim1
∆flox/∆flox
 hearts. Indeed, we 
observed a paradoxical reduction in epicardial TGFβ signalling in Crim1∆flox/∆flox embryos. This 
suggests that, in the epicardium, Crim1 may play a role other than growth factor regulation with 
Crim1 mutants representing an uncoupling of these growth factor signalling pathways and 
epicardial EMT. β-catenin distribution, however, at epicardial cell-cell junctions was altered in the 
absence of Crim1. Interestingly, XenopusCrim1 has been shown to interact via its cytoplasmic 
domain with β-catenin and N-cadherin, identifying a role for Crim1 in the formation or stabilization 
of cadherin-dependent junctional complexes in epithelial cells 
18
. Though Crim1 was not always 
present at sites of cadherin expression, it may interact with cadherins and β-catenin within the 
endoplasmic reticulum, where complex formation between the 3 interacting partners would occur, 
possibly displacing an existing stabilization mechanism 
18
. Crim1-mediated sequestration of β-
catenin from junctional complexes could also limit Wnt signalling. Hence, the link between Crim1 
and the β-catenin pathway, particularly in the developmental interactions between the epicardium 
and myocardium, remains to be explored. 
 
The altered myocardial thickness in the absence of Crim1 suggests a role for Crim1 in the 
regulation of signalling molecules from the epicardium, and possibly the myocardium as well, 
crucial for normal myocardial development. The underlying mechanism that controls the 
developing myocardium is not clear. Mouse mutants, including knockouts of VCAM-1, α4 integrin 
and WT-1 and mouse lines with altered retinoic acid signalling, show perturbation of epicardial 
formation with secondary myocardial defects during development
35-38
. Furthermore, microsurgical 
inhibition of epicardium formation in avian embryos results in hypoplastic ventricular compact 
myocardium
39,40
. Similarly, we observed a reduced compact myocardial thickness in Crim1
∆flox/∆flox
 
hearts at 13.0 dpc. However, epicardium-specific deletion of Crim1 did not recapitulate this 
phenotype, possibly due to incomplete penetrance within the WT1-CreERT2line during embryonic 
stages. Similarly, the myocardial depletion of Crim1 did not culminate in a thinner myocardium, 
nor did it reveal an effect on cardiomyocyte proliferation or apoptosis. In light of the fact that 
reciprocal signalling between the epicardium and myocardium is required for proper myocardial 
development to ensue, it is plausible that both epicardial and myocardial Crim1 are required for 
normal formation of the myocardium. An alternative interpretation of these results is that there is a 
non-cell-autonomous requirement for epicardial Crim1 in myocardial development. Embryonic 
cardiomyocytes respond to a variety of signalling molecules and express a broad range of receptors 
which can bind mitogenic factors 
19
. Indeed, IGFs, PDGFs and VEGFs secreted by the epicardium 
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may act as epicardial mitogens that stimulate ventricular development and cardiomyocyte 
proliferation 
41,42
. IGFBPs are known to regulate the activity of IGFs 
43
. The IGFBP domain of 
Crim1 has been shown to possess sequence similarity to IGFBP-7 
14
 potentially allowing it to bind 
IGFs and insulin to mediate the regulation of their downstream signalling. This is in accordance 
with our observation that ERK1/2 signalling in the myocardium of Crim1
∆flox/∆flox
 hearts is 
increased. Crim1 may serve to sequester growth factors secreted by the epicardium, without 
necessarily affecting the range of growth factor action in Crim1
∆flox/∆flox
 hearts, where these may be 
free to signal to the adjacent myocardium. This has been reported previously with respect to a role 
for Crim1 in VEGF sequestration in the glomerulus 
12
. Crim1 and the growth factors it binds have 
been reported to be co-expressed in the same cell 
12,13
, which would be consistent with a role in 
tethering epicardially-derived growth factors. Prolonged ERK1/2 phosphorylation has been shown 
to lead to cell death, whereas transient activation drives proliferation
44
. Thus, an increase in 
phospho-ERK1/2 activity in the compact myocardium could have a pro- or anti-apoptotic effect, 
depending on the activation of downstream effectors. Crim1 has also been shown to reduce the 
production and secretion of BMPs
13
. A lack of Crim1 could lead to increased growth factor 
production and signalling, and result in a high cell turnover in the myocardium of mutant hearts as a 
result of co-activation of proliferation and apoptosis.  It is important to note that the antagonistic or 
agonistic functions of Crim1 are context-dependent and could change for different cell types within 
the heart and at different stages of development.  
 
We also observed a decrease in the proliferative ability of EPDCs in the myocardium of 
Crim1
FLOX/FLOX
; WT1-CreERT2; R26R hearts, in spite of an increased migration of cells derived 
from the epicardium as seen in the Crim1
FLOX/FLOX
; WT1-CreERT2; R26R and Crim1
FLOX/FLOX
; 
WT1-Cre; R26R hearts. This was observed alongside a reduction in the number of cardiac 
fibroblasts, one of the major derivatives of the epicardium 
1,3,45
. Cardiac fibroblasts represent a 
crucial component of the myocardium, secreting a large number of ECM molecules required to 
support other resident cells of the heart, as well as growth factors and cytokines for the proper 
functioning of these cells 
46
. However, there is little known about the factors that contribute to 
cardiac fibroblast fate specification. These EPDCs that have lost Crim1 could remain 
undifferentiated cells residing in the compact myocardium, or preferentially „switch‟ to coronary 
vascular smooth muscle cells rather than cardiac fibroblasts. Cardiac fibroblasts generated after 
injury are crucial to cardiac repair in terms of both the ECM molecules secreted as well as overall 
cardiac performance 
29,47
. Our data indicate a cell-autonomous requirement for Crim1 in the 
production of cardiac fibroblasts. Further studies are required to validate the role of Crim1 in 
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lineage specification into fibroblasts and to also address whether it plays a cell-autonomous role in 
the differentiation of EPDCs into coronary vascular smooth muscle cells.  
 
In summary, this study reveals a role for epicardial Crim1 in normal heart development. Although 
thought to be a largely quiescent lining surrounding the myocardium, there has been significant 
recent focus on ways to reactivate the adult epicardium in response to injury and disease 
48
. This 
revolves around re-expression of embryonic epicardial genes and the release of paracrine and 
autocrine factors from the epicardium or EPDCs 
48
. An active participant in epicardially-regulated 
heart development, Crim1 modulation may therefore provide a potential avenue for future 
molecular and cellular therapeutic interventions in cardiac regeneration and repair. Moreover, 
whether or not abnormal CRIM1 expression plays a role in congenital human heart disease will be 
an important topic for future investigations. 
 
Methods 
Ethics statement 
The work performed in this study conformed to The University of Queensland‟s Animal Welfare 
Unit guidelines for animal use in research, and followed the National Institutes of Health Guide for 
the Care and Use of Animals and the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes. All experimental protocols were approved by The University of 
Queensland‟s Animal Ethics Unit (Animal Ethics Committee approval numbers: 
AIBN/274/08/NHMRC, SMBS/420/11/NHMRC). 
 
Animal breeding 
The mouse lines used in this study were the Crim1
FLOX
 conditional mutant 
15
, Crim1
∆flox
knock-out 
15
 
and Crim1
KST264
 genetrap line 
11
, ROSA26 Cre-reporter line (R26R) 
49
, WT1-Cre line 
25
, WT1-
CreERT2 line 
24,50
 and Mlc2v-Cre line 
20
. The Crim1
KST264
 mouse line was created as part of a 
genetrap screen 
51, with insertion of the β-Geo cassette into intron 1 of Crim1 resulting in the fusion 
of exon 1 and the β-Geo cassette within the Crim1 transcript, thereby creating a hypomorphic allele 
which expresses a minor, alternately spliced isoform of CRIM1
11
. The Crim1
FLOX
 conditional 
mutant mouse line was generated, using Cre/LoxP recombination, by flanking exons 3 and 4 with 
unidirectional LoxP sites 
15
. These Crim1
FLOX
 mice were crossed with a line that expressed Cre 
recombinase ubiquitously (CMV-Cre) to produce the Crim1
∆flox
 line. This deletion created an out-
of-frame transcript and a predicted non-functional protein and as such, Crim1 is deleted from all 
tissues in these mice 
15
. All lines were maintained on a C57Bl6 genetic background. Embryos were 
obtained from timed matings between Crim1
+/∆flox
 intercrosses, Crim1
+/KST264
 intercrosses, or 
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Crim1
FLOX/FLOX
; R26R females mated with Crim1
+/FLOX
; WT1-Cre, Crim1
+/FLOX
; +/WT1-CreERT2 or 
Crim1
+/FLOX
; Mlc2v-Cre males.  
 
Sample preparation 
Mouse embryos were obtained from timed matings between Crim1
+/∆flox
 intercrosses or 
Crim1
+/KST264
 intercrosses, with the presence of a vaginal plug regarded as 0.5 days post coitum 
(dpc). Embryonic hearts were dissected in PBS and fixed for 2 hours in 4% PFA/PBS at 4°C, 
washed in PBS, and photographed in whole-mount. Samples were then dehydrated and processed 
for paraffin infusion and embedding, and 7 µm sections were cut on a microtome. Hematoxylin and 
eosin staining was performed using standard protocols. Embryonic hearts collected from matings 
between Crim1
+/∆flox
 intercrosses collected at E13.0 and E13.5 were also fixed in 4% PFA/PBS at 
4°C, washed in PBS,cryo-protected in 30% sucrose/PBS at 4°C, embedded in OCT (Tissue-Tek) 
and 10 µm sections were cut on a cryostat and air-dried before proceeding with the 
immunofluorescence procedure. 
 
Timed matings were set up between Crim1
+/FLOX
; WT1-Cre males and Crim1
FLOX/FLOX
; R26R 
females to produce Crim1
+/FLOX
; WT1-Cre; R26R and Crim1
FLOX/FLOX
; WT1-Cre; R26R embryos 
collected at 15.5 dpc (at this stage, the myocardium has expanded and cells derived from the 
epicardium have started to differentiate into various lineages), Crim1
+/FLOX
; +/WT1-CreERT2 males 
and Crim1
FLOX/FLOX
; R26R females, for the production of Crim1
+/FLOX
; +/WT1-CreERT2; R26R and 
Crim
FLOX/FLOX
; +/WT1-CreERT2;R26R embryos collected at 15.5 dpc and 17.5 dpc (at 17.5 dpc, 
cells derived from the epicardium have differentiated into cardiac fibroblasts, coronary vascular 
smooth muscle cells, and a small proportion of coronary vascular endothelial cells), and between 
Crim1
+/FLOX
; Mlc2v-Cre males and Crim1
FLOX/FLOX
; R26R females to produce Crim1
+/FLOX
; Mlc2v-
Cre; R26R and Crim1
FLOX/FLOX
; Mlc2v-Cre; R26R embryos collected at 13.5 dpc (the myocardium 
has begun to expand at this stage through proliferation of cardiomyocytes).  
 
Embryonic samples from the WT1-Cre, WT1-CreERT2 and Mlc2v-Cre (β-galactosidase activity 
being a readout of Cre activity based on the R26R reporter) and Crim1
+/KST264
 intercrosses (β-
galactosidase activity being under the control of the endogenous Crim1 promoter) were X-Gal-
stained in whole-mount as previously described 
6
 before processing for paraffin embedding and 
sectioning as described above. Some X-Gal-stained sections were counterstained with nuclear fast 
red (NFR; Vector Laboratories). Others were subjected to cell biological and immunohistochemical 
analyses as detailed below. 
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Tamoxifen administration 
Tamoxifen (MP Biomedicals, 02156738) was dissolved in corn oil at a concentration of 20 mg/ml. 
To induce WT1-CreERT2
24,50
, two doses of 2 mg tamoxifen 
52
 were injected intraperitoneally to 
pregnant dams (at 9.5 dpc and 10.5 dpc), prior to harvesting the mouse embryos. 
 
Scanning electron microscopy 
13.5 dpc embryos were collected from intercrosses of Crim1
+/∆flox
 mice, and the hearts were 
dissected and fixed in 2.5% glutaraldehyde in PBS for 1 hour at room temperature. Samples were 
then washed 3 times with PBS and stored at 4°C until processing for scanning electron microscopy 
as previously described 
53
. Scanning electron microscopy was performed using a CM-500 Benchtop 
Scanning Electron Neoscope. 
 
Antibodies 
Primary antibodies/lectin used in the study were: rabbit polyclonal anti-phospho-Histone H3 
(pSer10; Millipore #06-570); rabbit monoclonal anti-cleaved caspase 3 (activated caspase 3; Cell 
Signalling Technology #9664); rabbit monoclonal anti-phospho-AKT (pSer473; D9E; Cell 
Signalling Technology #4060); rabbit monoclonal anti-phospho-ERK1/2 (pThr202/pTyr204; 
D13.14.4E; Cell Signalling Technology # 4370); rabbit monoclonal anti-phospho-SMAD1/5 
(pSer463/pSer465; Invitrogen #700047); rabbit polyclonal anti-phospho-SMAD2 
(pSer465/pSer467; Millipore AB3849); mouse monoclonal anti-smooth muscle α-actin (clone 1A4, 
Santa Cruz Biotechnology, sc-3225); rabbit anti-β-catenin (whole antiserum; Sigma Aldrich 
#C2206); rabbit polyclonal SM22 alpha (Abcam Ab14106); rabbit polyclonal anti-periostin (Abcam 
Ab92460); mouse monoclonal anti-Wilms‟ Tumor 1 (WT1; Dako #M3561); MF20 (supernatant, 
Developmental Studies Hybridoma Bank) and Isolectin B4 (Invitrogen). Secondary antibodies for 
immunofluorescence experiments were Alexa Fluor-488, -594 or -633-conjugated secondary 
antibodies (Invitrogen). TSA plus Cyanine 3 system was used for signal amplification in the case of 
pERK1/2 and pAKT (PerkinElmer #NEL744001KT) Secondary antibodies for 
immunohistochemistry experiments were anti-rabbit HRP (Promega; #W4011), anti-mouse HRP 
(Promega; #W4021), anti-rabbit biotin (Sigma; # B7389). The Vectastain Elite ABC kit (Standard) 
was also used (Vector Laboratories; #PK6100). 
 
Immunohistochemistry 
Experiments using mouse antibodies were blocked with mouse-on-mouse (Vector MOM kit; BMK 
2202) blocking reagent for one hour. Sections were primed with MOM diluent for five minutes after 
washes in 1xPBS twice. Mouse primary and secondary antibodies were diluted in MOM protein 
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diluent. Immunohistochemistry using pHH3 was performed and sections counterstained with 1% 
DAB followed by NFR staining. Immunohistochemistry to detect periostin used anti-rabbit biotin 
and Vectastain ABC as secondary and tertiary antibodies. Vectastain ABC reagents were prepared 
as per manufacturer‟s protocols. After one-hour incubation with anti-rabbit biotin, Vectastain ABC 
was added for 30 minutes in room temperature, followed by hematoxylin staining.  Indirect 
immunofluorescence on tissue sections was performed on paraformaldehyde-fixed, paraffin-
embedded samples as described 
6
. For immunofluorescence involving detection of cleaved caspase 
3 or PHH3, paraffin sections were subject to heat-induced antigen retrieval in a citrate buffer (pH 
6.0). Immunofluorescence on cryosectioned samples was performed to detect β-Catenin, MF20, 
phospho-SMAD1/5, phospho-SMAD2, phospho-AKT and phospho-ERK1/2. Tyramide 
amplification according to manufacturer‟s methods was used for signal amplification of phospho-
ERK1/2 and phospho-AKT. 
 
Primary epicardial explant cultures and migration assays 
11.5 dpc embryos were collected from intercrosses of Crim1
+/KST264
 mice, and the ventricular 
component was dissected from the rest of the heart in sterile PBS and cultured in DMEM 
supplemented with 10% FCS and penicillin/streptomycin in 4-well tissue culture plates. Once the 
epicardium had grown out from the primary culture, the ventricular mass was removed. The 
epicardial cells were grown to confluence and were passaged once and plated at a high confluence. 
After two days of further culture, the primary epicardial cells were used in a modified Boyden 
chamber assay. Epicardial cultures were collected after trypsin treatment to completely dissociate 
cells, washed and resuspended in DMEM (with 10% FCS). 1,000 cells in identical volumes were 
placed in the upper chamber of 6.5 mm transwell culture inserts (polycarbonate filter, 5.0 µm pore 
size, Corning). After 16 hours of culture, the cells in the upper part of the transwell inserts were 
removed using a cotton swab, and the cells that had migrated through the polycarbonate filter were 
quantified after fixation in 4% PFA in PBS and staining with DAPI. Epicardial identity was 
confirmed after enrichment by immunofluorescence for the transcription factor WT-1 
24,54
, using 
standard techniques as described 
6
. 
 
In situ hybridization 
Section in situ hybridization was performed as previously described 
55
. Whole-mount in situ 
hybridization was performed as previously described 
56
 with minor changes. Hybridization was 
performed with a riboprobe concentration of 0.4 µg/mL in pre-hybridization solution. Color 
detection was performed with the chromogenic substrate NBT/BCIP (Roche). Samples were then 
washed, post-fixed in 4% PFA/PBS, and photographed. At least three embryos of each 
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genotype/gene probe were analyzed. Some whole-mount samples were processed for paraffin 
infusion and sectioned as described above. 
 
Quantitative real-time PCR analysis 
Ventricular samples from Crim1
+/+
 and Crim1
Δflox/Δflox
hearts were microdissected, homogenized and 
total RNA was extracted using an RNeasy Mini Kit (Qiagen, #74104). Reverse transcription was 
performed using SuperscriptIII (Invitrogen) and qPCR was performed. Briefly, 500ng total RNA 
was reverse-transcribed with random primers and dNTPs. cDNA was diluted 1/5 with 
RNase/DNase-free water. qPCRs were carried out in a QuantStudio6 (Applied Biosystems) using 
SYBR green (Takara) and standard qPCR conditions. The data were analyzed with the 
QuantStudio6 software, with TFIID used as a relative standard. All samples were tested in 
triplicate. Relative transcript levels were assessed using the ΔCt method. Statistical analyses were 
performed using a two-tailed unpaired t-test. The primer sequences used in this study were 
purchased from Sigma-Aldrich, and are detailed below: 
 
Periostin: Forward 5‟-AAGCTGCGGCAAGACAAG-3‟ 
Periostin: Reverse 5‟-TCAAATCTGCAGCTTCAAGG-3‟ 
Collagen1a: Forward 5‟-AGACATGTTCAGCTTTGTGGAC-3‟ 
Collagen1a: Reverse 5‟-GCAGCTGACTTCAGGGATG-3‟ 
Collagen3a: Forward 5‟-ACGTAGATGAATTGGGATGCAG-3‟ 
Collagen3a: Reverse 5‟-GGGTTGGGGCAGTCTAGTG-3‟ 
Collagen5a: Forward 5‟-CTACATCCGTGCCCTGGT-3‟ 
Collagen5a: Reverse 5‟-CCAGCACCGTCTTCTGGTAG-3‟ 
Transgelin: Forward 5‟-CCTTCCAGTCCACAAACGAC-3‟ 
Transgelin: Reverse 5‟-CTAGGATGGACCCTTGTTGG-3‟ 
Alpha smooth muscle actin: Forward 5‟-ACTCTCTTCCAGCCATCTTTCA-3‟ 
Alpha smooth muscle actin: Reverse 5‟-ATAGGTGGTTTCGTGGATGC-3‟ 
Myosin heavy chain 11: Forward 5‟-ACGCCCTCAAGAGCAAACT-3‟ 
Myosin heavy chain 11: Reverse 5‟-CCCTTCTGGAAGGAACAATG-3‟ 
Calponin1: Forward 5‟-GAAGGTCAATGAGTCAACTCAGAA-3‟ 
Calponin1: Reverse 5‟-CCATACTTGGTAATGGCTTTGA-3‟ 
Myosin heavy chain 7: Forward 5‟-TGCTGAGGCCCAGAAACAAGTG-3‟ 
Myosin heavy chain 7: Reverse 5‟-CTGGATTTGAGTGTCCTTCAGCAG-3‟ 
Nkx2-5: Forward 5‟-ATTGACGTAGCCTGGTGTCTCG-3‟ 
Nkx2-5: Reverse 5‟-AGTGTGGAATCCGTCGAAAGTGC-3‟ 
 180 
Tie2: Forward 5‟-AGAGGCCGAACATTCCAAGTAGC-3‟ 
Tie2: Reverse 5‟-GGCCAAACAAACTGGCTTCTGC-3‟ 
PDGFRα: Forward 5‟-TTGCACAGCCTCTGTTTGTTGC-3‟ 
PDGFRα: Reverse 5‟-ATGGTGTCATGCAAGGCCCAAAG-3‟ 
PDGFRβ: Forward 5‟-CAGTCCCGGCTACCCTATCT-3‟ 
PDGFRβ: Reverse 5‟-GACCCAGAGTTTTCTCGGCA-3‟ 
Tcf21: Forward 5‟-CATTCACCCAGTCAACCTGA-3‟ 
Tcf21: Reverse 5‟-CCACTTCCTTCAGGTCATTCTC-3‟ 
TFIID: Forward 5‟-ACGGACAACTGCGTTGATTTT-3‟ 
TFIID: Reverse 5‟-ACTTAGCTGGGAAGCCCAAC-3‟ 
 
Imaging and data analysis  
Bright-field images of tissue sections were captured using an Olympus BX-51 BF/DF slide 
microscope with Canon digital cameras with DP Controller software (Olympus). Whole-mount 
images were captured using either an Olympus SZX-12 stereo-microscope with DP Controller 
software, or a Zeiss Stemi 2000 stereo-microscope with an AxioCam digital camera with 
AxioVision software (Zeiss). Fluorescent images of tissue sections were captured on an Olympus 
IX-81 laser scanning confocal microscope and an Olympus FV1000 upright laser scanning confocal 
microscope with Olympus Fluoview software (Ver3.1a). Images were adjusted for colour levels, 
brightness and contrast, and figures compiled, using Adobe Photoshop software. The number of 
samples included in data averages is indicated in the figure legends where applicable. To determine 
the statistical significance of the prevalence of phenotypes among mutant and control groups, a Z-
test was used (Fig. 2N). Epicardial defects examined and quantified include either a loss of 
squamous morphology or blebbing. For the analysis of 13.0 dpc compact myocardium thickness 
and cell density (Fig. 3), sections were immunolabelled for Acta2 and PECAM-1, and nuclei 
counter-stained with DAPI as described above. 40x fields of view of the ventricular compact 
myocardium were imaged on a laser scanning confocal microscope on each of three–five non-
consecutive sections for each sample analyzed. The compact myocardium was considered as the 
actin-positive area of the ventricular chambers, bounded on the endocardial side by the base of the 
trabeculae (delineated by PECAM-1 staining). To determine cell density, the area was determined 
from confocal images using either Olympus Fluoview or ImageJ software, and the number of 
DAPI-stained nuclei quantified using ImageJ software. For the quantification of the pHH3-positive 
and CC3-positive cells at 13.0 dpc, immunolabelling was performed as described above. The 
ventricular compact myocardium was imaged on a laser scanning confocal microscope (multiple 
images at 40x objective) on five–seven non-consecutive sections for each sample analyzed. Cells 
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were scored as epicardial or sub-epicardial if they were on the periphery of the section and were 
actin-negative. Statistical significance between pooled data from mutant and control groups was 
determined using a two-tailed, unpaired Student‟s t-test. 
 
For the analysis of epicardium-derived cells using the using the WT1-CreERT2 line, 2-4 non-
consecutive, coronal sections from each sample (X-Gal-positive; WT1-CreERT2) (Fig. 4I, M) were 
quantified and the average of X-Gal-positive cells in the mid-ventricular region per sample was 
measured. For analysis using the WT1-Cre line, 16 non-consecutive, coronal sections from each 
sample (X-Gal-positive; WT1-Cre) were quantified and the total number X-Gal-positive cells in the 
ventricles was counted (data not shown). Cells were scored as epicardial, sub-epicardial if they were 
on the periphery of the section, or intramyocardial. For the analysis of the location of epicardium-
derived cells (X-Gal-positive, WT2-CreERT2/ WT1-Cre; epicardial, sub-epicardial, or 
intramyocardial), a two-way ANOVA with Bonferroni‟s post-test was used. 
 
For quantification of β-Catenin (Fig. 5Q-U), sections were co-immunolabelled for MF20 and 40x 
images were acquired using a laser scanning confocal microscope from at least 2 sections for each 
sample.  Cells were scored as epicardial or sub-epicardial if they were on the periphery of the 
section and were MF20-negative. β-Catenin accumulation at adherens junctions between epicardial 
cells
27
 was quantified, with the junctions being defined as points of contact between two epicardial 
cells. Statistical significance between pooled data from mutant and control groups was determined 
using a two-tailed, unpaired Student‟s t-test. 
 
For quantification of cardiac fibroblasts and proliferating EPDCs (Fig. 6), 20X images were 
acquired using a slide microscope from a minimum of three non-consecutive sections for each 
sample. The number of X-Gal- and periostin-positive and X-Gal- and pHH3-positive cells were 
counted using ImageJ software and data analyzed using two-tailed, unpaired Student‟s t-test and 
two-way ANOVA respectively. Positive cells were identified as those that possessed both blue β-
gal and a corresponding brown nucleus denoted by DAB staining. 
 
For quantification of phospho-SMAD levels (Fig. 5A-H, Supplementary Fig. 6A-H), 40x images 
were acquired with a laser scanning confocal microscope from at least five sections for each sample 
and for phospho-ERK1/2 and phospho-AKT levels (Fig. 5I-P, Supplementary Fig. 6I-P), from at 
least 2 sections for each sample. To determine average signal intensity/cell, unsaturated confocal 
images were used, and signal intensity determined using the Integration function in Olympus 
Fluoview software. The number of DAPI-stained nuclei in the demarcated area was quantified using 
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ImageJ software. Average signal per cell determined was divided by 1000 for graphical 
representation. Statistical significance between pooled data from mutant and control groups was 
determined using a two-tailed, unpaired Student‟s t-test.  Quantified data shown are mean ± 
standard deviation. 
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Figures and figure legends 
 
 
Figure 1. Crim1 expression as monitored by the Crim1
KST264
 genetrap reporter reveals a dynamic 
pattern during heart development.  
A, micrograph of a histological section of a 9.5 dpc Crim1
+/KST264
 embryo that has been X-Gal-stained, 
paraffin-embedded, and counter-stained with nuclear fast red. B, higher magnification view of the boxed area 
in A. The proepicardial cells are X-Gal-positive (arrow, B). Note that X-Gal staining is localised close to 
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nuclei due to the targeting of the β-geo to cell bodies that was typical of the secretory trap vector used in the 
genetrap screen that generated the Crim1
KST264
 allele [49]. C–G, Whole-mount views of Crim1+/KST264 hearts 
after X-Gal staining (blue) at 12.5 dpc (C), 15.5 dpc (D), 16.5 dpc (E), 17.5 dpc (F), and 18.5 dpc (G). In 
addition to expression in the epicardium at these stages, note the Crim1-LacZ expression in the OFT 
mesenchyme (arrows) at 12.5 dpc, and the smooth muscle of the great vessels (arrows, D–G). H–J, 
Magnified left lateral views of the ventricles of the hearts shown in E–G, respectively. Note the Crim1-LacZ 
expression in the developing coronary vasculature (arrows) and in the epicardium (double open arrowheads). 
K-M, histological sections Crim1-LacZ expression in the epicardium (arrows) and M, in the coronary 
vasculature (open arrowhead). my, myocardium; pe, proepicardium. Scale bar A, 100 µm; B, 20 µm; C, 200 
µm; D–G, 500 µm; H–J, 200 µm; K-M, 20 µm. 
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Figure 2. Developmental defects in hearts of Crim1
Δflox/Δflox
embryos.  
A–B, D-E Representative whole-mount views of 14.5 dpc embryonic hearts (A, B, Crim1+/+; D, E, 
Crim1
Δflox/Δflox
). B, E, Magnified, left lateral views of A and D, respectively. C,F, Representative whole-
mount views of 17 dpc embryonic hearts (C, Crim1
+/+
; F, Crim1
Δflox/Δflox
). Note the reduced size of the 
ventricles in the Crim1
Δflox/Δflox
heart (D, E, F). Epicardial defects in Crim1
Δflox/Δflox
hearts. G-I, Hematoxylin 
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and eosin-stained sections of the ventricular region of 13.5 dpc G, Crim1
+/+
 and H,I, two different 
Crim1
Δflox/Δflox
hearts. Note the irregular appearance of the epicardium in Crim1
Δflox/Δflox
embryos, with one 
example showing blebbing (H). J–M, Scanning electron micrographs of the ventricular surface of 13.5 dpc 
Crim1
+/+
 (J, L) and Crim1
Δflox/Δflox
(K, M) hearts. K, Note the loss of the even spacing of cells of the 
mesothelial epicardium, and M, diffusely arranged microvilli. N, Quantification of penetrance of epicardial 
defects, specifically either epicardial blebbing or a loss of squamous morphology, between Crim1
+/+
 and 
Crim1
Δflox/Δflox
 hearts at 13.5 dpc. Z-score -3.8801. *, P<0.0001. cm, compact myocardium; ep, epicardium. 
Scale bars; A–F, 500 µm; G-I, 50 µm; J-K, 20 µm; L-M, 2 µm. 
 
 
Figure 3. Crim1 is necessary for normal compact myocardial development.  
A and B, Merged confocal images of left ventricular sections of 13.0 dpc hearts from Crim1
+/+
 (A) and 
Crim1
Δflox/Δflox
 (B) hearts stained with DAPI (blue), PECAM-1 (red), and actin (green). C, Compact 
myocardium cell density was unchanged in Crim1
Δflox/Δflox
hearts. D, Reduced ventricular compact myocardial 
thickness in Crim1
Δflox/Δflox
hearts at 13.0 dpc (n=6–8). E and F, Merged confocal images of ventricular 
sections of 13.0 dpc hearts stained with phospho- Histone H3 (pHH3, white), DAPI (blue), and actin (green). 
An epicardial cell (arrowhead, E) and myocardial cell (arrowhead, F) immuno-positive for pHH3 are shown. 
G, No difference in proliferation in the epicardium of Crim1
Δflox/Δflox
hearts. H, An almost two-fold increase in 
proliferation in the compact myocardium of Crim1
Δflox/Δflox
hearts. I and J, Examples of merged confocal 
images of ventricular sections of 13.0 dpc hearts stained with cleaved caspase 3 (CC3, white), DAPI (blue), 
and actin (green). An epicardial cell (arrowhead, I) and myocardial cell (arrowhead, J) immuno-positive for 
CC3 are shown. K, No difference in apoptosis in the epicardium of Crim1
Δflox/Δflox
 hearts. H, A four-fold 
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increase in apoptosis in the compact myocardium of Crim1
Δflox/Δflox
hearts. cm, compact myocardium; ep, 
epicardium; n.s., not significant. (n=4–5), *, P<0.05; **, P<0.01. Scale bars A, B, 50 μm; E, F, I, J, 20 μm.  
 
 
Figure 4. A cell-autonomous requirement for Crim1 to control epicardial migration and myocardial 
invasion in vitro and in vivo.  
A, Schematic of the transwell assay used for the in vitro migration assay. B, Representative micrograph of a 
primary 11.5 dpc ventricular explant after attachment and migration of epicardial cells. The front of the 
epicardial monolayer is indicated (arrows). The primary explant is denoted by an asterisk. C, Primary 
epicardial cells after removal of the ventricular explant, passage and subsequent culture. Note maintenance 
of a “cobblestone” appearance of the cellular monolayer. D, Epicardial identity after enrichment was 
confirmed by immunostaining for WT1 (green nuclear signal). The no-primary antibody control showed no 
signal (inset). E, Crim1
KST264/KST264
primary epicardial cells showed increased migration in vitro relative to 
controls (n=3–5 and representative of three independent experiments; *, P<0.05). F, J, Whole-mount dorsal 
views of 15.5 dpc embryonic hearts after X-Gal staining (blue) of Crim1
+/FLOX
; WT1-CreERT2; R26R and 
Crim1
FLOX/FLOX
; WT1-CreERT2; R26R genotype, respectively. Two doses of Tamoxifen were administered at 
9.5 dpc and 10.5 dpc prior to harvesting the embryos. G, K, Histological sections of hearts from Crim1
+/FLOX
; 
WT1-CreERT2; R26R and Crim1
FLOX/FLOX
; WT1-CreERT2; R26R 15.5 dpc embryos, respectively, and H, L, 
magnified views of boxed regions showing X-Gal-positive epicardial, sub-epicardial and intramural cells. I, 
M, Quantification of X-Gal-positive cells showing increased myocardial EPDCs in the right ventricles of 
mutant hearts (n=4-6; *P<0.05). ep, epicardial; se, sub-epicardial; my, intramyocardial; LV, left ventricle; 
RV, right ventricle. Scale bars, G, K, 20 μm; H, L, 10 μm.  
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Figure 5. Changes in epicardial and myocardial signalling, alongside localisation of β-catenin in 
Crim1
Δflox/Δflox
hearts.  
A-B, E-F, Confocal images of ventricular sections of 13.0 dpc hearts from Crim1
+/Δflox
 (A, B) and 
Crim1
Δflox/Δflox
(E, F) embryos stained for phospho-SMAD2/3 (white). A, B, merged images of DAPI (blue) 
and actin (green) to delineate the myocardium with the phospho-SMAD2/3 (white) from B and F, 
respectively. C, D, G, and H, There was a reduction in phospho-SMAD2 signal intensity in epicardial cells 
of left and right ventricles of Crim1
Δflox/Δflox
hearts, but the levels in compact myocardial cells was unchanged 
(n=4–5). Confocal images of ventricular sections of 13.5 dpc hearts from Crim1+/+ (I, J) and Crim1Δflox/Δflox(M 
and N) embryos stained for phospho-ERK1/2 (red). I, M, merged images of DAPI (blue) and phospho-
ERK1/2 (red). K, L, O and P, There was an increase in phospho-ERK1/2 signal intensity in compact 
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myocardial cells of left and right ventricles of Crim1
Δflox/Δflox
hearts, but the levels in epicardial cells was 
unchanged (n=8-6). Q-R, T-U, Confocal images of ventricular sections of 13.5 dpc hearts from Crim1
+/+
 (Q, 
R, S) and Crim1
Δflox/Δflox(T, U, V) embryos stained for β-catenin (red). Q, T, merged images of DAPI (blue) 
and MF20 (green) to delineate the epicardium with the β-catenin (red) from R, S and U, V respectively. S, V, 
magnified views of boxed regions in R and U. Note β-catenin distribution at epicardial cell-cell junctions of 
Crim1
+/+
 hearts (arrows, R, S), and a decreased accumulation at epicardial cell junctions in mutants (double 
arrowheads, V) . W, the percentage of epicardial cells with an accumulation of β-catenin at cell junctions 
(n=5-6). cm, compact myocardium; ep, epicardium; s.ep, sub epicardium. n.s., not significant. *, P<0.05. 
Scale bars, A-B, E-F, 10 μm; I-J, M-N, 50 μm; Q-R, T-U; 10 μm.  
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Figure 6. Epicardium-restricted Crim1 loss-of-function results in decreased proliferation of EPDCs 
and cardiac fibroblasts in both left and right ventricles.  
A,B, phospho-Histone H3 immunohistochemistry on X-Gal stained Crim1
+/FLOX
; +/WT1-CreERT2; R26R 
and Crim1
FLOX/FLOX
; +/WT1-CreERT2; R26R sections at 15.5 dpc, counter stained with 1% DAB followed by 
NFR staining for visualisation of nuclei, showing A, pHH3- and X-Gal-positive nuclei (arrow) and B, a 
pHH3-positive nucleus (open arrowhead). C,D, Quantification of proliferating EPDCs showing no change in 
the epicardium, but a significant reduction in the number of pHH3-positive EPDCs in mutant hearts 
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compared to control in the myocardium (n=6-4). E-G, Periostin immunohistochemistry on X-Gal stained 
Crim1
+/FLOX
; +/WT1-CreERT2; R26R and Crim1
FLOX/FLOX
; +/WT1-CreERT2; R26R sections at 17.5 dpc, 
counter stained with 1%DAB followed by Hematoxylin staining, showing E, a periostin- and X-Gal-positive 
cardiac fibroblast (arrow), F, an X-Gal-positive EPDC (open arrowhead) and G, a periostin-positive cardiac 
fibroblast (double open arrowheads). H,I, quantification of % periostin-positive cells among X-Gal-positive 
myocardial cells in left and right ventricles, showing a decrease in number of cardiac fibroblasts (n=3-5). *, 
P<0.05. n.s., not significant; LV, left ventricle; RV, right ventricle. Scale bars A,B 50 µm; E-G, 10 µm. 
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Supplementary Information 
 
 
Supplementary figure 1. Crim1 is expressed in the outflow tract, mitral valve leaflets and 
coronary vascular smooth muscle cells.  
A, Periostin immunohistochemistry on an X-Gal stained Crim1
+/KST264
 transverse section at 12.5 dpc. B, 
higher magnification view of the boxed area in A, showing periostin- and X-Galpositive outflow tract 
mesenchymal cells (arrows). C, Periostin immunohistochemistry on an X-Gal stained Crim1
+/KST264
 coronal 
section at 13.5 dpc. D, higher magnification view of boxed area in C, showing periostin- and X-Gal-positive 
mesenchymal cells (arrows). E, 3 Periostin immunohistochemistry on an X-Gal stained Crim1
+/KST264
 coronal 
section at 18.5 dpc, showing periostin- and X-Gal-positive mitral valve leaflet cells (arrows). F, Transgelin 
immunohistochemistry on an X-Gal stained Crim1
+/KST264
 coronal section at 18.5 dpc, showing transgelin- 
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and X-Gal-positive coronary vascular smooth muscle cells (arrows). Scale bars, A, C, 100 µm; B, D, E, 40 
µm; F, 10 µm. 
 
 
Supplementary figure 2. Congenital heart defects in Crim1
KST264/KST264
 embryos.  
A–C, 18.5 dpc littermate hearts stained with X-Gal to reveal Crim1-LacZ expression (blue). A, Crim1+/KST264 
18.5 dpc heart. B, Crim1
KST264/KST264
 18.5 dpc heart. C, Quantification of the 5 size of the ventricular 
component at 18.5 dpc, showing a significant reduction in the width of Crim1
KST264/KST264
 hearts (n=7–9). D-
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F, Coronal sections of 18.5 dpc hearts stained with XGal and counter-stained with nuclear fast red. The right 
atrium (RA) is labelled. D, Crim1
+/KST264
 18.5 dpc heart showing normal morphology. E,F, Crim1
KST264/KST264
 
hearts displaying a prominent VSD, a communication between left and right ventricles (arrow). G, Another 
section of the heart in F, showing the VSD. H, View of the inset in G. Note the Crim1-LacZ-positive cells 
(arrows) in the IVS either side of the communication between the ventricles. I, Quantification of prevalence 
of VSDs in Crim1
+/KST264
 and Crim1
KST264/KST264
 hearts (n=5). Z-Score -2.582. *, P<0.01. LV, left ventricle; 
RV, right ventricle. Scale bars D, 500 μm; H, 50 μm; K, 10μm. 
 
 
Supplementary figure 3. Crim1 is not necessary for specification or early development of the 
proepicardium.  
A-F, Micrographs of 9.5 dpc embryos from Crim1
+/+
 (A, C, E) and Crim1
Δflox/Δflox
(B, D, F) embryos stained 
for Gata4 mRNA expression (purple stain, A and B) and Tbx18 mRNA expression (purple stain, C and D). 
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E, F, Micrographs of histological sections of wholemount in situ hybridization-stained embryos showing 
Tbx18 expression. The PE is indicated (arrows). Scale bars A and E, 50 µm. 
 
 
Supplementary figure 4. Myocardial deletion of Crim1 does not affect cardiomyocyte 
proliferation and survival and thickness of compact myocardium.  
A, D representative whole mount images of X-Gal stained Crim1
+/FLOX
; Mlc2v- Cre; R26R and 
Crim1
FLOX/FLOX
; Mlc2v-Cre; R26R hearts at 13.5 dpc. B, E merged confocal images of DAPI (blue) and 
pHH3 (red), with a pHH3-positive nucleus (arrow). C, F merged confocal images of DAPI (blue) and CC3 
(red), with a CC3-positive nucleus (arrow). G, No significant difference in percentage of pHH3-positive cells 
in the compact myocardium of left and right ventricles in control and mutant hearts (n=4-6). H, No 
significant difference in percentage of CC3-positive cells in the compact myocardium of left and right 
ventricles in control and mutant hearts (n=4-5). I, No significant difference in thickness of compact 
myocardium in the left ventricle of control and mutant hearts (n=3). cm, compact myocardium; ep, 
epicardium; n.s, not significant. Scale bars B, C, E, F 20 µm. 
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Supplementary figure 5. Fidelity of the WT1-Cre and WT1-CreERT2 lines.  
A-E, MF20 immunohistochemistry performed on A-C, 15.5 dpc WT1-Cre X-Gal stained sections showing 
MF20-negative epicardium (arrows) and MF20-negative EPDCs (open arrowheads), D, WT1-CreERT2 13.5 
dpc X-gal stained section showing that most epicardial cells are X-Gal-positive (arrow), and E, WT1-
CreERT2 17.5 dpc X-Gal stained section showing MF20-negative EPDCs (open arrowheads), confirming 
that the EPDCs are not cardiomyocytes. ep; epicardium. Scale bars A-C, 25µm; D-E, 50 µm. 
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Supplementary figure 6. Phospho-SMAD1/5 and phospho-AKT levels are not significantly 
changed in the epicardium or myocardium of Crim1
Δflox/Δflox
hearts.  
Confocal images of ventricular sections of 13.0 dpc hearts from Crim1
+/Δflox
(A, B) and Crim1
Δflox/Δflox
(E, F) 
embryos stained for phospho-SMAD1/5 (white). A and E, merged images of DAPI (blue) and actin (green) 
to delineate the myocardium with the phosphoSMAD1/5 (white) from A and E, respectively. C, D, G, and H, 
Quantification of the average signal intensity/cell after indirect immunofluorescence to detect phospho-
SMAD1/5 showed there was no change in the levels in the epicardium or compact myocardium of left and 
right ventricles of Crim1
Δflox/Δflox
hearts in comparison to controls (n=5). Confocal images of ventricular 
sections of 13.5 dpc hearts from Crim1
+/+
(I, J) and Crim1
Δflox/Δflox
(M, N) embryos stained for phospho-AKT 
(red). Quantification of signal intensity/ cell after 10 immunofluorescence to detect phospho-AKT revealed 
no change in the levels in the epicardium or compact myocardium of left and right ventricles of 
Crim1
Δflox/Δflox
hearts in comparison to controls (n=5-6). cm, compact myocardium; ep, epicardium; n.s., not 
significant. Scale bars, A, B, E, F 10µm; I, J, M, N, 50 µm. 
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Supplementary figure 7. No visible change in filamentous actin morphology in the epicardium 
or myocardium of Crim1
Δflox/Δflox
hearts at 13.5 dpc.  
A-F, Representative confocal images of ventricular sections of 13.5 dpc hearts from Crim1
+/+
(A, B, C) and 
Crim1
Δflox/Δflox
(D, E, F) hearts at 13.5 dpc. A, D merged images of DAPI (blue) and MF20 (green) to delineate 
the myocardium with Phalloidin (red) from B and E, respectively (n=4-5). C, F, magnified views of boxed 
regions in B and E respectively. Scale bars A – F, 20 µm. 
 
 
Supplementary figure 8. No change in the expression of key cardiac genes in 
Crim1
Δflox/Δflox
hearts at 17.5 dpc.  
A, qPCR with fibroblast, smooth muscle and cardiomyocyte markers showing no significant difference in 
fold change between Crim1
+/+
and Crim1
Δflox/Δflox
ventricular samples at 17.5 dpc. Note that for Collagen1a, 
P=0.0556. (n=4-5). 
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Abstract 
Endothelial cells form a critical component of the coronary vasculature, yet the factors regulating 
their development remain poorly defined. Here we reveal a novel role for the transmembrane 
protein CRIM1 in mediating cardiac endothelial cell development. In the absence of Crim1 in vivo, 
the coronary vasculature is malformed, the number of endothelial cells reduced, and the canonical 
BMP pathway dysregulated. Moreover, we reveal that CRIM1 can bind IGFs, and regulate IGF 
signalling within endothelial cells. Finally, loss of CRIM1 from human cardiac endothelial cells 
results in misregulation of endothelial genes involved in an increased inflammatory response and 
cytolysis, reminiscent of endothelial cell dysfunction in cardiovascular disease pathogenesis. 
Collectively, these findings implicate Crim1 in endothelial cell development and homeostasis in the 
coronary vasculature. 
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Introduction 
Endothelial cells play an important role in angiogenesis and vasculogenesis, and regulate vessel 
permeability and vascular tone (Aird, 2012). The heart contains several subtypes of endothelial cells 
- the endocardial lining of the heart chambers and valves, myocardial microvessels, and coronary 
macrovessels - which differ considerably in their function and gene expression (Hendrickx et al., 
2004). Endothelial cells both produce and respond to a variety of cytokines and growth factors, and 
their misregulation contributes to cardiac disease progression (Pate et al., 2010). 
 
Bone Morphogenetic Proteins (BMPs) (Dyer et al., 2014) and Insulin-like Growth Factor (IGF) 
(Delafontaine et al., 2004) are crucial to endothelial cell biology, and as such, these growth factors 
undergo regulation at multiple levels.Modulators such as chordin, noggin and crossveinless-2 
contain cysteine-rich repeats (CRRs), which potentiate binding to BMPs (Larraín et al., 2000, 
Zimmerman et al., 1996, Groppe et al., 2002, Zhang et al., 2010). Endothelial cells also express 
IGF-binding proteins (IGFBPs), CRR-containing proteins which act to mediate the effect of IGF 
binding by controlling the availability of IGFs as well as reducing their activity by sequestering 
them such that they cannot bind to and activate IGF receptors (Hwa et al., 1999).  
 
Another protein implicated in the regulation of growth factor activity during development is 
cysteine rich transmembrane BMP regulator 1 (CRIM1) (Kolle et al., 2000, Wilkinson et al., 2003, 
Wilkinson et al., 2007). It contains six CRRs via which it binds growth factors such as TGFβ, BMP 
and VEGF when both are co-expressed in the same cell (Kolle et al., 2000, Wilkinson et al., 2003, 
Wilkinson et al., 2007), as well as an IGFBP domain (Kolle et al., 2000), though the significance of 
the latter remains to be determined. Crim1 has been previously implicated in cardiac development 
(Iyer et al., 2016), but how this factor mediates cardiac endothelial cell biology is unknown.  Here 
we reveal a role for CRIM1 in cardiac microvascular endothelial cell development, demonstrating 
that canonical BMP signalling is dysregulated in the absence of Crim1, that CRIM1 can bind IGF-1, 
and that the IGF signalling pathway is altered upon loss of CRIM1 function. We also report the 
misexpression of a number disease-related endothelial genes in the absence of CRIM1, collectively 
defining a role for CRIM1 in normal endothelial cell function in the heart. 
 
Results 
Absence of Crim1 affects coronary endothelial cell endowment. 
Crim1 mutant embryos display developmental defects including reduced ventricular size, 
abnormal epicardial morphology and malformed vasculature (Iyer et al., 2016). However, the 
effect of Crim1-deficiency in coronary endothelial cells is unknown. Analysis ofCrim1
Δflox/Δflox 
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embryos revealed a decrease in endothelial cell endowment in the compact myocardium of the 
ventricular free walls at 17.5 dpc (Figure 1A-F). To address whether Crim1 is required cell-
autonomously for coronary vascular endothelial cell development, we conditionally ablated 
Crim1 from endothelial cells using aTie2-Cre line(Kisanuki et al., 2001, Li et al., 2005). As with 
the constitutive knockout, we detected a significant reduction in endothelial cell endowment in 
the ventricular myocardium of conditional mutants in comparison to controls at 17.5 dpc (Figure 
1G-L). This phenotype was not due to apoptosis at this stage, given the limited death of 
endothelial cells (Figure S1A-F), nor did we observe marked alterations in endothelial cell 
proliferation in mutant embryos (Figure S1G-L). As such we hypothesised that the lack of Crim1 
led to alterations in growth factor signalling that led to reduced endothelial cell endowment.  
 
Canonical BMP signalling is perturbed in the absence of Crim1. 
CRIM1 binds to growth factors, including BMPs, which are known to drive cardiac 
development. To investigate whether BMP signalling was abnormal within coronary vascular 
endothelial cells of Crim1-deficient embryos, we assessed phosphorylated SMAD1/5 
(pSMAD1/5) expression as a proxy for BMP activity, as phosphorylation of these intracellular 
effectors is part of the canonical signalling pathway downstream of BMPs (Dyer et al., 2014). 
Quantification of fluorescent labelling revealed a reduction in pSMAD1/5 signal intensity in 
Crim1
Δflox/Δflox 
hearts at 17.5 dpc in all cells, as well as specifically within endothelial cells 
(Figure 1M-T).  
 
CRIM1 regulates cell viability and growth factor signalling. 
Having implicated Crim1 in the modulation of BMP signalling in cardiac endothelial cells in 
vivo, we next sought to further characterise signalling pathways perturbed upon reduction of 
CRIM1 expression. Using shRNA-mediated knockdown of CRIM1 (Fan et al., 2014) in Human 
Cardiac Microvascular Endothelial Cells (HCMVECs) we achieved approximately a 75% reduction 
in CRIM1 expression, a finding correlated with reduced cellular viability (Figure 2A, B). Next, 
analysis of protein lysates from CRIM1 knockdown HCMVECsrevealed significant decreases in 
pSMAD1/5 and phosphorylated IGF-1 receptor (pIGF-1Rβ) expression in CRIM1-knockdown 
lysates compared to scrambled shRNA controls, whereas no change in pERK1/2 and pAKT was 
observed (Figure 2C, D). These findings suggest that the activity of BMP and IGF signalling 
pathways is aberrant when CRIM1 expression is perturbed. Interestingly, an interaction between 
CRIM1 and IGF signalling has not previously been reported. To probe this further, 2 splice variants 
of IGF-1, IGF-1 Ea-HA and IGF-1 Eb-HA (Hede et al., 2012), were co-immunoprecipitated with 
CRIM1-myc (Figure S2A). Using a series of CRIM1 expression constructs (Figure 3A), coupled 
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with co-immunoprecipitation, we found that CRIM1 binds to IGF-1 via CRRs 3-6 and its IGFBP 
domain (Figure 3B, C). Collectively, these findings suggest that CRIM1 may regulate multiple 
signalling pathways to mediate cardiac endothelial development and homeostasis.  
 
Misregulation of endothelial genes in the absence of CRIM1 
Lastly, we investigated the mechanisms through which CRIM1 regulates endothelial cell biology by 
assessing the transcriptional consequences of CRIM1 knockdown in HCMVECs using a Human 
Endothelial Cell Biology qPCR array. Of the 84 genes analysed, 29 were significantly misregulated 
upon Crim1 knockdown (>2-fold up/downregulation) (Figure 4A, Table S1). Ingenuity Pathway 
Analysis further revealed enrichment of genes involved in cellular functions including 
inflammation, cytolysis and immune cell infiltration, many of which are also implicated in 
cardiovascular disease (Figure 4B, C). Together, these data provide an initial mechanistic insight 
into the cascade of perturbed signalling events arising from aberrant CRIM1 expression in 
endothelial cells.  
 
Discussion  
Our findings provide a platform for understanding the role that CRIM1 plays in the development 
and function of cardiac endothelial cells. Our data demonstrate that Crim1 regulates endothelial cell 
endowment, and that CRIM1 can bind IGF, and can modulate BMP and IGF downstream 
signalling. Given that CRIM1 deficiency leads to reduced IGF-1 and BMP signalling, we posit that 
in the heart CRIM1 serves as an agonist of IGF-1 and BMP signalling. BMPs and IGFs are 
required for the development of endothelial cells (Suzuki et al., 2008, Langenfeld and 
Langenfeld, 2004, Higashi et al., 2014), and thus it is plausible that a reduction in BMP and IGF 
signalling due to loss of CRIM1 could lead to endothelial stress and dysfunction, which leads to 
reduced endothelial cell endowment.  Interestingly, Crim1
FLOX/FLOX
; Tie2 Cre mice survive to 
adulthood (data not shown), suggesting that the reduced endowment of endothelial cells during 
development does not preclude survival. However, given our qPCR array findings, further 
analysis of the response of these adult mice to cardiac stress and injury, as well as their 
inflammatory responses, would serve to deepen our understanding of the role of CRIM1-
mediated endothelial cell development and how this affects cardiac function later in life.  
 
One caveat of this study is that the binding of CRIM1 to IGF-1 was assessed only when both 
CRIM1 and the growth factor were co-expressed by the same cell. Examination of interactions 
between CRIM1 and growth factors expressed by paracrine sources may provide a greater 
mechanistic understanding of CRIM1 function within the complex milieu of the nascent heart. 
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Finally, these data also suggest that aberrant CRIM1 expression may culminate in abnormal 
signalling correlated with inflammation and heart disease. The development of atherosclerosis, a 
leading cause of coronary artery disease and risk factor for myocardial infarction, has been linked to 
activation of the endothelium and orchestration of an inflammatory response (Hansson, 2005). 
Initiation of atherogenesis involves this recruitment of inflammatory cells to the endothelium, and is 
further exacerbated by stimuli such as hyperlipidemia, high blood pressure and a consequently 
heightened pro-inflammatory cascade (Libby et al., 2011). Furthermore, the limited ability of the 
endothelium to repair itself has made it critical to uncover molecules that can counter or prevent  
endothelial dysfunction. Thus, the presence of CRIM1 could counter the pathophysiology of 
various diseases that are directly involved with endothelial abnormalities.  Given these findings, 
understanding how CRIM1 may mediate endothelial cell biology within the mature heart is an 
exciting field of future research.  
 
Materials and Methods  
Ethics Statement 
All experimental protocols were approved by The University of Queensland‟s Animal Ethics 
Committee (AIBN/274/08/NHMRC, SMBS/420/11/NHMRC), and followed the National Institutes 
of Health Guide for the Care and Use of Animals, and the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes.  
 
Mouse lines 
The mouse lines used in this study were the Crim1
FLOX
conditional knock-out (Chiu et al., 2012); 
Crim1
Δflox
constitutive knock-out (Chiu et al., 2012), and Tie2-Cre mouse lines (Kisanuki et al., 
2001). Embryos were used at 17.5 dpc. 
 
Antibodies 
Primary antibodies used were: rabbit anti-phosphohistone H3 (pSer10, #06-570; Millipore); rabbit 
anti-cleaved caspase 3 (#9664; Cell Signaling Technology); rabbit anti-pSMAD1/5 
(pSer463/pSer465, #700047; Invitrogen); total SMAD1/5/8/9 (NB100-56656; Novus Biologicals); 
rat anti-CD31 (PECAM-1, #550274; BD Pharmingen); pIGF-1Rβ (#3024S; Cell Signalling); total 
AKT (#9272; Cell Signalling); total ERK1/2 (sc-93; Santa Cruz); total IGF-1R (sc-712; Santa 
Cruz); GAPDH (#2118; Cell Signalling); β-tubulin (#2146; Cell Signalling); Angiogenesis sampler 
kit (#8696; Cell Signalling); rabbit HA tag (#3724; Cell Signalling); mouse myc tag (#2276; Cell 
Signalling); normal mouse IgG2a isotype control (#02-6200; Thermofisher Scientific).  Secondary 
antibodies were Alexa Fluor-488, and 594-conjugated secondary antibodies (Invitrogen) rabbit HRP 
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(#W4011; Promega), mouse HRP (#W4021; Promega), IgG mouse IRDYE (#926-32212; Licor) 
and IgG rabbit IRDYE (#926-68073; Licor). 
 
Cell Culture 
H-CMVECs (Lonza, CC-7030) were cultured in EGM-2MV BulletKit media (Lonza, CC-3202). 
The cell line was authenticated and tested for contamination by Lonza Walkersville/Lonza 
Australia. Cells before passage six were used in all experiments. shRNA targeting CRIM1 mRNA 
(Fan et al, 2014) was acquired from TRC Mission Library (TRCN0000063862, Invitrogen). 
Lentiviral particles were synthesized by transfecting CRIM1 shRNA, scrambled shRNA and the 
lentiviral packaging vectors into HEK293T cells using Lipofectamine 2000 and collecting the 
supernatant containing lentiviral particles at 48 hours after transfection. Cells at 80% confluence 
were incubated with lentiviral particles together with 8 μg/mL polybrene for 2 days and then treated 
with 2 μg/mL puromycin for 2 days to enrich the infected cell population. After puromycin 
removal, cells were used in subsequent experiments.  
 
Trypan Blue Viability Assay 
Control and CRIM1-knockdown CMVECs (5000 cells) were plated into wells of a 24-well plate at 
time zero. The number of viable cells at 24 hours and 48 hours was counted based on Trypan Blue 
exclusion. 
 
q-PCR Array  
RNA was extracted using the RNeasy Mini Kit (Qiagen). cDNA was prepared using RT
2
 First 
Strand Kit (Qiagen). Quantitative PCR to assess percentage CRIM1 knockdown was performed 
with QuantiFast SYBR Green PCR kit (Qiagen). The RT
2
 SYBR Green ROX qPCR Mastermix was 
used for Human Endothelial cell Biology Profiler PCR Array (Plate E). Signals were detected using 
the Roche LightCycler and Applied Biosystems QuantStudio 7 system and gene expression levels 
were calculated using the standard curve method. Gene analyses were performed using the Qiagen 
Gene Globe Data Analysis Center and the Ingenuity Pathway Analysis. 
 
Generation of deletion constructs 
Full-length myc-tagged CRIM1(Wilkinson et al., 2003) was used as a template to generate myc-
tagged CRIM1 deletion constructs. Primers were designed as follows: 
 
CRIM1-3.1-InF-RV-F 
5‟-TGGAATTCTGCAGATATGTACTTGGTGGCGGGG 
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CRIM1-3.1-InF-RV-R 
5‟-GCCACTGTGCTGGATTCATAGGTCTTCTTCTGA-3‟ 
 
CRIM1-IGFBPsplice-InF-F 
5‟-GAGAACTGGACTGATGAC-3‟ 
 
CRIM1-IGFBPsplice-InF-R 
5‟-ATCAGTGCAGTTCTCCGCCCGGGTGCCGGAGCGCGC-3‟ 
 
CRIM1-D1-2-IF-F 
5‟-GAAGAACCAACCATCATC-3‟ 
  
CRIM1-D1-2-IF-R 
5‟-GATGGTTGGTTCTTCGGCTGGCTTTGTATCATTAAC-3‟ 
  
CRIM1-D3-6-IF-F 
5‟-CCAGAAATGTATGTCCCA-3‟ 
  
CRIM1-D3-6-IF-R 
5‟-GACATACATTTCTGGAGTGCCCGACAGGATGGGTGG-3‟ 
 
CRIM1-D1-6-IF-R 
5‟-GACATACATTTCTGGGGCTGGCTTTGTATCATTAAC-3‟ 
 
Cloning was performed using the In-Fusion Kit (Clontech, #638910). Constructs were sequenced to 
confirm deletion.  
 
Co-Immunoprecipitation 
HEK293 cells were grown to 80% confluence and transfected with full length myc-tagged 
CRIM1(Wilkinson et al., 2003), myc-tagged CRIM1 deletion constructs, and HA-tagged IGF-1 Ea 
and IGF-1 Eb constructs (Hede et al., 2012) using Lipofectamine 2000 (Invitrogen). After 24 hours, 
the cells were lysed in RIPA containing protease inhibitor and phosphatase inhibitor on ice. 
Immunoprecipitation was performed by the addition of α-myc antibody for 2 hours at 4 degrees, 
followed by addition of 30 μL of Protein A Agarose (Roche, #11719408001) and a further 1 
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hourincubation at 4 degrees. The beads were pelleted and washed five times with cold PBS 0.1% 
Triton X-100. Protein was eluted by addition of SDS-PAGE loading buffer and boiled for 4 
minutes.  Western Blotting was performed according to standard methods. 
 
Data Analysis 
Fluorescent images of tissue sections were captured on an Olympus FV1000 upright laser scanning 
confocal microscope. For all quantification, 40x images were acquired of the left and right mid-
ventricular myocardial free wall from at least two-three non-consecutive sections of each sample. 
The number of PECAM-1 positive cells were counted and divided by total cell number to determine 
the PECAM-1-positive percentage of endothelial cells. For quantification of pSMAD1/5 levels, 
Olympus Fluoview software (ver3.1a) was used to determine total signal intensity in, and area of, 
the specified region of interest. The number of DAPI-stained nuclei in the demarcated area was 
quantified using ImageJ software. Signal intensity within specifically endothelial cells was 
determined using the IMARIS software (ver8.2.0). Endocardial / trabecular endothelial cells were 
not included in the quantifications. 
 
Immunoblots were visualised either with a chemi-luminescent reagent (Merck Millipore) via 
exposure to X-ray film, or by using the Licor Odyssey scanner. All densitometry quantitation on 
immunoblots was performed using ImageJ software. All test values were normalised to respective 
loading and experimental controls and graphed with Prism 6. 
 
Statistical significance between pooled data from mutant and control groups was determined using a 
two-tailed, unpaired Student‟s t-test or a standard one-way ANOVA with Dunnett‟s post-test, as 
specified in the figure legend. Quantified data shown are mean ± standard deviation. GraphPad 
Prism v6.0 was used to conduct all analyses and generate graphs. 
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Figures and Figure legends 
 
 
Figure 1: Loss of Crim1 results in reduced coronary endothelial cell endowment, and 
dysregulation of canonical BMP signalling, in vivo. 
A-D, M-P, Confocal images of ventricular sections of 17.5 dpc hearts from Crim1
+/+
, Crim1
 +/Δflox
 (A, B, 
M, N) and Crim1
Δflox/Δflox 
(C, D, O, P) embryos, immunostained with PECAM-1 (A-D), and PECAM-1 
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and pSMAD1/5 (M-P). E, F, Reduced endothelial cell endowment as observed by a reduced percentage of 
PECAM-1+ve endothelial cells in the ventricular compact myocardium of Crim1
Δflox/Δflox
 hearts (n=4). Q, R, 
Reduction in pSMAD1/5 levels in all cells of both ventricles of Crim1
Δflox/Δflox 
hearts and S, T, endothelial 
cells of the left ventricle (n=4). G-J, Confocal images of ventricular sections of 17.5 dpc hearts from 
Crim1
+/FLOX
; Tie2-Cre (G, H) and Crim1
FLOX/FLOX
; Tie2-Cre (I, J) embryos, immunostained with PECAM-
1 (G-J). K, L, Reduced endothelial cell endowment as observed by a reduced percentage of PECAM-1+ve 
endothelial cells in the ventricular compact myocardium ofCrim1
FLOX/FLOX
; Tie2-Cre hearts (n=9-7). RV, 
right ventricle; LV, left ventricle; ep, epicardium; en, endocardium; n.s, not significant.Two-tailed, 
unpaired Student‟s t-test; *P<0.05. Scale bars A-D, G-J, M-P, 50 μm. Error bars, SD 
 
 
Figure 2: CRIM1 ablationresults in decreased endothelial cell viability and reduced 
pSMAD1/5 levels 
A, Approx. 75% CRIM1 knockdown in HCMVECs (n=3). B, Trypan Blue Viability Assay demonstrating 
decrease in cell viability in CRIM1 knockdown HCMVECs compared to scrambled shRNA controls after 24 
and 48 hours respectively, after plating 5000 cells per well of a 24 well plate (n = 3, and each n represents an 
average of 3 replicates).C, D, Reduction in pSMAD1/5 and pIGF-1Rβ levels as a proxy to assess BMP and 
IGF-1 signalling in CRIM1 knockdown HCMVECs, but no change in pERK1/2 and pAKT levels, compared 
to scrambled shRNA control HCMVECs (n = 4-7).Two-tailed, unpaired Student‟s t-test; *P < 0.05, **P < 
0.01, ****P < 0.0001.Error bars, SD. 
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Figure 3: CRIM1 binds IGF-1 via the IGFBP domain and CRRs 3-6. 
A, Representation of CRIM1 deletion constructs as generated using InFusion cloning.  1. Full length CRIM1-
myc, 2. CRIM1ΔIGFBP-myc lacking the IGFBP domain, 3.CRIM11-2-myc lacking CRRs 1 and 2, 
4.CRIM13-6-myc lacking CRRs 3, 4, 5 and 6, 5.CRIM11-6-myc lacking all 6 CRRs. 6. 
CRIM1ΔIGFBP1-6-myc lacking the IGFBP domain and all six CRRs. B, C, CRIM1 binds IGF-1 Eb via the 
IGFBP domain and CRRs 3-6. A, HEK293 cells transiently co-transfected with full length CRIM1-myc, 
CRIM1ΔIGFBP-myc, CRIM1Δ1-2-myc, CRIM1Δ3-6-myc, CRIM1Δ1-6-myc, CRIM1ΔIGFBPΔ1-6-myc, and 
IGF-1 Eb-HA. Control cells transiently co-transfected with only CRIM1-myc and only IGF-1 Eb-HA. 
Immunoprecipitation performed with anti-myc and immunoblotting with anti-HA. IB bands were detected 
only when both CRIM1 and IGF-1 Eb were co-transfected. B, CRIM1 binds IGF-1 Eb via the IGFBP domain 
and CRRs 3-6, as indicated by 1-way ANOVA analysis with Dunnett‟s post-test, which reveals that deletion 
of the IGFBP domain and CRRs 3-6 of CRIM1 significantly reduces binding of CRIM1 to IGF-1 Eb. 
Deletion of CRRs 1-2 does not affect binding to IGF-1 Eb. (3 independent IPs performed. Representative 
blot chosen).**P < 0.01, ***P < 0.001. Error bars, SD. 
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Figure 4. Misregulation of genes involved in endothelial cell function in the absence of CRIM1.  
A, Scatterplot displaying misregulation of 29 genes out of 84, involved in endothelial cell function, with a 
fold-change cut-off of 2. The scatter plot compares the normalized expression of every gene on the array 
between the two selected groups by plotting them against one another to visualize gene expression changes. 
The central line indicates unchanged gene expression. The dotted lines indicate the selected fold regulation 
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threshold.B, C, IPA analysis of genes misregulated in the human endothelial cell biology qPCR array, 
indicating an increase in genes predicted to be associated with a heightened inflammatory response and 
cytolysis (B, Table S1), along with heart failure, infarction and vascular lesions (C, Table S1). Z scores > 2 
are significant. (n = 4, with 2 technical repeats). 
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Supplementary Information 
 
 
Supplementary figure 1: Increase in apoptosis but no change in proliferation of endothelial 
cells that have lost Crim1. 
A-D, G, H, Confocal images of ventricular sections of 17.5 dpc hearts from Crim1
+/FLOX
; Tie2-Cre (A, B, 
G) and Crim1
FLOX/FLOX
; Tie2-Cre (C, D, H) embryos, immunostained with PECAM-1 and Cleaved 
Caspase-3 (CC3) (A-D) and PECAM-1 and Phosphohistone H3 (PHH3) (G, H). E, F, Limited apoptosis in 
the left ventricles of Crim1
FLOX/FLOX
; Tie2-Cre hearts, immunostained with CC3 (n=6-7). I-L, No change in 
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proliferation of endothelial cells in both ventricles of Crim1
FLOX/FLOX
; Tie2-Cre hearts as assessed with 
PHH3 (I, J) and Ki67 (K, L). RV, right ventricle; LV, left ventricle; ep, epicardium; en, endocardium. 
*P<0.05. Scale bars A, C, G, H, 50 μm. B, D, 10 μm. Error bars, SD 
 
 
Supplementary figure 2: COIP revealing that CRIM1 can bind IGF-1 Ea and IGF-1 Eb 
A, HEK293 cells transiently co-transfected with full length CRIM1-myc and IGF-1 Ea-HA and IGF-1 Eb-
HA. Immunoprecipitation performed with anti-myc and immunoblotting with anti-HA. IB bands were 
detected only when both CRIM1 and IGF-1 Ea/Eb were co-transfected. (n=3). 
 
Table S1: List of all 84 endothelial genes assessed in the human endothelial cell biology array, with 
fold regulation and P values, after CRIM1 knockdown. Significantly misregulated genes (>2-fold 
up/downregulation) are highlighted in bold font. 
 
NUMBER GENE REFSEQ FOLD REGULATION P-VALUE 
1 ACE NM_000789 1.0909 0.290151 
2 ADAM17 NM_003183 -2.5219 0.00018 
3 AGT NM_000029 -1.4969 0.076943 
4 AGTR1 NM_031850 -1.1724 0.522084 
5 ALOX5 NM_000698 1.0231 0.969908 
6 ANGPT1 NM_001146 -1.8019 0.007017 
7 ANXA5 NM_001154 -2.2338 0.000006 
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8 APOE NM_000041 -1.6211 0.044427 
9 BAX NM_004324 -1.0566 0.281637 
10 BCL2 NM_000633 -1.5905 0.030518 
11 BCL2L1 NM_138578 -1.3774 0.000041 
12 CALCA NM_001741 1.0374 0.488782 
13 CASP1 NM_033292 5.1266 0.00003 
14 CASP3 NM_004346 1.0501 0.424219 
15 CAV1 NM_001753 -2.0448 0.000345 
16 CCL2 NM_002982 1.1958 0.04106 
17 CCL5 NM_002985 15.0637 0.000131 
18 CDH5 NM_001795 -1.4064 0.000322 
19 CFLAR NM_003879 -1.0154 0.820888 
20 COL18A1 NM_030582 -1.3561 0.007195 
21 CX3CL1 NM_002996 6.139 0.026342 
22 EDN1 NM_001955 -1.8019 0.000243 
23 EDN2 NM_001956 1.0073 0.925998 
24 EDNRA NM_001957 -1.431 0.154058 
25 ENG NM_000118 -1.2393 0.007858 
26 F2R NM_001992 1.32 0.01127 
27 F3 NM_001993 3.7529 0.000074 
28 FAS NM_000043 1.8797 0.000744 
29 FASLG NM_000639 1.0374 0.488782 
30 FGF1 NM_000800 1.32 0.277886 
31 FGF2 NM_002006 -1.0566 0.535619 
32 FLT1 NM_002019 -1.1266 0.145134 
33 FN1 NM_002026 -2.2611 0.0004 
34 HIF1A NM_001530 -1.0457 0.107155 
35 HMOX1 NM_002133 -1.1247 0.142892 
36 ICAM1 NM_000201 1.7207 0.000004 
37 IL11 NM_000641 -2.117 0.013737 
38 IL1B NM_000576 7.0153 0.001666 
39 IL3 NM_000588 1.0374 0.488782 
40 IL6 NM_000600 1.7752 0.002456 
41 IL7 NM_000880 1.6621 0.124883 
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42 ITGA5 NM_002205 -1.2414 0.001696 
43 ITGAV NM_002210 -2.3983 0.00012 
44 ITGB1 NM_002211 -2.8669 0.000001 
45 ITGB3 NM_000212 -1.5099 0.003451 
46 KDR NM_002253 -1.0996 0.224994 
47 KIT NM_000222 -3.7373 0.000736 
48 KLK3 NM_001648 -1.0845 0.479634 
49 MMP1 NM_002421 -1.5204 0.000071 
50 MMP2 NM_004530 -1.2986 0.012208 
51 MMP9 NM_004994 2.247 0.008745 
52 NOS3 NM_000603 1.0629 0.378124 
53 NPPB NM_002521 -3.0042 0.007349 
54 NPR1 NM_000906 1.8188 0.005741 
55 OCLN NM_002538 -2.3367 0 
56 PDGFRA NM_006206 -1.456 0.104707 
57 PECAM1 NM_000442 1.0091 0.766073 
58 PF4 NM_002619 -4.2047 0.030872 
59 PGF NM_002632 -1.7255 0.000027 
60 PLAT NM_000930 -1.4459 0.126347 
61 PLAU NM_002658 1.0556 0.288138 
62 PLG NM_000301 1.0374 0.488782 
63 PROCR NM_006404 -2.3327 0.000002 
64 PTGIS NM_000961 -2.0028 0.008857 
65 PTGS2 NM_000963 2.6126 0.000009 
66 PTK2 NM_005607 -1.3967 0.000021 
67 SELE NM_000450 7.0641 0.000001 
68 SELL NM_000655 1.6364 0.000056 
69 SELPLG NM_003006 -2.1803 0.029765 
70 SERPINE1 NM_000602 -4.6251 0.000001 
71 SOD1 NM_000454 -1.7863 0.000009 
72 SPHK1 NM_021972 -2.1391 0.000192 
73 TEK NM_000459 -2.2532 0 
74 TFPI NM_006287 -1.2986 0.000011 
75 TGFB1 NM_000660 -1.1092 0.093609 
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76 THBD NM_000361 -2.4487 0.000072 
77 THBS1 NM_003246 -1.5878 0.000133 
78 TIMP1 NM_003254 1.3269 0.004462 
79 TNF NM_000594 1.7752 0.0015 
80 TNFSF10 NM_003810 9.5666 0.000001 
81 TYMP NM_001953 4.494 0.000058 
82 VCAM1 NM_001078 5.056 0 
83 VEGFA NM_003376 -1.0677 0.210602 
84 VWF NM_000552 -1.2117 0.025954 
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Abstract 
The regulation of growth factor localization, availability and activity is critical during 
embryogenesis to ensure appropriate organogenesis. This process is regulated through the 
coordinated expression of growth factors and their cognate receptors, as well as via proteins that 
can bind, sequester or localize growth factors to distinct locations. One such protein is the 
transmembrane protein Crim1. This protein has been shown to be expressed broadly within the 
developing embryo, and to regulate organogenesis within the eye, kidney and placenta. 
Mechanistically, Crim1 has been revealed to mediate organogenesis via its interaction with growth 
factors including TGFβs, BMPs, VEGFs and PDFGs. More recently, Crim1 has been shown to 
influence cardiac development, providing further insights into the function of this protein. This 
review will provide an overview of the role of Crim1 in organogenesis, largely focusing on how this 
protein regulates growth factor signaling in the nascent heart. Moreover, we will address the 
challenges ahead relating to further elucidating how Crim1 functions during development. 
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Introduction  
 
Cysteine-Rich Transmembrane BMP Regulator-1 (Crim1) is a novel,N-glycosylated transmembrane 
protein encoded by the Crim1gene (Kolle et al., 2000; Glienke et al., 2002). Crim1 genes are 
evolutionarily conserved in vertebrates including rodents and humans(Kolle et al., 2000), as well as 
zebrafish (Kinna et al., 2006), the chicken (Kolle et al., 2003) and Xenopus(Ponferrada et al., 
2012). Interestingly, a Crim1 homolog called crm-1 has been described in Caenorhabditis elegans 
as well, although the role of this factor in the nematode has only received limited attention (Fung et 
al., 2007). Crim1is expressed in various organs during embryogenesis, including the spinal cord, 
lens, kidney, vasculature and placenta (Kolle et al., 2000; Lovicu et al., 2000; Glienke et al., 2002; 
Kolle et al., 2003; Pennisi et al., 2007; Pennisi et al., 2012; Phua et al., 2012; Fan et al., 2014), 
indicative of a role in their development. Structurally, the presence of six cysteine-rich repeat 
(CRR) motifs, an Insulin-like Growth Factor (IGF) Binding Protein (IGFBP) like domain and an 
Arginyl-glycyl-aspartic acid motif(RGD)(Kolle et al., 2000)suggests thatCrim1 can bind a variety 
of different proteins. In support of this, the CRRs have been shown to mediate the binding of 
CRIM1 to TGFβ, BMP, VEGF and PDGF when Crim1 is co-expressed in the same cell as the 
growth factor (Wilkinson et al., 2003; Wilkinson et al., 2007). Recently, Crim1 has also been 
shown to interact with β1 Integrin via its RGD domain (Zhang et al., 2016). However, the 
functional significance of the IGFBP motif remains unknown. Interestingly, Crim1 has been 
demonstrated to localize in the endoplasmic reticulum and golgi, where post translational 
modification of proteins are known to occur, and also the cell surface, where ligand-receptor 
interactions occur (Glienke et al., 2002; Wilkinson et al., 2003), Pennisi lab, unpublished data). 
 
The importance of proteins that regulate growth factor signalling has been highlighted by recent 
findings that implicate molecules containing multiple cysteine-rich regions, such as chordin and 
noggin, during development. For example, BMP signal transduction is regulated by various proteins 
that exert either a pro- or anti-BMP effect. Mediation of this pathway can occur at multiple levels, 
such as by sequestering BMPs and either facilitating or inhibiting BMP-receptor interactions, 
hindering BMP transport across cells and thus disturbing the BMP gradient required for 
downstream signaling, or by maintaining some BMPs in inactive form by preventing the cleavage 
of pre-BMPs and reducing the amount of mature, secreted BMPs (Wilkinson et al., 2003; Umulis et 
al., 2009).Chordin is an antagonist that directly binds BMPs (Larraín et al., 2000), and noggin, a 
cysteine-knot protein that binds BMPs and prevents them from binding to type I and type II cell 
surface BMPRs via masking of receptor binding sites (Zimmerman et al., 1996; Groppe et al., 
2002). On the other hand, crossveinless-2 potentiates BMP signaling by forming a ternary complex 
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with both chordin and BMP, and reduces the affinity of chordin for BMP, thus allowing BMPs to 
activate their downstream effectors via the BMPRs (Zhang et al., 2010).Importantly, the action of 
these proteins is dependent of the developmental context in which they, and the molecules they 
interact with, are expressed. This has been highlighted by Crim1-deficient mice, which exhibit 
phenotypes that indicate Crim1 can perform both agonistic and antagonistic functions on growth 
factor signaling during organogenesis.  
 
To explore the role of Crim1 in development, a number of transgenic mice have been generated. 
Firstly, a genetrap line was created by random insertion of a β-geo cassette into intron 1 of the 
Crim1 gene (called Crim1
KST264
)(Leighton et al., 2001; Pennisi et al., 2007). Secondly, a conditional 
loss-of-function allele was generated (Crim1
FLOX
), by flanking exons 3 and 4 of the Crim1gene with 
LoxP sites(Chiu et al., 2012). The Crim1
FLOX
 line, when crossed with the CMV-Cre deletor line, 
generated Crim1
Δflox
 mice, intercrosses from which produced mice lacking a functional Crim1 
gene(called Crim1
Δflox/Δflox
) (Chiu et al., 2012). We have previously described perinatal lethality in 
mice homozygous for the Crim1
KST264
genetrap and in Crim1
∆flox
/
∆flox 
mice(Pennisi et al., 2007; Chiu 
et al., 2012). Both strains display defects in multiple organ systems including the kidney, eye and 
placenta(Lovicu et al., 2000; Glienke et al., 2002; Pennisi et al., 2007; Pennisi et al., 2012; Phua et 
al., 2012; Fan et al., 2014), highlighting the importance of Crim1 during development. In this 
review we discuss the role of Crim1 in organogenesis, with a specific focus on the developing heart, 
as well as providing mechanistic insight into how it can regulate the activity of growth factors. 
 
The role of Crim1 in organogenesis 
In the past 15 years a number of studies have begun to map the expression of Crim1 within the 
developing embryo, and have used the different transgenic mouse lines described above to decipher 
the role for Crim1 in organogenesis. A summary of these findings is detailed below. 
 
Kidney 
Perhaps the most widely studied organ in the context of Crim1 function is the kidney. In the 
embryonic murine kidney, Crim1 is expressed in pericytes lining the endothelium and within the 
parietal epithelial cells, mesangial cells and podocytes of the glomeruli from 15.5 days post coitum 
(dpc) (Georgas et al., 2000; Pennisi et al., 2007; Wilkinson et al., 2007). Studies of transgenic 
animals have provided significant insights into the role of Crim1 during kidney development. 
Kidneys from Crim1
KST264/KST264
mice at 15.5 dpc were significantly smaller than their wild type 
littermates, indicating a role for Crim1 in nephrogenesis(Pennisi et al., 2007). Further analysis 
revealed multiple lesions in the glomerulus and glomerular capillary defects, and podocyte 
 227 
effacement (Wilkinson et al., 2007). In their elegant study, Wilkinson et al. showed Crim1 to be co-
expressed with VEGF-A in the podocytes of the renal glomerulus. In mice lacking Crim1, there was 
an increased diffusion of VEGF-A away from the podocytes at 17.5 dpc, and a concomitant 
activation of the VEGF-A receptor Flk1 in adjacent vascular endothelial cells, supporting the 
observation of glomerular defects in these homozygotic mice(Wilkinson et al., 2007). To assess 
whether renal abnormalities were present in the adult kidney, Wilkinson et al. made use of 
Crim1
KST264/KST264
 outbred mice, as a proportion of these homozygous animals survive to adulthood 
(Wilkinson et al., 2007). The kidneys of these adult mice displayed multiple glomerular cysts, 
interstitial fibrosis and endothelial cell thickening (Wilkinson et al., 2007), accompanied by further 
evidence of increased vascular leakiness and compromised extraglomerular vasculature (Wilkinson 
et al., 2009).Furthermore,a later study revealed renal fibrosis in Crim1
KST264/KST264
 adult mice along 
with endothelial aberrations, including an increase in vascular permeability and a discontinuous 
endothelium displaying abnormal collagen deposits (Phua et al., 2012). This could be due to the 
association of Crim1 with TGFβ-1, which is known stimulate endothelial-to-mesenchymal 
transformation (EndoMT)(Kim et al., 2001; Varga and Wrana, 2005; Phua et al., 2012). In the adult 
human kidney, CRIM1 has been shown to be localized in the podocytes, both qualitatively, using 
renal tissue in immunohistochemical experiments, and quantitatively, using immortalised human 
podocytes (Nyström et al., 2009), where BMPs and VEGFs are also expressed(Simon et al., 1995; 
Godin et al., 1999), indicating a possible role for CRIM1 in tethering these growth factors and 
releasing them into the local environment in a controlled manner. 
 
Placenta 
The placenta plays a central role during embryogenesis. It comprises a labyrinthine zone consisting 
of syncytiotrophoblast cells and junctional zone consisting of spongiotrophoblast and glycogen 
trophoblast cells. In mice, Crim1 is expressedin various placental cell types including chorionic 
trophoblasts at 9.5 dpc, synctiotrophoblasts at 13.5 and 15.5 dpc, and spongiotrophoblasts from 13.5 
dpc(Pennisi et al., 2012).Crim1 is important for placental development as, in the absence of this 
gene, placental size is reduced from 13.5 dpc until 17.5 dpc, with a consequent reduction in the size 
of Crim1
KST264/KST264
 embryos at the later stage(Pennisi et al., 2012). There is also a decrease in the 
number of sinusoidal-trophoblast giant cells and an increase in glycogen cells of Crim1
KST264/KST264
 
placentae at 15.5 dpc, hypothesized to be due to a possible dysregulation of multiple signalling 
pathways (Pennisi et al., 2012), such as the IGF and VEGF pathways (Charnock-Jones et al., 1994; 
Randhawa and Cohen, 2005). 
 
Lens and retinal vasculature 
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In the developing murine embryonic eye, Crim1 expression is observed from 9.5 dpc until at least 
day postnatal day (P) 21 (Lovicu et al., 2000). Initially, Crim1 is detected in the precursor to the 
lens, the lens placode, and subsequently is expressed by all lens cells by 11.5 dpc.Crim1 transcripts 
are also present in the corneal epithelium and endothelium by 15.5 dpc, as well as the retinal 
epithelium and retinal ganglion cells at 18.5 dpc. At P21, Crim1 expression persists only in the lens 
(Lovicu et al., 2000). Analysis ofCrim1
glcr11
(glaucoma relevant 11)mutants, termed so because of 
their glaucoma and cataract phenotype, revealsmultiple lens defects that are evident from 16.5 dpc, 
including abnormal cell adhesion at epithelial adhesion junctions, disrupted polarity and a reduction 
in the number of proliferating lens epithelial cells, which collectively culminate in a smaller, 
atypical lens(Zhang et al., 2016). By P60, Crim1 mutant mice also display lens cataracts and 
abnormal cellular proliferation within the retina. Mechanistically, the adhesion defects in these 
Crim1 mutants are consistent with an interaction observed between Crim1 and β1 integrin, which is 
also expressed in both lens epithelial cells and lens fiber cells (Zhang et al., 2016). Indeed, analysis 
of β1 integrin signalling reveals that Crim1 regulatesthe phosphorylation status of its downstream 
effectors focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK), resulting in 
modulation of lens morphogenesis by membrane-bound Crim1 (Zhang et al., 2016).  
 
As Crim1 is expressed in vivo and in vitro in vascular endothelial cells (Glienke et al., 2002), and in 
the vasculature of the embryonic mouse hindbrain and postnatal retinas (Fan et al., 2014), its role in 
the retinal vasculature has also been analysed. Crossing the Crim1
Flox
 allele to Pdgfrb-iCreERmice 
to enable inducible deletion of Crim1 from endothelial cells reveals thatdefective retinal vascular 
development occurs in the absence of Crim1 from the vasculature (Fan et al., 2014). The 
phenotypes observed included reduced vessel density, length and branchpoint number, and vessel 
regression in the first week of postnatal development (Fan et al., 2014). Indeed, these authors 
revealed modulation of the autocrine activity of VEGF-A by Crim1, indicating that it has an 
important regulatory role in the formation and development of the vasculature(Fan et al., 2014). 
The distribution of the cell adhesion molecule VE-Cadherin at the angiogenic front of Crim1
flox/flox
; 
Pdgfb-iCreERretinal vasculature preparations was also altered (Fan et al., 2014), a finding 
consistent with the impaired endothelial tube formation evident in HUVECs in the absence of 
CRIM1(Glienke et al., 2002). This is suggestive of a cell adhesion anomaly. A possible role for the 
conserved RGD motif in Crim1 in this context is possible, as this domain of Crim1 potentially binds 
integrins and so modulates cellular attachment(Kolle et al., 2000). The intracellular domain of 
Crim1 could also play a role in cell adhesion, as the cytoplasmic domain of Crim1 has been shown 
to indirectly bind β-catenin and N-cadherin in Xenopus(Ponferrada et al., 2012).  
Nervous system 
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Preliminary investigations have also shown that Crim1 may be important for the development of the 
nervous system. For instance, in the developing mouse spinal cord, Crim1 is expressed from 9.5 dpc 
in the floor plate, and in pools of motor neurons at later stages of development (Kolle et al., 2000). 
Moreover, Crim1 expression is observed in other regions of the nascent mouse neuraxis, including 
the forebrain and hindbrain from 11.5 dpc, and in the midbrain at 13.5dpc, (Kolle et al., 2000). 
Despite this, studies have yet to elucidate the mechanistic function of Crim1 in the developing 
nervous system. Looking forwards, using our understanding of the role of Crim1 in other 
developmental contexts may provide insights into the role of this factor within the developing 
nervous system. For example, the colocalization of Crim1 and β1 integrinsat the leading edges of 
lens epithelial cell projections regulates cell adhesion and polarity (Zhang et al., 2016). As cellular 
adhesion and polarity are critical components that underlie the proliferation and subsequent 
differentiation of neural stem cells within the embryonic brain, a role for Crim1 in mediating these 
aspects during neural development is plausible.  
 
The role of Crim1 in cardiac development 
Overview of organogenesis of the heart 
Another organ in which Crim1 plays an important role during development is the heart. The heart is 
the first organ to form and function in the vertebrate embryo (Yutzey and Kirby, 2002), and cardiac 
progenitor cells are among the earliest to migrate through the primitive streak during gastrulation 
(Garcia-Martinez and Schoenwolf, 1993; Schoenwolf and Garcia-Martinez, 1995). Splanchnic 
mesenchymal cells, the principal cardiac precursors, arise from primary heart fields in the lateral 
plate mesoderm (Waldo et al., 2001) and aggregate in the cardiogenic region to form angioblastic 
cords. These canalize to form two thin-walled endocardial heart tubes. Their subsequent fusion 
forms a single two-layered heart tube (Manasek, 1969) comprising the outer mesenchymal 
myocardial mantle which forms the myocardium, and the inner endothelial tube which forms the 
endocardium, separated by myocardium-produced cardiac jelly (Waldo et al., 1999).  
 
The epicardium of the heart develops from a transient structure, the proepicardium (PE) (Virágh 
and Challice, 1981; Männer, 1993; Virágh et al., 1993; Gittenberger-de Groot et al., 1998), that is 
located between the sinus horns and liver primordium (Virágh et al., 1993), and which is derived 
from the lateral plate mesoderm (Serluca, 2008). The PE contains smooth muscle, fibroblast and 
endothelial progenitors (Mikawa and Gourdie, 1996; Dettman et al., 1998; Gittenberger-de Groot et 
al., 1998; Männer, 1999; Pérez-Pomares et al., 2002), but whether it is the sole contributor of 
endothelial cells to the coronary vasculature is contentious, as the liver bud and sinus venosus have 
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also beensuggested as sources of the same (Poelmann et al., 1993; Ishii et al., 2007; Red-Horse et 
al., 2010; Cossette and Misra, 2011).  
 
Proepicardial cells attach to the inner curvature of the atrioventricular junction of the rudimentary 
heart (Männer, 1993; Ishii et al., 2010) to form its outermost layer – the epicardium. Species-
specific migration of proepicardial cells to the myocardium occurs either by proepicardial vesicle 
budding or via an extracellular matrix bridge to potentially guide the translocation (Nahirney et al., 
2003). It has been suggested that the proximity between the liver bud and the PE affects 
proepicardial attachment to the heart and differentiation via an associated effect on proepicardial 
marker genes (Ishii et al., 2007). Following the attachment, a population of epicardial cells undergo 
EMT to form subepicardial cells, including those contributing to the subepicardial coronary 
vasculature, whereas another subset of these cells traverse the subepicardial space and migrate into 
the myocardium (Virágh and Challice, 1981) to give rise to various cell types, including coronary 
vascular smooth muscle cells, coronary vascular endothelial cells and cardiac fibroblasts (Virágh 
and Challice, 1981; Männer, 1993; Virágh et al., 1993; Mikawa and Gourdie, 1996; Gittenberger-de 
Groot et al., 1998).  
 
Crim1 and cardiac development 
What evidence is there that Crim1 plays a role in cardiac development? Firstly, studies on the 
Crim1
KST264
 genetrap line (which carries a LacZ reporter), have shown that Crim1-promoter 
mediated LacZ expression is evident in the murine proepicardium at 9.5 dpc, and within the 
epicardium throughout cardiac development. It is also observed in coronary vascular smooth muscle 
cells and, to a weaker extent, in coronary vascular endothelial cells, at later stages of heart 
development (Pennisi et al., 2007). LacZ expression is also observed in the outflow tract 
mesenchyme, bicuspid and tricuspid valve leaflets and atrial septum at 18.5 dpc(Iyer et al., 2016). 
These sites of expression imply that Crim1 may regulate many aspects of cardiac development. 
Interestingly, there aremany cardiac phenotypes, such as chamber septation and valve defects, 
hypoplastic ventricular walls and coronary vasculature defects, that arise as a result of dysregulation 
of growth factors such including TGFβs, BMPs, VEGFs and IGFs (Kim et al., 2001; Chen et al., 
2004; Goldman et al., 2009; Uchimura et al., 2009; Li et al., 2011; Wu et al., 2012). This indicates 
that growth factor activity is normally tightly controlled during cardiogenesis. Given the interaction 
of Crim1 with many of these factors in other organ systems, and preliminary data indicating 
thatCrim1 mutant cardiac phenotypesare reminiscent of these phenotypes, we posit that Crim1 
mediates cardiogenesis, at least in part, via the regulation of growth factor signalling.  
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For example, epicardial EMT is a vital process that occurs during normal heart development, and 
several growth factors have been implicated in both EMT, and the differentiation of epicardial cells 
into their correct lineages. A number of distinct molecular processes work cooperatively in order to 
initiate and promoteepicardial EMT. As the heart develops, there is significant cross-talk between 
the epicardium and myocardium, with epicardial signalling via its secreted factors and epicardium-
derived cells, as well as signalling from the myocardium, being essential for myocardial growth and 
differentiation (Sucov et al., 2009) and coronary vascular development (Kang and Sucov, 2005). 
Thus, it is this reciprocal signalling between the epicardium and myocardium which provides cues 
to ensure the proper and timely differentiation of epicardial lineages, maturation of the myocardium 
and the coronary vasculature, and, ultimately, the development and functioning of the heart. For 
instance, TGFβs stimulate epicardial EMT (Dokic and Dettman, 2006; Olivey et al., 2006; Sánchez 
and Barnett, 2012). Binding of TGFβ2 and TGFβ3 to TGFβR2, and the subsequent activation of 
TGFβR1, leads to the phosphorylation of SMAD2/3 proteins and upregulation of transcription 
factors such as snail1 and slug. These factors repress the expression of E-cadherin, while promoting 
the expression of Vimentin, RhoA and various ECM molecules (Xu et al., 2009), thus facilitating a 
transition away from epithelial characteristics. Using the WT1-Cre and WT1-CreERT2 cell lines, we 
have shown that EMT and epicardial migration are increased in the absence of Crim1(Iyer et al., 
2016). The epicardium of Crim1 null mutant hearts surprisingly shows a reduced phospho-SMAD2 
level, indicative of reduced TGFβ signalling(Iyer et al., 2016), at 13.5 dpc, despite enhanced EMT. 
This indicates that there could be a role for Crim1 in the formation or stabilization of cadherin-
dependent junctional complexes in epithelial cells, via which it could serve to normally restrain 
epicardial EMT. β-catenin is a crucial component of adherens junctions, and has been previously 
shown to complex indirectly with Crim1 (Ponferrada et al., 2012). Indeed, assessment of β-Catenin 
distribution at epicardial cell-cell junctions is altered in Crim1-deficient mice, indicating a loss of 
stability at these contact points within the developing heart (Iyer et al., 2016).  
 
Epithelial and mesenchymal cells secrete PDGF-A, which may act as a mitogen that stimulates 
ventricular development and cardiomyocyte proliferation(Kang et al., 2008). Moreover, PDGF-B 
can stimulate proepicardial cells expressing smooth muscle markers to undergo epicardial EMT and 
subsequently commit to the coronary smooth muscle cell lineage, mediated through PDGFR-β (Lu 
et al., 2001), while PDGFR-α plays an important role in the formation of cardiac fibroblasts(Smith 
et al., 2011). Both PDGF receptors are implicated in EMT, whereby epicardium-derived cells 
(EPDCs) give rise to myocardial fibroblasts and vascular smooth muscle cells(Mellgren et al., 
2008; Smith et al., 2011). We have recently reported a reduction in the number of EPDC-derived 
myocardial fibroblasts withinCrim1mutant mice (Iyer et al., 2016). Although Crim1 has been 
 232 
shown to capable of binding PDGF-B (Wilkinson et al., 2007), direct evidence to support a role of 
Crim1 in the modulation of this pathway in the heart is currently lacking. Future work aimed at 
investigating this exciting prospect will undoubtedly advance our understanding of the mechanism 
through which Crim1 regulates the biology of EPDC-derived cells. Moreover, PDGF-B is also 
expressed by endothelial cells is required for the endothelial-cell-mediated recruitment for coronary 
vascular smooth muscle cells to the developing coronary vessels (Van den Akker et al., 2008). 
Given the nature of the Crim1 protein, this cysteine-knot protein could also potentially antagonise 
this aspect of cardiac development by tethering PDGFs to the cell surface and limiting their action, 
another fruitful avenue of future research. 
 
Interestingly, in support of this hypothesis, Wilkinson et al.previously identified that 
Crim1potentially functions as an antagonistic regulator of certain members of the BMP family. 
Crim1 interacts intracellularly with both BMP4 and BMP7 (Wilkinson et al., 2003), and co-
localizes with their respective pre-BMPs within the golgi via its CRRs, ultimately reducing the 
secretion of mature BMPs. Furthermore, a proportion of the BMPs released remain bound to Crim1 
(Wilkinson et al., 2003). Crim1 has also been implicated in tethering BMPs to the cell, which may 
serve to restrict their functional potential, and, since BMPs are known to act across a restricted 
distance (Jones et al., 1996), possibly to act in the presentation of BMP ligands to neighbouring 
cells. BMPs are well known for their role in cardiac development. For instance, BMP2 increases 
epicardial EMT via TGFβR3 activation in epicardial cell lines (Sánchez and Barnett, 2012), 
andBMP4 has been shown to play an important role in both atrioventricular and outflow tract 
septation (Jiao et al., 2003; Liu et al., 2004). The absence of Bmp10 leads to impaired ventricular 
trabeculation and formation of thin ventricular walls (Neuhaus et al., 1999), a phenotype 
recapitulated in mice lacking both Bmp 6 and Bmp7(Kim et al., 2001). Given the need for exquisite 
spatial and temporal modulation if BMP signaling, it is likely that Crim1 also regulates this family 
of molecules during cardiac development, Indeed, hypoplastic ventricles are observed in Crim1 null 
mice, alongside a concomitant increase in apoptosis of intramural cells, indicating that Crim1 is 
necessary for the formation of the myocardium, potentially via the modulation of BMP signalling 
(Iyer et al., 2016). The use of next generation sequencing in Crim1-deficient mice, coupled with 
proteomic approaches, could provide a future avenue to determine the role Crim1 plays in the 
modulation of BMP biology during cardiac development. 
 
IGFs have been also implicated as epicardial mitogenic factors during heart formation. For instance, 
IGF-2 is secreted from the epicardium and exerts a mitogenic effect on the formation of the 
compact myocardium(Li et al., 2011). Could the IGFBP motif of Crim1, along with the CRR 
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domains, bind IGFs and regulate their activity?Interestingly, there is an increase in ERK1/2 
signalling in the myocardium of Crim1–deficient hearts at 13.5 dpc (Iyer et al., 2016). This 
indicates that Crim1 regulates signalling molecules secreted by the epicardium, or by the 
myocardium itself, and is thus essential for myocardial maturation in the early stages of heart 
development. A large number of growth factors are known to activate the ERK pathway, including 
IGFs, and downstream ERK signalling can be both pro- and anti-apoptotic, making it important to 
identify which growth factors are specifically involved in this process, and exactly how this 
augmented ERK1/2 signalling affects the development of the myocardium. It would thus be useful 
to assess whether Crim1 can indeed bind IGFs, and further whether Crim1 can modulate this 
important growth factor in the context of the developing heart. 
 
Concluding remarks 
While the broad role of Crim1 in developmental organogenesis is now well established, much 
remains unclear as to how this transmembrane protein exerts its biological influence. Critically, the 
mechanisms by which Crim1 mediates growth factor signalling in different developmental contexts 
are still poorly defined. For example, in C. elegans, crm-1 acts as an agonist of a BMP-like 
pathway, the DBL-1 pathway, in a non-cell-autonomous fashion(Fung et al., 2007), although it is 
not known whether this occurs through an interaction with the ligand or its receptor. In contrast to 
this agonistic role with regards to BMP signalling, the Drosophila homolog of Crim1, CRIMPY, 
antagonizes the function of the BMP ligand Glass bottom boat (Gbb) in motorneurons at the 
neuromuscular junction (NMJ), and restrains the expansion of the NMJ(James and Broihier, 2011). 
The full-length Gbb precursor associates preferentially with the extracellular domain of CRIMPY to 
regulate synaptic development, before Gbb is secreted from the motorneuron terminal(James and 
Broihier, 2011). Similarly, Crim1 binds to and antagonistically modulates the processing of pre-
BMPs and the secretion of mature BMPs in COS7 cells (Wilkinson et al., 2003). These findings 
highlight the fact that the function of Crim1 in organogenesis is context-dependent, and that the 
timing and site of Crim1 expression, coupled with that of the multitude of growth factors it can 
potentially interact with, will influence its biological function. 
 
Looking to the future, investigations into Crim1 function during development will enable us to 
probe the mechanisms underlying a variety of pathological disorders. For instance, the adult 
myocardium has limited regenerative capacity. New technologies have made the generation of 
cardiomyocytes from induced stem cells a possibility, but it remains essential to clarify the growth 
factors and signalling molecules germane to this process to make this feasible. BMPs, for instance, 
regulate stem cell renewal and differentiation into cardiomyocytes, and cooperate with other 
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signalling pathways to further modulate gene expression of transcription factors(Varga and Wrana, 
2005; van Wijk et al., 2007).As Crim1 can regulate BMP processing, investigating the intersection 
between Crim1 biology and BMP signalling during the generation of cardiomyocytes in vitro could 
be a valuable approach. Similarly, research on the reactivation of the adult epicardium following 
myocardial damage has increased in recent years, and the modulation of growth factors such as 
BMPs, TGFβ, VEGF and PDGF by Crim1 is an attractive avenue of research that remains to be 
explored. Moreover, as myocardial injury stimulates epicardial cells to give rise to fibroblasts and 
smooth muscle cells(Limana et al., 2011; Zhou et al., 2011; Duan et al., 2012; Huang et al., 2012; 
van Wijk et al., 2012), our recent observation that, in the absence of Crim1, the number of cardiac 
fibroblasts is reduced(Iyer et al., 2016), is another step towards deciphering its role not only in 
lineage specification but also potential therapeutic interventions to improve cardiac performance 
after damage.  
 
With relation to other pathological disorders, the analysis of serum from chronic heart failure 
patients shows an increase in CRIM1 levels, along with an increase in secreted factors involved in 
fibrosis, indicating a positive correlation between CRIM1 and pro-fibrotic activity (Eleuteri et al., 
2014), though whether these increases are reflected within cardiac tissue is not clear. Moreover, 
CRIM1 is expressed at higher levels in drug-resistant leukaemia cells, implicating it as a potential 
drug resistance marker(Prenkert et al., 2010). The intronic regions of CRIM1 and ZEB2have been 
demonstrated to be downregulated in breast cancer epithelial cells(Kim et al., 2015), andCRIM1 has 
also been suggested to be a target of the Hippo pathway, and to be overexpressed in gastric cancer 
tissues(Lim et al., 2014). These tantalising vignettes into the role of CRIM1 in cancer biology and 
disease provide a platform on which to further investigate the role of this gene in pathological 
conditions. Indeed, studies from development have illustrated that Crim1 may act at the nexus of 
many critical signalling pathways, and so the manipulation of Crim1 expression may provide a 
parsimonious mechanism by which cellular functions such as proliferation, differentiation and 
repair can be efficiently manipulated following injury and tumorigenesis.  
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